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INTRODUCTION
Cardiovascular disease is, and will remain so for many years to come, one of the leading 
causes or morbidity and mortality, especially in the Western World.1 Improving and expand-
ing insight into the pathogenesis of cardiovascular disease is an important part of managing, 
treating and preventing cardiovascular disease.
The cardiovascular system can be described as a closed conduit with a central pump with the 
principal function of supplying blood to all parts of the body. However simple, this descrip-
tion and nomenclature also indicate those components of the system, in which problems 
can arise: the blood vessels and the heart. Apart from delivery of blood throughout the body, 
the arterial system decreases the pulsatility of the flow, generated by the heart, resulting 
in a continuous flow at the level of the capillaries, so that a constant amount of blood is 
delivered to tissues and organs. A very important function of the (elastic) arteries is to store 
volume energy in order to limit the rise in the systolic blood pressure. This is achieved by 
the viscoelastic properties of the arterial wall. Key structural elements, that play a large role 
in this process, are innate structural components of the arterial wall, such as collagen and 
elastin. Throughout life physiological changes in the arterial wall result in stiffening of the 
vessel walls, which is more pronounced in the central (mostly elastic) arteries, compared to 
distal, more muscular, arteries.2,3
Increased arterial stiffness has been associated with hypertension, diabetes mellitus, renal 
disease and atherosclerosis and, by now, it has also been established as an independent risk 
factor for cardiovascular disease.4-13 Arterial stiffness increases with age, independently of the 
presence of cardiovascular risk factors. Traditionally it was considered a physiological part of 
ageing, but the increase in stiffness may depend on several factors, environmental as well as 
genetic.8 Indeed, heritability estimates, mostly ranging from 0.30-0.40, were found for arterial 
stiffness.14 Insight into the pathogenesis of arterial stiffness may offer possibilities for further 
research into treatment and prevention or cardiovascular disease and its sequelae. 
For long, non-invasive techniques to adequately measure arterial stiffness were not available, 
making large-scale research not feasible. However, nowadays stiffness can be measured with 
various non-invasive techniques, such as pulse wave velocity measurements for aortic stiff-
ness, the distensibility coefficient determination of the carotid arteries and pulse pressure, 
as a more general measure of stiffness. Other currently used measures of stiffness include 
central pulse wave analyses, such as the Augmentation Index (AIx), and local indices as the 
carotid Young´s modulus.15,16 These new techniques facilitate more extensive and in depth 
study into determinants of arterial stiffness.
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The aim of the studies, described in this thesis is to examine the influence of variation in 
genes that may affect arterial stiffness and cardiovascular events. 
The first part of this thesis focuses on genetic variation in pleiotropic genes that influence in-
flammation and cardiovascular events. Chapter 2.1 focuses on the relation of the interleukin 
6 -174 G/C promoter polymorphism and coronary heart disease. In chapter 2.2 the study is 
described on the relation between polymorphisms in the transforming growth factor β1 gene 
and risk of myocardial infarction and stroke. The second part of this thesis focuses on genetic 
variation and the relation with arterial stiffness. First inflammatory genes are considered. In 
chapter 3.1 the association between the interleukin 6 -174 G/C promotor polymorphism, lev-
els of interleukin 6 and C-reactive protein and arterial stiffness is described. In chapter 3.2 the 
association between several polymorphisms in the C-reactive protein and arterial stiffness is 
set out. Chapter 3.3 focuses on polymorphisms in the transforming growth factor β1 gene in 
relation to arterial stiffness. Chapter 3.4 describes the relation between genetic variation in 
the fibrinogen α and γ gene, fibrinogen levels and arterial stiffness. Also non-inflammatory 
genes that influence the structure of the vascular wall are considered. In chapter 4.1 the asso-
ciation between polymorphisms in the renin-angiotensin system genes and arterial stiffness 
is described. Chapter 4.2 aims to describe the relation between the angiotensin converting 
enzyme insertion/deletion polymorphism and blood pressure changes. Chapter 4.3 focuses 
on a study of polymorphisms in the matrix-metalloproteinase 3 gene and arterial stiffness. 
Finally, the main findings of this thesis and suggestions for future research are discussed.
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Genetic Determinants of 
Cardiovascular Disease

Chapter 2.1
Interleukin 6 -174 G/C Promoter Polymorphism and 
Risk of Coronary Heart Disease
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Background and purpose - Inflammation plays a pivotal role in the pathogenesis of 
atherosclerosis. Interleukin 6 (IL-6) has many inflammatory functions and the IL-6 -174 G/C 
promoter polymorphism appears to influence IL-6 levels. Findings of previous studies on 
the relation between this polymorphism and risk of cardiovascular diseases are inconsistent. 
We investigated this polymorphism in relation to risk of coronary heart disease (CHD) in a 
population-based study and meta-analysis.
Methods - 6434 participants of the Rotterdam Study were genotyped. Analyses on the rela-
tion between genotype and CHD were performed using Cox proportional hazards analyses, 
and the association between genotype and plasma levels of IL-6 and CRP was investigated. All 
analyses were adjusted for age, sex and common cardiovascular risk factors. A meta-analysis 
was performed, using a random effects model. 
Results - No association between genotype and risk of CHD was observed. The polymorphism 
was not associated with IL-6 levels, but the C-allele was associated with higher CRP levels (p 
< 0.01). Our meta-analysis did not show a significant association between the genotype and 
risk of CHD.
Conclusions - We conclude that the polymorphism is not a suitable genetic marker for 
increased risk of CHD in subjects aged 55 years and older.
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INTRODUCTION
Inflammatory processes play a pivotal role in the pathogenesis of atherosclerosis.1-4 Within 
the inflammatory pathway, cytokines fulfill a multitude of functions. Interleukin 6 (IL-6) is a 
pleiotropic inflammatory cytokine. It plays an important part in the acute-phase response 
and inflammatory cascade, such as up-regulation of acute-phase proteins as C-reactive 
protein (CRP).5,6 CRP levels have been found to be associated with risk of coronary heart 
disease (CHD).7,8 Several studies have also shown an association between IL-6 plasma levels 
and cardiovascular pathology.9-17 Ridker et al. found elevated IL-6 levels to be associated with 
increased risk of myocardial infarction (MI).12 This finding was replicated in another large 
population by Bennet et al., who found an increased risk of MI for those in the upper quartile 
levels of IL-6 versus those in the lowest quartile levels, and by Cesari et al., when comparing 
subjects with highest and lowest IL-6 tertiles in an American population.10,15 Fishman et al. 
detected a functional polymorphism (G->C) in the promoter region of the human IL-6 gene 
(174 base pairs upstream from the start site).18 This polymorphism appears to influence the 
transcription of the IL-6 gene and also plasma levels of IL-6, and IL-6 is therefore a candidate 
gene for further study into its role in cardiovascular disease.18 However, results from previous 
studies on the -174 G/C polymorphism and CHD were inconsistent.15,19-26 Five studies, most 
of which case-control studies, conducted in Western, mainly Caucasian, populations, found 
the C-allele to be associated with (an increased risk of ) CHD or cardiovascular disease.21-24,26 
Four other studies, however, did not find a significant association.15,19,20,25 We studied the IL-6 
-174 G/C polymorphism in relation to risk of CHD in a large population-based study. Also a 
meta-analysis was conducted including studies on this polymorphism and CHD.
METHODS
Study Population
The Rotterdam Study is an ongoing prospective cohort study including 7983 participants 
of 55 years and older. Its general aims are to investigate determinants of chronic diseases.27 
During the first phase of this study (1990-1993), all inhabitants of a Rotterdam suburban area 
(Ommoord) aged 55 years and over, were invited to participate in this study. The response 
rate was 78%. Baseline investigations included an interview and visits to the research center, 
where a number of clinical measurements were performed. Approval of the Medical Ethics 
Committee of the Erasmus University Rotterdam was obtained for the Rotterdam Study. From 
all participants written informed consent was acquired. A more in depth description of the 
Rotterdam Study was published previously.27 
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Clinical Characteristics
Trained investigators collected information using a computerized questionnaire during the 
home visits. The information included current health status, medical history, use of medica-
tion and smoking behavior. During the two subsequent visits to the center, blood samples 
were obtained and established cardiovascular risk factors were measured as described 
elsewhere.28 Hypertension was defined as a systolic blood pressure of 160 mmHg and over, 
and/or a diastolic blood pressure of 100 mmHg and over, and/or use of antihypertensive 
medication (with indication hypertension). Diabetes mellitus (DM) was defined as a non-fast-
ing serum glucose level of 11.1 mmol/l and over, and/or use of antidiabetic medication. A 
12-lead electrocardiogram was recorded and analyzed by the Modular ECG Analysis System 
(MEANS).29 Evaluation of the atherosclerotic status of participants was accomplished using 
ultrasonography (carotid arteries), radiographic detection (aorta), ankle-arm index (AAI) 
(via blood pressure measurements); these methods have been extensively described previ-
ously.30
Measurement of IL-6 and CRP Plasma Levels
A venapuncture was performed by application of minimal stasis with a 21-gauge Butterfly 
needle with tube (Surflo winged infusion set, Terumo). Non-fasting blood was collected in 
tubes containing 0.129 mol/L sodium citrate at 4°C. The ratio of blood to sodium citrate was 
9:1. Plasma was collected after centrifugation for 10 minutes at 3000 rpm. Subsequently, 
platelet-free plasma was obtained by centrifugation for 10 minutes at 10000 rpm, immedi-
ately frozen in liquid nitrogen, and stored at -20 degrees centigrade. All tubes were stored 
on ice before and after blood sampling. Plasma levels of IL-6 were measured by using a com-
mercially available enzyme-linked immunosorbent assay (Quantikine HS from R&D Systems 
Europe, Oxon, United Kingdom). CRP plasma levels were measured in samples stored at -20 
degrees centigrade, by sensitive immunological methods based on rate near infrared particle 
immunoassays (IMMAGE from Beckman Coulter Netherlands).
Genotyping
Genotyping of the IL-6 -174 G/C polymorphism was performed using samples stored earlier 
at -80 degrees centigrade. DNA was isolated using standard procedures. Genotypes were 
determined in 2-ng genomic DNA with the Taqman allelic discrimination assay (Applied 
Biosystems, Foster City, California). Primer and probe sequences were optimized by using the 
SNP assay-by-design service of Applied Biosystems (for details, see http://store.appliedbio-
systems.com). Reactions were performed with the Taqman Prism 7900HT 384 wells format in 
2 μl reaction volume. 
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Follow-up Procedures and Definition of Events 
General practitioners (GPs) in the research district, with whom 85% of the participants of the 
Rotterdam Study were enlisted, reported fatal and non-fatal cardiovascular events. Research 
assistants verified all information by checking medical records at the GPs’ offices. All medical 
records of the participants under the care of general practitioners outside the study area 
were checked annually for possible events. Letters and, in case of hospitalization, discharge 
reports from medical specialists were obtained. With respect to the vital status of participants, 
information was also obtained regularly from the municipal health authorities in Rotterdam. 
After notification, the cause and circumstances of death were established by a questionnaire 
from the GPs. Two research physicians independently coded all reported events according 
to the International Classification of Diseases, 10th edition (ICD-10).31 Codes on which the 
research physicians disagreed were discussed in order to reach consensus. Finally, a medical 
expert in cardiovascular disease, whose judgement was considered final, reviewed all events. 
CHD was defined (based upon ICD-10) as the occurrence of an MI (I21), revascularization 
procedure (percutaneous transluminal coronary angioplasty or coronary artery bypass graft) 
(Z95.5 & Z95.1), ischaemic heart disease (I20, I22-25), sudden cardiac death (I46), ventricular 
fibrillation or tachycardia (I49), congestive heart failure (I50) or sudden death undefined (R96) 
during follow-up. Sudden death was defined as death occurring instantaneously or within 1 
hour after onset of symptoms. Incident MI was defined as the occurrence of a fatal or non-
fatal MI after the baseline examination. 
Meta-analysis
For the meta-analysis, published data were used from previously published studies, concern-
ing the IL-6 -174 G/C polymorphism and CHD, until December 2004. In addition our own data 
were also included. Studies were found with Pubmed/Medline using key words: interleukin 
6, -174, polymorphism, cardiovascular disease, myocardial infarction, coronary heart disease, 
and using references from retrieved articles. Eight studies were identified, of which seven 
were included in the analysis.15,19-25 One study was excluded because no genotype frequen-
cies were available specified for cases and controls.23 All studies were conducted in European 
populations. As endpoint in the analyses, we used CHD, defined as the occurrence of an MI, 
revascularization procedure (percutaneous transluminal coronary angioplasty or coronary 
artery bypass graft), ischaemic heart disease, (sudden) cardiac death, ventricular fibrillation 
or tachycardia, sudden death undefined, or congestive heart failure. 
Statistical Analyses
Baseline characteristics were tested for differences between the genotypes using ANOVA 
analyses for continuous variables (age, BMI [body mass index], SBP [systolic blood pressure], 
cholesterol levels, IL-6 plasma levels, CRP plasma levels) and Pearson chi-square tests for 
discrete variables (sex, smoking, diabetic status, history of MI). All values above mean plus 
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three times the standard deviation were excluded, as correction for outliers. Natural-log 
transformed (ln-transformation) values of IL-6 and CRP plasma levels were used to normalize 
the distribution of these variables; presented data are back-transformed. Cox proportional 
hazards analyses were performed in order to obtain relative risks. All analyses were adjusted 
for age and sex, and additionally for BMI, SBP, high-density lipoprotein (HDL-) and total cho-
lesterol levels, baseline smoking and DM. Subjects with prevalent MI were excluded from the 
analyses. Additional analyses were performed in various age strata (10 year strata starting 
from 55 years, and above and below 75 years), in strata of sex, smoking, and DM, and in 
various strata of atherosclerosis (tertiles of aorta calcification and carotid plaques, and AAI 
above and below 0.9). A p-value of 0.05 and smaller was considered significant in all analyses. 
The statistical analyses were performed using SPSS 11 and S-Plus 6.0 for MS-Windows. 
For the meta-analysis the method of moments has been used to calculate the relative 
risks in a random-effects model for the pooled data.32 We used the funnel plots to examine 
publication bias of reported associations. The meta-analysis and heterogeneity analysis were 
performed using Review Manager 4.2.7 (RevMan Analyses version 1.0; Cochrane Collabora-
tion - Wintertree Software Inc.).
RESULTS
Rotterdam Study Results 
Genotyping of the IL-6 -174 G/C polymorphism was successfully performed in 6434 subjects. 
The main characteristics of the study population are summarized in Table 1 (2612 male and 
3822 female). Mean age was 69.5 (± 9.1) years. 2301 participants (36%) had the GG-genotype 
(wildtype), 3050 (47%) had the GC-genotype and 1083 (17%) had the CC-genotype. Genotype 
and allele proportions were in Hardy Weinberg equilibrium (p = 0.18).
IL-6 plasma levels were determined in a random subgroup of 641 subjects, after exclusion 
of outliers (2%). No significant difference in mean IL-6 plasma levels between the genotypes 
was observed (Figure 1). CRP plasma levels were successfully determined in 5924 cases, after 
exclusion of outliers (1%). The level of CRP was significantly higher in CC (p < 0.01) and GC (p 
< 0.01) individuals as compared to the individuals with the wildtype genotype GG (Figure 1). 
The C-allele was significantly associated with higher CRP plasma levels (p < 0.01).
During a mean follow-up period of 6.8 (± 2.3) years, there were 648 cases of CHD and 280 
cases of MI. After exclusion of patients with previous MI, there were 463 newly diagnosed 
cases of CHD and 208 cases of incident MI.
There was no significant difference in relative risk of CHD or MI when comparing the GC- or 
CC-genotypes and C-allele carriership with the -174 GG wildtype genotype, although there 
appeared to be a slightly, but not significantly, increased risk for the subjects with the GC- 
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Table 1. Baseline Characteristics
Baseline Characteristics
Characteristic Overall
IL-6 –174 Genotype
GG GC CC
Number (%) 6434 (100) 2301 (36) 3050 (47) 1083 (17)
Age – yrs 69.5 ± 9.1 69.2 ± 9.0 69.5 ± 9.1 69.9 ± 9.3
Male sex – number (%) 2612 (41) 958 (42) 1234 (41) 420 (39)
BMI – kg/m2 26.3 ± 3.7 26.1 ± 3.7 26.4 ± 3.8 26.2 ± 3.6*
SBP – mm Hg 139 ± 22.2 139 ± 22.3 139 ± 22.4 140 ± 21.6
Total cholesterol – mmol/l 6.6 ± 1.2 6.6 ± 1.2 6.6 ± 1.2 6.6 ± 1.2
HDL-cholesterol – mmol/l 1.3 ± 0.4 1.4 ± 0.4 1.3 ± 0.4 1.3 ± 0.4
Smoking – number (%)
- Current
- Former
- Never
1423 (21)
2618 (41)
2214 (34)
506 (22)
950 (41)
781 (34)
696 (23)
1223 (40)
1044 (34)
221 (20)
445 (41)
389 (36)
Diabetes – number (%) 657 (10) 222 (10) 333 (11) 102 (9)
History of MI (%) 750 (12) 255 (11) 377 (12) 118 (11)
BMI = body mass index
SBP = systolic blood pressure
HDL = high density lipoprotein
MI = myocardial infarction
Continuous values are depicted as mean ± SD
* = GC different from GG (p = 0.04)
Figure 1. Plasma Levels of IL-6 and CRP per Genotype
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and CC-genotype (Table 2). Adjusting for age, BMI, SBP, total and HDL-cholesterol, smoking 
and DM did not alter these results.
No difference in survival and event-free survival was found between the genotypes CC, GC 
and GG for CHD in men (p = 0.36) or women (p = 0.79). There was also no difference in survival 
between the genotypes for MI in men (p = 0.81) or women (p = 0.63). Further adjustment for 
covariates did not alter these findings. 
No significant associations between the -174 genotype and risk of CHD or MI were observed 
in strata of age, smoking, diabetic status and levels of atherosclerosis (data not shown). 
Table 2. Risk of CHD and MI by IL-6 Genotype
CHD MI
Events/ total RR 95% CI p Events/ total RR 95% CI p
Males GG* 84/801 1 - - 44/801 1 - -
GC 116/1019 1.10 0.83-1.46 0.49 54/1019 0.96 0.65-1.44 0.86
CC 43/352 1.19 0.83-1.72 0.35 21/352 1.10 0.66-1.86 0.71
Carrier 159/1371 1.13 0.86-1.47 0.38 75/1371 1.00 0.69-1.45 1.00
Females GG* 74/1245 1 - - 29/1245 1 - -
GC 106/1654 1.05 0.78-1.41 0.76 43/1654 1.09 0.68-1.75 0.71
CC 40/613 1.02 0.70-1.50 0.92 17/613 1.14 0.63-2.08 0.67
Carrier 146/2267 1.04 0.79-1.38 0.78 60/2267 1.11 0.71-1.72 0.66
* = Reference genotype
CI = Confidence interval
CHD = coronary heart disease
MI = myocardial infarction
Data are age adjusted
Figure 3. Meta-analysis Funnel Plot
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Meta-Analysis Results
In the meta-analysis were a total of 13434 C-allele carriers of whom 36% (n = 4799) were CHD 
cases; and 6364 subjects with the wildtype GG genotype of whom 33% (n = 2128) were CHD 
cases. 
The meta-analysis did not show a significant association between the polymorphism and 
CHD. Subjects with the CC-genotype compared to individuals with the GG-genotype had a 
relative risk of 1.03 (0.92-1.16) (p = 0.59). Also when carriers of the C-allele were compared to 
the GG-genotype, there was no significant difference in risk, 1.12 (0.97-1.29) (p = 0.12) (Figure 
2). There was evidence for heterogeneity (p = 0.003). This was caused by the study of Licastro 
et al., which was an outlier with a very high odds ratio (Figures 2 and 3).24 We did not exclude 
this study, as the exclusion would only shift the non-significant results further towards the 
null value, and would not lead to a significant difference in the overall outcome.
DISCUSSION
In this prospective population-based study no significant association between the IL-6 -174 
G/C genotype and CHD or MI was found, nor was there an association with plasma levels of 
IL-6. A higher CRP plasma level was found among subjects with the C-allele. Adjusting for 
possible confounders and analyses in various substrata, did not alter these findings. A meta-
analysis, including our own study, showed no significant association between the genotype 
and risk of CHD. 
Our study is based on a large ongoing population based study in a relatively homogeneous 
population, as 98% of the participants in our study are Caucasians and are all living in the 
same area, a suburb of Rotterdam. In contrast to case control studies, the prospective nature 
of our study makes our results less prone to survival bias. We adjusted all analyses for estab-
lished risk factors, but this did not change the estimates.
Results from previous studies on this IL-6 -174 G/C polymorphism and CHD were incon-
sistent (Table 3).15,19-26 In the LURIC cohort and several other studies no association between 
this polymorphism and CHD was found.15,19,20,25 Other studies as the ECTIM Study and a study 
based on the CHS cohort, found a higher risk of CHD associated with the C-allele.21-24,26 All 
studies on IL-6 genotype and CHD were performed in Western populations with predomi-
nantly male subjects with an average age of 50 years and over. It is therefore unlikely that 
differences in findings are due to ethnicity, gender or age differences between the studies.
In order to provide a better overview of (inconsistent) findings of various studies, we also 
studied the association between the IL-6 genotype and risk of CHD by performing a meta-
analysis, which made it possible to study a very large number of events. This meta-analysis 
also did not show an association between the genotype and risk of CHD. Publication bias is 
always an important potential source of bias in meta-analyses. However, studies have been 
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published both with positive and negative findings on the association between the polymor-
phism and risk of CHD and the funnel plot does not suggest a strong publication bias.
There is also no consensus on the effect of the genotype on plasma levels of IL-6 and 
CRP.14,15,19-21,23,25,26 The C-allele in our study was significantly associated with higher CRP 
plasma levels. In most studies showing an effect of the C-allele on plasma levels, the C-allele 
was associated with higher plasma levels of both IL-6 and CRP. 20,21,26,33 This is pathophysi-
ologically plausible as CRP is produced in the liver and IL-6 is a hepatocyte stimulant, so 
elevated IL-6 levels will result in higher CRP levels. However, IL-6 has been described to be 
too unstable in time (plasma half-life of less than 2 hours) to be measured precisely.34,35 In 
Table 3. Overview of Studies on the IL-6 –174 G/C Polymorphism and Risk of Coronary Heart Disease
Study Population
RR
GG GC CC
Georges et al., 
2001
(ref. 22)
Cases:
Controls:
Population:
Age:
640
719
UK, France – males
25-64 yrs
1.0 * 1.35 † (1.05-1.73) 1.31 (0.94-1.84)
Humphries et 
al., 2001
(ref. 21)
Follow-up:
Population:
Age (mean):
2751 (2560 cases and 160 controls)
UK – males
57 yrs (cases) / 56 yrs (controls)   
1.0 * 1.54 † (1.06-2.22) 1.11 (0.67-1.83)
Basso et al., 
2002
(ref. 20)
Cases:
Controls:
Population:
Age (mean):
498
1109
Scotland – males
56 yrs (cases & controls)
1.0 * 1.07 (0.77-1.48) 1.26 (0.83-1.91)
Nauck et al., 
2002.
(ref. 19)
Cases:
Controls:
Population:
Age (mean):
2559
729
Germany – males & females
64 yrs (cases) / 58 yrs (controls) 
1.0 * 0.98 (0.79-1.16) 0.95 (0.75-1.20)
Jenny et al., 
2002
(ref. 23)
Cases:
Controls:
Population:
Age (mean):
770 + 250
500
USA (Caucasians + African) – males 
& females
73 yrs 
1.0 * 1.50 † (1.05-2.14)
Bennet et al., 
2003
(ref. 15)
Cases:
Controls:
Population:
Age (mean):
1179
1528
Sweden – males & females
59 yrs (males, cases & controls)
63 yrs (females, cases & controls)
1.0 *
1.0 *
-
-
1.1 ‡ (0.8-1.4)
0.8 § (0.6-1.3)
Licastro et al., 
2004
(ref. 24)
Cases:
Controls:
Population:
Age (mean):
139
198 
Italy - males
65 yrs (cases) / 57 yrs (controls) 
1.0 * 2.65 † (1.53-4.62)
Lieb et al., 2004
(ref. 25)
Cases:
Controls:
Population:
Age (mean):
1322
1023 
Germany – males & females
58 yrs & 56 yrs (2 case groups) /
52 yrs (controls)
1.0 * 0.92 || (0.78-1.10)
* reference, † significant, ‡ men, § women, || not provided in original article; the relative risk mentioned is 
derived from our meta-analysis
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addition, there was a limited sample size of IL-6 plasma levels. Given the short half-life, larger 
numbers would have been needed to detect a relatively small difference in IL-6 levels. This 
might explain the lack of association between the genotype and IL-6 plasma levels in our 
study. 
In our study, we did not find a clear association between genotype and risk of CHD. This may 
be related to the fact that the functionality of the polymorphism, at least with respect to the 
extent of the influence on IL-6 plasma levels, has not been definitively established. Although 
an effect on transcription and IL-6 levels was described, the view presented by Terry et al., 
whereby the effect is cell-specific and dependent on complex interactions between several 
polymorphisms, rather then on an individual polymorphism, might be more applicable.18,33,36 
This implies that the solitary -174 G/C genotype might influence plasma levels, but not in a 
substantial way. 
There is evidence for the IL-6 -174 G/C polymorphism to be in linkage disequilibrium (LD) 
with other functional, but less frequently investigated, polymorphisms -597 G/A and -572 
G/C, and with possibly functional polymorphisms in the -373 AT run.37-42 Because of this LD, 
these polymorphisms were not considered in our analyses, as analyzing these would provide 
similar information.
In conclusion, we did not find a significant relation between the IL-6 promoter polymor-
phism -174 G/C and risk of CHD. Based on our analyses and results from our meta-analysis, we 
conclude that the polymorphism does not have a prominent role in the pathogenesis of CHD 
and is therefore not a suitable genetic marker for increased risk of CHD. 
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Transforming Growth Factor-β1 Polymorphisms and 
Myocardial Infarction and Stroke
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Background and purpose - Inflammation plays a pivotal role in the pathogenesis of ath-
erosclerosis and of cardio- and cerebrovascular complications. Transforming growth factor 
β1 (TGF-β1) is a pleiotropic cytokine with a central role in inflammation. Little is known of 
the relation of variations within the gene and risk of cardio- and cerebrovascular disease. We 
therefore investigated five polymorphisms in the TGF-β1 gene (-800 G/A, -509 C/T, codon 10 
Leu/Pro, codon 25 Arg/Pro and codon 263 Thr/Ile) in relation to risk of myocardial infarction 
and stroke in a population-based study.
Methods - 6456 participants of the Rotterdam Study were included in the current study. 
Analyses on the relations of the genotypes with risk of myocardial infarction and stroke were 
performed using Cox proportional hazards methods. All analyses were adjusted for age, sex, 
conventional cardiovascular risk factors and medical history.
Results - We found no association with risk of myocardial infarction. A significantly increased 
risk of stroke was found, associated with the T-allele of the -509 C/T polymorphism (RR = 
1.26, CI 1.06-1.49) and with the Pro-variant of the codon 10 polymorphism (RR = 1.24, CI 
1.04-1.48). 
Conclusions - No association of the TGF-β1 polymorphisms and myocardial infarction was 
observed; however, the -509 C/T and codon 10 Leu/Pro polymorphisms were associated with 
risk of stroke.
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INTRODUCTION
Inflammation is an essential part in the pathogenesis of atherosclerosis and consequently, of 
coronary heart disease and cerebrovascular disease.1,2 Inflammation is influenced by many 
different cytokines, such as transforming growth factor β1 (TGF-β1), the most common variant 
of three isoforms.3 TGF-β has many different functions, both pro- and anti-atherogenic. Some 
consider the overall effect of TGF-β to be protective, reducing risk of cardio- and cerebrovas-
cular disease.4-10 Others describe TGF-β as inducing or facilitating cardio- and cerebrovascular 
pathology such as vascular stenosis and thrombogenesis.11-16 
The TGF-β1 gene is located on chromosome 19q13.2. There are several commonly known 
(potentially) functional polymorphisms in this gene. Cambien et al. described the -988 C/A, 
-800 G/A, -509 C/T polymorphisms (promoter region); a C-insertion at position +72 (non-
translated region); and codons 10 Leu/Pro (c10) and 25 Arg/Pro (c25) (signal peptide se-
quence) and 263 Thr/Ile (c263) (precursor part of the protein).17 Strong linkage disequilibrium 
(LD) between the polymorphisms was described.17,18 The +72 was in almost complete linkage 
disequilibrium (with c25); -988 C/A was extremely rare.17 Grainger et al. described the -509 
C/T polymorphism to be associated with levels of TGF-β1.19 
The c25 polymorphism was associated with cardiovascular disease in several studies, as 
was the c10 polymorphism.17,20-22 However, other studies reported no association with cardio-
vascular disease.17,18,20,23 To our knowledge, none of the polymorphisms was ever studied in 
relation to risk of stroke in a general population. 
We studied the TGF-β1 -800 G/A, -509 C/T, c10, c25 and c263 polymorphisms in relation to 
the risk of myocardial infarction and stroke in a large population-based study.
METHODS
Study Population
The Rotterdam Study is an ongoing prospective cohort study including 7983 participants 
of 55 years and older. Its general aims are to investigate determinants of chronic diseases.24 
During the first phase (1990-1993), all inhabitants of the Rotterdam suburban area (Om-
moord) aged 55 years and over were invited to participate. Baseline investigations included 
an interview and visits to the research center, where a varied number of measurements were 
performed. Approval of the Medical Ethics Committee of the Erasmus University Rotterdam 
was obtained for the Rotterdam Study. From all participants written informed consent was 
acquired. An in depth description of the Rotterdam Study was given in previously published 
literature.24 
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Clinical Characteristics
Skilled investigators collected information using a computerized questionnaire. The informa-
tion included current health status, medical history, drug and smoking behavior. Blood sam-
ples were obtained and established cardiovascular risk factors were measured as described 
elsewhere.25 Diabetes mellitus (DM) was defined as a non-fasting / post-load serum glucose 
level of 11.1 mmol/l and over, and/or use of antidiabetics. A 12-lead electrocardiogram was 
recorded and was analyzed by the Modular ECG Analysis System (MEANS).26 A diagnosis of 
atrial fibrillation was based on ECG data and/or confirmation by a subject’s general practitio-
ner (GP).
Follow-up Procedures and Definition of Events 
General practitioners in the research district, with whom 85% of the participants were en-
listed, reported fatal/non-fatal cardiovascular events. Research assistants verified all informa-
tion by checking medical records at the GPs’ offices. All medical records of the participants 
under the care of general practitioners outside the study area were checked annually. Letters 
and discharge reports from medical specialists were obtained. Information on the vital status 
of participants was obtained regularly from the municipal health authorities in Rotterdam. 
After notification, cause and circumstances of death were established by a questionnaire 
from the GPs. Two research physicians independently coded all reported cardiovascular 
events according to the International Classification of Diseases, 10th edition (ICD-10) (World 
Health Organization, 1992).27 Codes on which the research physicians disagreed were dis-
cussed in order to reach consensus. Finally, a medical expert in cardiovascular disease, whose 
judgement was considered final, reviewed all events. Incident myocardial infarction (MI) 
was defined as the occurrence of a fatal or non-fatal MI (ICD-10 code I21) after the baseline 
examination. Medical records of subjects with history of stroke were verified. For reported 
events, additional information was obtained from hospital records. Information on all poten-
tial strokes and transient ischaemic attacks were reviewed by both a research physician and 
an experienced stroke neurologist (P.J.K.) to verify all diagnoses. Subarachnoid hemorrhages 
and retinal strokes were excluded. Stroke was subclassified as ischaemic when a CT or MRI 
scan, made within 4 weeks after the stroke occurred, ruled out other diagnoses, or when 
indirect evidence (deficit limited to 1 limb or completely resolved within 72 hours, atrial fibril-
lation in absence of anticoagulants) pointed at an ischaemic nature of the stroke. A stroke 
was subclassified as hemorrhagic when a relevant hemorrhage was shown on CT or MRI scan, 
or when the subject lost consciousness permanently or died within hours after onset of focal 
signs. If a stroke could not be subclassified, it was called unspecified.
Genotyping
Genotyping of the TGF-β1 polymorphisms (-800 G/A [rs1800468], -509 C/T [rs1800469], codon 
10 Leu/Pro [T/C] [rs1982073], codon 25 Arg/Pro [G/C] [rs1800471] and codon 263 Thr/Ile [C/T] 
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[rs1800472]) was performed, regardless of disease status, using blood samples, acquired by 
venepuncture, stored earlier at -80 degrees centigrade. DNA was isolated using standard 
procedures. Genotypes were determined in 2-ng genomic DNA with the Taqman allelic dis-
crimination assay (Applied Biosystems, Foster City, California). Primer and probe sequences 
were optimized by using the SNP assay-by-design service of Applied Biosystems (for details, 
see http://store.appliedbiosystems.com). Reactions were performed with the Taqman Prism 
7900HT 384 wells format in 2 μL reaction volume. The polymorphisms were selected based 
on (potential) functionality (-800 G/A and -509 C/T located in promotor; codons 10, 25 and 
263 resulting in an amino-acid change) and literature, making comparison and replication 
feasible.
Measurement of IL-6 and CRP Plasma Levels
Levels of IL-6 and CRP were determined in samples obtained at baseline. These methods have 
been described previously.28
Population for Analysis
The Rotterdam Study is comprised of 7983 subjects. The current study included participants 
based on the largest successfully genotyped group, i.e., 6456 participants (for the -800 G/A 
polymorphism). Of these, 6392 subjects were successfully genotyped for the -509 C/T poly-
morphism, and 6187 for codons 10, 25 and 263.
Statistical Analyses
Chi-square tests were performed to test for deviations from HWE. Missing data were im-
puted using Expectation-Maximization algorithms. Baseline characteristics were tested using 
analyses of variance and logistic regression analyses adjusted for age and sex. As correction 
for outliers in serum measurements all values above mean plus three times the standard 
deviation were excluded. Natural-log transformed (ln-transformation) values of IL-6 and CRP 
levels were used to normalize the distribution of these variables. Cox proportional hazards 
analyses were performed in order to obtain relative risks. All analyses were adjusted for age 
and sex, and additionally for body mass index (BMI), systolic blood pressure, high-density 
lipoprotein (HDL) and total cholesterol levels, baseline smoking and DM, and additionally 
with adjustment for a history of MI/stroke/atrial fibrillation, or with exclusion of subjects with 
a history of MI/stroke. A p-value of 0.05 and smaller was considered significant. Statistical 
analyses were performed using SPSS version 11.0.1 for MS-Windows. 
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RESULTS
A total of 6456 participants were included. Baseline characteristics are described in Table 
1. Few and small differences in clinical characteristics between the genotypes were found 
(Table 2). During a mean follow-up of 9.2 (± 3.0) years, 358 incident cases of MI and 540 
incident cases of stroke, of which 312 ischaemic strokes and 51 haemorrhagic strokes were 
identified. At baseline 756 (12%) subjects had a history of MI and 191 (3%) of stroke.
Genotyping of the TGF-β1 polymorphisms was performed for all five polymorphisms: -800 
G/A (n = 6456), -509 C/T (n = 6392), c10 (n = 6187), c25 (n = 6187) and c263 (n = 6187). All 
Table 1. Baseline Characteristics
Characteristic
Overall MI Stroke Ischaemic 
Stroke
Total number 6456 358 540 312
Age – yrs 69.5 ± 9.1 70.3 ± 7.8 74.3 ± 8.5 71.9 ± 7.5
Male sex – % 41 61 42 46
Body mass index – kg/m2 26 ± 4 26 ± 3 26 ± 4 27 ± 3
Systolic blood pressure – mm Hg 139 ± 22 143 ± 21 149 ± 22 147 ± 20
Diastolic blood pressure – mm Hg 74 ± 11 74 ± 11 75 ± 12 75 ± 11
Total cholesterol – mmol/l 6.6 ± 1.2 6.9 ± 1.2 6.5 ± 1.2 6.6 ± 1.2
HDL-cholesterol – mmol/l 1.3 ± 0.4 1.2 ± 0.3 1.3 ± 0.4 1.3 ± 0.4
Smoking – % Current
 Former
 Never
22
43
34
24
51
24
24
40
36
27
43
31
Diabetes – % 10 17 19 16
CRP*† – mg/L 1.8 (0.8-3.5) 1.9 (1.6-3.7) 1.7 (0.9-3.0) 2.1 (1.0-3.3)
IL-6*‡ – pg/L 1.9 (1.2-2.9) 2.1 (1.0-4.3) 2.3 (1.6-3.7) 2.0 (1.5-3.7)
Incident events
Incident MI – no. (%) 358 (6) - - 33 (6) 21 (7)
Incident stroke – total – no. (%) 540 (8) 33 (9) - - - -
Incident stroke – ischaemic – no. (%) 312 (5) 21 (6) 312 (58) - -
Data on CT/MRI available – no. (%) - - - - 326 (60) 280 (90)
History
History of MI – no. (%) 756 (12) 84 (24) 91 (17) 59 (19)
History of stroke – no. (%) 191 (3) 17 (5) 47 (9) 25 (8)
History of atrial fibrillation – no (%) 327 (5) 17 (5) 55 (10) 24 (8)
Continuous variables: mean ± SD
CRP = C-reactive protein
IL-6 = interleukin 6
MI = myocardial infarction
* Median (interquartile range)
† Based on n = 5941
‡ Based on n = 643
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genotype and allele proportions were in HWE, except for c263 (p = 0.00078), which was not 
included in the analyses. 
For any of the four analyzed polymorphisms, no significant associations with risk of MI 
were found, when comparing individuals heterozygous and homozygous for the risk allele 
with those with the wildtype genotype (Table 3). Also when comparing homozygotes versus 
non-homozygotes, and carriers versus non-carriers, no evidence for an association with risk 
of MI was found. 
Continuous variables: mean ± SD
CRP = C-reactive protein
IL-6 = interleukin 6
* Median (interquartile range)
† Based on n = 5941
‡ Based on n = 643
§ -800 GA > GG (p = 0.05)
|| -800 GA < GG (p = 0.04)
# -800 GA < GG (p = 0.05)
** -509 TT < CC (p = 0.09) and TT < CT (p = 0.02)
†† -509 TT > CT (p = 0.01)
‡‡ c10 Leu/Pro < Leu/Leu (p = 0.04)
§§ c10 Pro/Pro < Leu/Leu (p=0.03)
All analyses are age and sex adjusted
Table 3. Relative Risk of Myocardial Infarction by Genotype
Myocardial Infarction
Polymorphism Genotype Events/total (%) RR 95% CI
-800 G/A GG 288/5359 (5) 1.00
GA 66/1050 (6) 1.22 0.93-1.59
AA 4/47 (9) 1.59 0.59-4.26
A-Carrier 70/1097 (6) 1.23 0.95-1.60
-509 C/T CC 171/3214 (5) 1.00
CT 156/2597 (6) 1.15 0.93-1.43
TT 28/581 (5) 0.88 0.59-1.31
T-Carrier 184/3178 (6) 1.10 0.89-1.35
c10 Leu/Pro Leu-Leu 135/2457 (5) 1.00
Leu-Pro 164/2862 (6) 1.04 0.83-1.31
Pro-Pro 44/868 (5) 0.88 0.63-1.24
Pro-Carrier 208/3730 (6) 1.00 0.81-1.24
c25 Arg/Pro Arg-Arg 297/5289 (6) 1.00
Arg-Pro 45/868 (5) 0.89 0.65-1.22
Pro-Pro 1/30 (3) 0.49 0.07-3.49
Pro-Carrier 46/898 (5) 0.88 0.64-1.20
Wildtype is reference
Analyses are age/sex adjusted
RR = Relative risk
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Subjects with the -509 CT genotype had a significantly increased risk of stroke compared 
with those with the wildtype genotype (CC) (relative risk (RR) 1.27, 95% confidence interval 
(CI) 1.06-1.51, p=0.01) (Table 4). Also T-allele-carriers had a significantly increased relative risk 
of 1.26 (CI 1.06-1.49, p=0.01) compared with non-carriers. For ischaemic stroke, we found an 
increased risk for both subjects with the CT genotype compared with the wildtype CC (RR 
1.29, CI 1.02-1.63, p=0.03) and T-allele-carriers in comparison with non-carriers (RR 1.29, CI 
1.03-1.61, p=0.03) (Table 5).
For the c10 polymorphism, a significantly increased risk of stroke of 1.24 (CI 1.03-1.50, 
p=0.03) for subjects with the Leu/Pro genotype was found, compared with the wildtype 
genotype (Leu/Leu) (Table 4). Pro-carriers also were at increased risk when compared with 
non-carriers: RR 1.24 (CI 1.04-1.48, p=0.02). For ischaemic stroke a consistently, but non-sig-
nificantly, increased risk was observed for subjects with the Leu/Pro genotype and Pro/Pro 
genotype, as well as for Pro-carriers (Table 5). 
The -800 G/A and c25 polymorphisms were not associated with risk of (ischaemic) stroke 
(Tables 4 & 5).
Table 4. Relative Risk of Stroke by Genotype
Stroke
Polymorphism Genotype Events/total (%) RR 95% CI
-800 G/A GG 450/5359 (8) 1.00
GA 89/1050 (8) 1.03 0.82-1.29
AA 1/47 (2) 0.25 0.04-1.78
A-Carrier 90/1097 (8) 1.00 0.79-1.25
-509 C/T CC 243/3214 (8) 1.00
CT 241/2597 (9) 1.27 1.06-1.51 *
TT 49/581 (8) 1.21 0.89-1.65
T-Carrier 290/3178 (9) 1.26 1.06-1.49 †
c10 Leu/Pro Leu-Leu 185/2457 (8) 1.00
Leu-Pro 259/2862 (9) 1.24 1.03-1.50 ‡
Pro-Pro 76/868 (9) 1.23 0.94-1.61
Pro-Carrier 335/3730 (9) 1.24 1.04-1.48 §
c25 Arg/Pro Arg-Arg 445/5289 (8) 1.00
Arg-Pro 74/868 (9) 1.02 0.80-1.30
Pro-Pro 1/30 (3) 0.35 0.05-2.48
Pro-Carrier 75/898 (8) 0.99 0.78-1.27
Wildtype is reference
Analyses are age/sex adjusted
RR = Relative risk
* p = 0.01
† p = 0.01
‡ p = 0.03
§ p = 0.02
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All analyses were adjusted for age and sex. Further adjustments for BMI, systolic blood 
pressure, HDL- and total cholesterol levels, smoking and diabetes mellitus, did not essentially 
change our estimates (data not shown). Additional analyses, either with adjustment for his-
tory of cardiovascular disease, or with exclusion of subjects with a history of cardiovascular 
disease, yielded essentially similar results (data not shown).
Separate analyses for males and females yielded no consistent results different from the 
overall analyses (data not shown).
DISCUSSION
In this prospective population-based study we found no significant association between four 
common TGF-β1 polymorphisms and risk of MI. We did find, however, an increased risk of 
stroke, associated with the risk alleles of the -509 C/T and c10 Leu/Pro polymorphisms. 
To date, few studies have been published on the association of the TGF-β1 polymorphisms 
-800 G/A, -509 C/T, c10 and c25 and risk of myocardial infarction. To our knowledge, there are 
no previous studies on the association of these polymorphisms with risk of stroke in a general 
population. 
Table 5. Relative Risk of Ischaemic Stroke by Genotype
Ischaemic Stroke
Polymorphism Genotype Events/total (%) RR 95% CI
-800 G/A GG 263/5359 (5) 1.00
GA 48/1050 (5) 0.95 0.70-1.30
AA 1/47 (2) 0.43 0.06-3.03
A-Carrier 49/1097 (4) 0.93 0.69-1.26
-509 C/T CC 138/3214 (4) 1.00
CT 140/2597 (5) 1.29 1.02-1.63 *
TT 31/581 (5) 1.28 0.86-1.88
T-Carrier 171/3178 (5) 1.29 1.03-1.61 †
c10 Leu/Pro Leu-Leu 109/2457 (4) 1.00
Leu-Pro 142/2862 (5) 1.15 0.89-1.47 
Pro-Pro 48/868 (6) 1.26 0.90-1.77
Pro-Carrier 190/3730 (5) 1.17 0.93-1.49
c25 Arg/Pro Arg-Arg 261/5289 (5) 1.00
Arg-Pro 37/868 (4) 0.86 0.61-1.21
Pro-Pro 1/30 (3) 0.58 0.08-4.14
Pro-Carrier 38/898 (4) 0.85 0.60-1.19
Wildtype is reference
Analyses are age/sex adjusted
RR = Relative risk
* p = 0.03
† p = 0.03
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The TGF-β polymorphisms have been studied before in relation to coronary heart disease 
(CHD) (Table 6): the c25 polymorphism was associated with risk of CHD in several larger and 
smaller studies, as was the c10 polymorphism.17,20-22 However, (other) studies reported no 
associations with risk of CHD.17,18,20,23 Overall, the sparse results available are not consistent.
TGF-β is a pleiotropic cytokine with a diversity of effects, both pro- and anti-atherogenic. It 
is not known yet what the overall effect of TGF-β is on atherogenesis and associated morbid-
ity. Some consider an adequate level of TGF-β to be protective, reducing risk of cardio- and 
cerebrovascular disease.4-10 Indeed, Cipollone et al. postulated a stabilizing effect of increased 
expression of TGF-β on atherosclerotic plaques.29 Others assume that high levels are the 
cause of adverse events, inducing or facilitating cardio- and cerebrovascular pathology such 
as vascular stenosis and thrombogenesis.11-16 
The -800 G/A and -509 C/T polymorphisms are located in the promoter region. Their precise 
effect is still unknown, but due to their location, they are considered possible modulators 
of expression of the TGF-β gene and levels.17,19 The c10 and c25 polymorphisms are located 
in the signal peptide sequence; this sequence is involved in export of synthesized proteins 
across membranes of the endoplasmatic reticulum.17 They are also located at potentially 
Table 6. Literature Overview on Studies of TGF-β Polymorphisms and Coronary Heart Disease 
Study N (cases) Population Polymorphism Events Result Remarks
Cambien et 
al. (ECTIM 
study, 1996)
1192 (563) France/UK -988 C/A
-800 G/A
-509 C/T
+72 C-insertion
c10 Leu/Pro
c25 Arg/Pro
c263 Thr/Ile
Myocardial 
infarction
For c25 Pro-carriers vs 
non-carriers overall risk 
of MI: 1.40 (p<0.05)
Rao et al. 
(HEMO Study, 
2004)
183 (115) USA (44% 
African-
American)
c10 Leu/Pro
c25 Arg/Pro
Vascular disease For c25 heterozygotes 
vs. wildtype risk of 
vascular disease: 3.05 
(p<0.01)
End-stage renal 
disease patients
Syrris et al. 
(1998)
899 (655) UK -800 G/A
-509 C/T
c10 Leu/Pro
c25 Arg/Pro
c263
CAD No association with 
CAD (p>0.05 for all 
polymorphisms)
Wang et al. 
(1998)
371 Australia -509 C/T CAD severity 
and myocardial 
infarction
No association with 
severity of CAD 
(p=0.646) or history 
of MI
Number of events 
and p-value for MI 
not specified
Yokota et al. 
(2000)
906 (315) Japan c10 Leu/Pro Myocardial 
infarction
For male c10 Leu-
carriers vs. non-carriers 
risk of MI: 3.5 (p<0.001)
Holweg et al. 
(2001)
252 (72 
of 236 
surviving 
patients)
Netherlands c10 Leu/Pro
c25 Arg/Pro
Graft vascular 
disease (GVD) 
(form of 
accelerated 
CAD)
For c10 Pro-Pro vs. 
wildtype risk of GVD: 7.7 
(p=0.03)
For c25 no associations 
(p=0.09)
Heart 
transplantation 
patients
CAD = coronary artery disease, MI = myocardial infarction
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important positions that influence activation of the TGF-β protein.18 We found an association 
with increased risk of (ischaemic) stroke for the -509 C/T and c10 Leu/Pro polymorphisms. 
For c10 Leu/Pro the findings in the overall stroke group were somewhat stronger than in the 
ischaemic stroke group; we have no explanation for this. Overall, the associations between 
the polymorphisms and (ischaemic) stroke may very well be due to changes in expression or 
activity of TGF-β. It is unclear why similar effects on risk of MI were not observed.
Our study is based on a large ongoing population-based study in a relatively homoge-
neous population, as 98% of the participants are Caucasian and living in the same area. In 
contrast to case-control studies, the prospective nature of our study makes our results less 
prone to survival bias. We adjusted for common cardiovascular risk factors, including history 
of cardiovascular disease. Because of high linkage disequilibrium between the four polymor-
phisms (D’ ≥ 0.97, data not shown), we did not use haplotypes/haplotype-based analyses. 
Unfortunately, no levels of TGF-β were determined. Therefore we were not able to elucidate 
the effect of the polymorphisms on levels. Despite the fact that the Rotterdam Study is a large 
study, (small) effects may have been missed due to the limited number of cases.
In conclusion, we found no association between the TGF-β1 -800 G/A, -509 C/T, c10 and 
c25 polymorphisms and risk of MI. We observed, however, a significant but small associa-
tion between the -509 C/T and c10 Leu/Pro polymorphisms and risk of stroke. These results 
warrant further studies, with larger numbers, to consolidate these findings, to investigate 
the functional effects of these polymorphisms and to study the underlying pathophysiologi-
cal mechanism. Only after replication in other studies implications of these findings can be 
discussed.
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Background and purpose - Arterial stiffness increases with age and is a precursor of car-
diovascular disease. Interleukin 6 is an inflammatory cytokine influencing the acute-phase 
response and inflammatory cascade, such as up-regulation of C-reactive protein. The inter-
leukin 6 -174 G/C promoter polymorphism influences levels of inflammatory markers, which 
are associated with arterial stiffness. We studied the association of this polymorphism and 
plasma levels of interleukin 6 and C-reactive protein with arterial stiffness.
Methods - The study (n=3849) was embedded in the population-based Rotterdam Study. 
Analyses on the association between the -174 G/C polymorphism and arterial stiffness were 
performed using analyses of variance. Analyses on the plasma levels of inflammatory mark-
ers and arterial stiffness were performed using linear regression analyses. All analyses were 
adjusted for age, sex, mean arterial pressure, heart rate, known cardiovascular risk factors and 
atherosclerosis. 
Results - We found pulse wave velocity to be 0.3 m/s higher for CC vs. GG-homozygotes 
(p=0.024) with evidence for an allele-dose effect (p=0.029), and a similar, although non-sig-
nificant, pattern for pulse pressure. No apparent consistent association with the distensibility 
coefficient was found. C-reactive protein plasma levels were associated with pulse wave 
velocity (p=0.007), and inversely, although not significantly, with the distensibility coeffi-
cient. Interleukin 6 plasma levels were similarly, but not significantly, associated with arterial 
stiffness.
Conclusions - The interleukin 6 -174 G/C polymorphism and CRP plasma levels are associated 
with increased arterial stiffness.
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INTRODUCTION
Arterial stiffness increases with age and has been associated with hypertension, diabetes 
mellitus (DM), end-stage renal disease and atherosclerosis.1-6 Arterial stiffness has recently 
been established as a predictor of cardiovascular events.7-10 The extent of the increase in stiff-
ness may depend on various factors, such as genetic variations. 
Inflammatory markers, such as interleukin 6 (IL-6) and C-reactive protein (CRP), and general 
systemic inflammation have been found to be associated with arterial stiffness.11-14 However, 
it is not clear whether this is a causal relation, or a (confounding) effect via atherosclerosis. 
After all, inflammation has an important role in atherosclerosis and the atherosclerotic 
process itself implies increased stiffness. Therefore, further study into genetic variation in 
the inflammatory pathway in relation to arterial stiffness may provide more information on 
potential pathophysiological mechanisms. Significant heritability estimates have been found 
for arterial stiffness, suggesting a role of genetic factors.15
Interleukin 6 is a pleiotropic cytokine with many different functions. It plays an important 
role in the acute-phase response and inflammatory cascade, such as up-regulation of acute-
phase proteins as CRP.16-19 An association between IL-6 levels and increased arterial stiffness 
has been described.12,20,21 Also elevated CRP levels have been shown to be associated with 
increasing pulse pressure and increased arterial stiffness.11-14 Fishman et al. detected a func-
tional polymorphism in the promoter region of the human IL-6 gene (G -> C, 174 bp upstream 
from the start site).22 This polymorphism appears to influence the IL-6 gene transcription and 
is associated with elevated CRP levels.22-26 
To the best of our knowledge, the IL-6 gene has not been studied in relation to arterial 
stiffness. We therefore studied the association of the interleukin 6 -174 G/C promoter poly-
morphism, arterial stiffness and plasma levels of interleukin 6 and C-reactive protein within 
the Rotterdam Study.
METHODS
The Rotterdam Study is an ongoing prospective cohort study including 7983 participants of 
55 years and older. Its general aims are to investigate determinants of chronic diseases.27 Dur-
ing the first phase of this study (1990-1993), all inhabitants from a Rotterdam suburban area 
(Ommoord) aged 55 years and over were invited to participate in this study. The response rate 
was 78%. The third examination phase took place from 1997-1999, during which measures of 
arterial stiffness were performed. Approval of the Medical Ethics Committee of the Erasmus 
University Rotterdam was obtained for the Rotterdam Study. From all participants written 
informed consent was acquired. A more in depth description of the Rotterdam Study was 
published previously.27
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Genotyping
Genomic DNA was extracted from samples of peripheral venous blood according to standard 
procedures. Genotyping methods were described more in-depth previously.24
Measurement of IL-6 and CRP Plasma Levels
Levels of IL-6 and CRP were determined in plasma samples obtained at baseline during the 
first phase of the Rotterdam Study. The methods were described previously.24 
Arterial stiffness
Arterial stiffness was measured using the carotid-femoral pulse wave velocity (PWV) as mea-
sure of aortic stiffness and the distensibility coefficient (DC) of the common carotid artery 
as measure of common carotid arterial stiffness, and in addition also pulse pressure (PP). 
Validation studies have been performed.6,28 All measures were obtained during the same 
session. The methods were described more in-depth previously.9,14,29
Clinical Characteristics
Information on cardiovascular risk factors was collected during the third follow-up exami-
nation by trained investigators. At the research center, measurements were performed by 
skilled, as described previously.27 Blood pressure was measured twice on the right arm using 
a random-zero sphygmomanometer. The average of the two blood pressure values was used 
in the analyses. Length and weight were measured and body mass index (kg/m2) (BMI) was 
calculated. Serum total cholesterol and high-density lipoprotein (HDL) cholesterol values 
were determined by an automated enzymatic procedure (Boehringer Mannheim System). 
Diabetes mellitus (DM) was defined as use of anti-diabetic medication and/or a fasting serum 
glucose level of equal to or above 7.0 mmol/L.30 Evaluation of the atherosclerotic status of 
participants was accomplished using ultrasonography (carotid intima-media thickness [IMT]) 
and radiography (aortic calcification); the methods used, are similar to those that have been 
extensively described and validated previously.6,31-33
Population for Analysis
A total of 4024 subjects, generally Caucasian, underwent the physical examination of the 
third phase and PWV was measured in 3550 subjects; 69 subjects (1.9%) were excluded from 
the analyses because of poor quality of the PWV index recordings, leaving 3481 subjects 
(3207 successfully genotyped) whereas common carotid distensibility was measured in 
3098 subjects (2836 successfully genotyped). PP measurements could be determined for all 
subjects participating in the third phase (3833 successfully genotyped). For 3849 genotyped 
subjects, data were available on one or more measures of arterial stiffness. Missing informa-
tion on measures of arterial stiffness was almost entirely due to logistic reasons. 
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Statistical Analyses
Chi-square tests were performed to test for deviations from Hardy-Weinberg equilibrium. 
Missing data in clinical characteristics were imputed using Expectation-Maximization algo-
rithms available in SPSS. For serum measurements all values above mean plus three times 
the standard deviation were excluded, as correction for outliers. Natural-log transformed (ln-
transformation) values of IL-6 and CRP plasma levels were used to normalize the distribution 
of these variables. The association between genotype and arterial stiffness was investigated 
using analyses of variance. Analyses on the association of IL-6 and CRP levels and arterial 
stiffness were performed using linear regression. All analyses were adjusted for age and sex, 
and (if applicable) additionally for mean arterial pressure (MAP) and heart rate (model 1), and 
additionally for body mass index, high-density lipoprotein (HDL) and total cholesterol levels, 
smoking and diabetes mellitus (model 2) and finally also for atherosclerosis (carotid IMT and 
aortic calcification) (model 3). A p-value of 0.05 and smaller was considered significant in all 
analyses. The statistical analyses were performed using SPSS version 11.0.1 for MS-Windows. 
RESULTS
General characteristics are described in Table 1 (ln-transformed data are back transformed). 
Genotype and allele proportions were in Hardy Weinberg equilibrium (p=0.18). 
Figure 1. Association of IL-6 –174 G/C and Pulse Wave Velocity
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The C-allele of the -174 G/C polymorphism (frequency: 40%) was significantly associated 
with an increased PWV, with evidence for an allele-dose effect (Figure 1). After adjustment 
for age, gender, MAP and heart rate, this trend was significant (model 1, p=0.027), and re-
mained significant after further adjustment for cardiovascular risk factors (model 2, p=0.040) 
and atherosclerosis (model 3, p=0.029). The association was lost after additional adjustment 
for plasma levels of IL-6 and CRP (data not shown). CC-homozygotes had a 0.3 m/s higher 
PWV than wildtype GG homozygotes (model 1, p=0.028; model 2 p=0.036; model 3 p=0.024) 
(Figure 1). 
The association of the IL-6 polymorphism and the carotid DC is less clear; it was increased in 
the heterozygotes (-174 GC) compared with the wildtype genotype, but this was not shown 
in CC-homozygotes (Figure 2). No significant trend was observed (model 1 p=0.564, model 2 
p=0.483, model 3 p=0.487).
Table 1. Population Characteristics by IL6 –174 G/C Genotype
Characteristic GG GC CC
Total number – No. (%) 1390 (36) 1830 (48) 629 (16)
Age – yrs 72 ± 7 72 ± 7 73 ± 7
Male sex – % 42 43 41
Body mass index – kg/m2 27 ± 4 27 ± 9 27 ± 4
Systolic blood pressure – mm Hg 143 ± 21 143 ± 22 144 ± 21
Diastolic blood pressure – mm Hg 75 ± 11 75 ± 11 75 ± 11
Mean Arterial Pressure – mm Hg 106 ± 13 107 ± 13 107 ± 13
Total cholesterol – mmol/l 5.8 ± 1.0 5.8 ± 1.0 5.8 ± 0.9
HDL-cholesterol – mmol/l 1.4 ± 0.4 1.4 ± 0.4 1.4 ± 0.4
Smoking – % Current 28 32 30
 Former 39 37 38
 Never 33 31 32
Diabetes – % 8 9 10
Intima Media Thickness – mm 0.77 ± 0.14 0.78 ± 0.12 0.78 ± 0.14
Aortic calcifications – %* 22 23 20
Pulse Wave Velocity – m/s 13.4 ± 2.9 13.5 ± 3.1 13.8 ± 3.2
Distensibility Coefficient – 1/MPa 10.4 ± 4.2 10.6 ± 4.4 10.1 ± 4.3
Pulse Pressure – mm Hg 68 ± 17 68 ± 18 69 ± 17
C-reactive protein – mg/L†§ 2.2 ± 2.3 2.6 ± 2.8 2.5 ± 2.7
Interleukin-6 – pg/mL‡§ 2.1 ± 1.5 2.3 ± 1.7 2.2 ± 1.8
Continuous values are depicted as mean ± SD
Numbers based on genotyped subjects with data on either pulse wave velocity (PWV) and/or 
distensibility coefficient (DC) and/or pulse pressure (PP)
* Percentage of subjects with aortic calcification over a length of ≥ 2.5 cm
† Data available for 3556 subjects (n = 1285 [GG], n = 1694 [GC], n = 577 [CC])
‡ Based on random subgroup of 433 subjects (n = 158 [GG], n = 212 [GC], n = 63 [CC])
§ Measured in samples obtained during first phase of Rotterdam Study
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The -174 G/C polymorphism appeared to be related to increased PP in a similar pattern as 
for PWV, although these findings were not significant (age/gender-adjusted trend p=0.061, 
after further adjustment trend p=0.094) (Figure 3).
CRP plasma levels were significantly associated with PWV (regression coefficient [natural 
log transformed] 0.208 mg/L, 95% CI 0.119 - 0.298) (Table 2). This association remained sig-
nificant after full adjustment (Table 2). An inverse, but after full adjustment non-significant, 
relation of CRP levels and the DC was shown (Table 2).
Analyses of IL-6 plasma levels showed a positive, although not significant, association with 
PWV (Table 3). A significant inverse association was found between IL-6 plasma levels and the 
DC within model 1 (Table 3). After full adjustment, this association remained near significant 
(Table 3).
All analyses stratified by gender yielded no results essentially different from the overall 
analyses.
Table 2. Association of Pulse Wave Velocity and Distensibility Coefficient with Levels of C-reactive protein
Pulse Wave Velocity (n=2995) β 95% CI p
Model 1 0.208 0.119 – 0.298 < 0.000
Model 2 0.159 0.067 – 0.250 0.001
Model 3 0.124 0.034 – 0.215 0.007
Distensibility Coefficient (n=2634) β 95% CI p
Model 1 -0.219 -0.347 – -0.091 0.001
Model 2 -0.098 -0.231 – 0.034 0.147
Model 3 -0.058 -0.191 – 0.074 0.389
Presented values are natural-log transformed
Models 1-3 are described in the methods section
Table 3. Association of Pulse Wave Velocity and Distensibility Coefficient with Levels of Interleukin-6 
Pulse Wave Velocity (n=316) β 95% CI p
Model 1 0.411 -0.135 – 0.956 0.139
Model 2 0.259 -0.300 – 0.818 0.362
Model 3 0.149 -0.402 – 0.701 0.594
Distensibility Coefficient (n=281)
Model 1 -0.696 -1.316 – -0.076 0.028
Model 2 -0.631 -1.281 – 0.018 0.057
Model 3 -0.593 -1.237 – 0.051 0.071
Presented values are natural-log transformed
Models 1-3 are described in the methods section
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Figure 2. Association of IL-6 –174 G/C and Distensibility Coefficient
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Figure 3. Association of IL-6 –174 G/C and Pulse Pressure
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DISCUSSION
We studied a well-known functional polymorphism in the promoter region of the Interleukin 
6 gene, -174 G/C in relation to arterial stiffness. The C-allele of the polymorphism was signifi-
cantly associated with increased PWV and showed a similar relation with PP, although not 
significantly. CRP plasma levels were significantly associated with PWV. Plasma levels of IL-6 
also appeared to be related (although not significantly) with arterial stiffness.
The -174 G/C polymorphism is located in the promotor of the IL-6 gene and may influence 
gene-transcription. In some studies no effect of this polymorphism on IL-6 and CRP levels 
was found.34-37 However, other studies describe it to influence IL-6 and of CRP levels.22,23,25,26,38,39 
Indeed, in a previous study in the Rotterdam Study the C-allele was associated with increased 
CRP plasma levels, but not with IL-6 plasma levels.24 However, we consider an association 
with IL-6 levels biologically likely, and contribute our finding to a very limited number of IL-6 
samples.24
Interleukin 6 (IL-6) is a pleiotropic cytokine with many different inflammatory functions, 
e.g. upregulation of CRP.16-19 IL-6 levels have been associated with arterial stiffness. Diamant 
et al. described a positive association of IL-6 and CRP levels and increased arterial stiffness 
in a small Dutch population (n=32) in both type 2 DM patients as well as in healthy con-
trols.20 Mahmud et al. described an association of IL-6 and CRP levels and PWV in a study 
of Irish hypertensives (n=78).21 In a Greek healthy population (n=100) Vlachopoulos et al. 
also showed IL-6 and CRP levels to be correlated with PWV.12 In a much larger study of 9867 
healthy Americans, CRP levels were associated with PP, a manifestation of arterial stiffness.40 
Within the Rotterdam Study an association between CRP plasma levels and PWV was shown 
in 866 subjects, which was confirmed in our larger sample of 2995 subjects.14 Further, Kullo et 
al. found a relation between CRP levels and PWV in an American population (n=214).11 
As CRP and IL-6 plasma levels are associated with arterial stiffness, our findings of a signifi-
cant association of the polymorphism and increased PWV, is biologically plausible. Although 
not significant, the similar findings for PP are in concordance herewith. We consider the 
higher DC for heterozygous a chance finding and unlikely to reflect the true relation of the -
174 G/C polymorphism and the DC, since literature and our other analyses suggest an inverse 
association (i.e., increased arterial stiffness). 
We also found a significant association of CRP plasma levels and PWV. The number of cur-
rently available CRP levels within the Rotterdam Study was more than three times larger than 
the number available at the time of our previous analyses; the results of our present study 
are, also after additional adjustment for atherosclerosis, in concordance with these earlier 
findings.14 Our findings suggest IL-6 levels to be related to PWV, although this association 
was not significant. IL-6 has been described to be too unstable in time (plasma half-life of less 
than 2 hours) to be measured precisely.41,42 In addition, the sample size of subjects with IL-6 
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measurements was limited. This might explain the lack of a significant association between 
PWV and IL-6 plasma levels.
Our study is based on a large ongoing population-based study in a relatively homogeneous 
population, as 98% of the participants in our study are Caucasian and are all living in the 
same area, a suburb of Rotterdam. We adjusted all analyses for established cardiovascular risk 
factors. The DC has a strong correlation with mean arterial pressure; a higher mean arterial 
pressure in the artery stretches the elastin and collagen fibres in the arterial wall, making the 
arteries less distensible. Therefore, the analyses were adjusted for mean arterial pressure. 
Some additional issues need to be addressed: findings on PWV were significant, but on 
the DC were not. To interpret these findings, several methodological aspects of the mea-
sures of stiffness need to be discussed. First, using the distance between the carotid and the 
femoral arteries leads to an overestimation of the real distance travelled by the pulse wave, 
resulting in higher mean values of aortic PWV. Second, the use of a tape measure over the 
surface of the body may lead to an overestimation of the distance travelled by the pulse 
wave, and therefore we adjusted for body mass index. Third, in computing the carotid DC, 
we used the brachial PP rather than the carotid PP. Information on comparisons between 
carotid and brachial PPs indicates that there is a difference between these pressures.43 These 
findings indicate that using brachial artery PP instead of carotid artery PP may have led to an 
underestimation of the distensibility. This may lead to an underestimation of the association 
with the genotype. It has been suggested to derive carotid artery PP with the use of brachial 
artery PP.44 However, to perform this procedure, brachial mean pressure should be measured 
directly, whereas in our study this was computed from blood pressure components by the 
Korotkoff sound method. Therefore, we cannot exclude the possibility that other methods 
for assessing carotid distensibility show a clearer association with the genotype. The meth-
odological aspects, however, are not likely to be related to the genotype and will thus not 
have biased our results.
Furthermore some general remarks: data on measures of stiffness were not available for 
all subjects who visited the research center. However, missing information was primarily due 
to logistic reasons, which is likely to be random and thus will not have biased our results. 
Second, the cross-sectional design may limit the ability to infer a causal relationship between 
the IL-6 -174 G/C polymorphism and arterial stiffness. Furthermore, because our study was 
performed in a population of predominantly elderly Caucasian subjects, the generalizability 
of our findings to younger individuals or other ethnicities remains uncertain. Finally, there 
are more polymorphisms in the IL-6 gene in addition to the -174 G/C polymorphism. Indeed, 
there is evidence for the IL-6 -174 G/C polymorphism to be in linkage disequilibrium (LD) with 
other functional, but less frequently investigated, polymorphisms -597 G/A and -572 G/C, 
and with possibly functional polymorphisms in the -373 AT run.45-50 Because of this LD, these 
polymorphisms were not considered in our analyses.
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In conclusion, the C-allele of the interleukin 6 -174 G/C promoter polymorphism is as-
sociated with increased PWV, independently of atherosclerosis. Our results consolidate the 
finding that CRP plasma levels are associated with PWV in an elderly population. It is likely, 
that the gene influences stiffness through its association with CRP and IL-6 plasma levels, as 
the effect was attenuated when the analyses were adjusted for levels.
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Background and purpose - With age arterial stiffness increases and has been found to 
predict cardiovascular disease. C-reactive protein (CRP) is an inflammation marker and has 
been found to be associated with arterial stiffness and risk of cardiovascular disease. Genetic 
factors account for part of the variance in CRP serum level. We studied the association of the 
total common variation in the CRP gene by polymorphisms 1184 C/T, 2042 C/T, 2911 C/G and 
haplotypes with arterial stiffness within the Rotterdam study.
Methods - The study (n=3615) was embedded in the Rotterdam Study, a prospective, 
population-based study among subjects aged 55 years and older. Associations of genotypes 
and haplotypes with the CRP serum level and measures of arterial stiffness were examined 
using linear regression and analyses of variance. Measures of arterial stiffness included aortic 
pulse wave velocity, carotid distensibility and pulse pressure. Analyses were adjusted for age, 
sex, mean arterial pressure, heart rate, known cardiovascular risk factors and measures of 
atherosclerosis. 
Results – The CRP serum level was significantly associated with pulse wave velocity (p<0.001) 
and pulse pressure (p<0.05), also after adjusting for cardiovascular risk factors. CRP level was 
also increased for carriers of the 1184 T-allele and 2911 G-allele and decreased for carriers 
of the 2042 T-allele (all p<0.001). Genotype and haplotype analyses showed no consistent 
associations of genetic variation with pulse wave velocity, carotid distensibility and pulse 
pressure.
Conclusions - No consistent associations of the CRP polymorphisms 1184 C/T, 2042 C/T, 2911 
C/G and corresponding haplotypes were found with measures of arterial stiffness, although 
CRP serum levels were associated with pulse wave velocity and pulse pressure, and the indi-
vidual polymorphisms were associated with the CRP serum level.
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INTRODUCTION
With age arterial stiffness increases and has been associated with hypertension, diabetes 
mellitus, end-stage renal disease and atherosclerosis.1-6 Arterial stiffness has been found to 
predict cardiovascular events in various populations.7-10 The extent of the increase in stiffness 
may also depend on genetic variation. 
Arterial stiffness has been found to be associated with inflammatory markers such as C-re-
active protein (CRP).11-16 However, it is not clear whether the association is causal, or whether 
the effect is mediated through atherosclerosis. After all, inflammation has been established 
as marker of atherosclerosis and the atherosclerotic process itself affects arterial stiffness. 
Studies of genetic variation in the inflammatory pathway in relation to arterial stiffness may 
provide more insight into the underlying mechanisms. Heritability estimates for levels of CRP 
vary from 27% up to 40%, which suggests genetic variation to have an effect on bioavail-
ability of CRP.17,18 If genetic variation in CRP can be found to be related to arterial stiffness, this 
would support evidence for a causal role of CRP in the loss of elasticity of the vessel wall.
The CRP gene is located on chromosome 1 (1q21-q23). SeattleSNPs (part of the National 
Heart Lung and Blood Institute’s Programs for Genomic Applications) reports that four CRP 
gene haplotypes are present in populations of European descent. These haplotypes repre-
sent all common variation across the CRP gene in these populations and can be inferred from 
three tagging polymorphisms, 1184 C/T, 2042 C/T and 2911 C/G. 
In order to clarify the role of genetic variation in the CRP gene in the development of arte-
rial stiffness, we set out to investigate CRP polymorphisms 1184 C/T, 2042 C/T and 2911 C/G 
and resultant haplotypes in relation to arterial stiffness within the Rotterdam Study.
METHODS
The Rotterdam Study is an ongoing prospective cohort study including 7983 participants 
of 55 years and older. Its general aims are to investigate determinants of chronic diseases, 
including cardiovascular disease, dementia and osteoporosis.19 During the first phase of 
this study (1990-1993), all inhabitants of a Rotterdam suburban area (Ommoord) aged 55 
years and over, were invited to participate in this study. The response rate was 78%. The third 
examination phase took place from 1997-1999, during which measurements of arterial stiff-
ness were performed. Approval of the Medical Ethics Committee of the Erasmus University 
Rotterdam was obtained for the Rotterdam Study. From all participants written informed 
consent was acquired. A more in depth description of the design of the Rotterdam Study was 
published previously.19
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Measurement of CRP Serum Levels
Serum levels of CRP were determined in blood samples obtained during the third examina-
tion phase of the Rotterdam Study and stored at -80 degrees centigrade. High-sensitivity 
CRP measurements were performed using rate near-infrared particle immunoassay (Immage 
Immunochemistry System; Beckman Coulter, San Diego, CA). 
Genotyping and Haplotyping
The Seattle SNPs Program for Genomic Applications has identified 31 SNPs in the CRP gene 
and has established that, based on SNPs with overall frequencies above 5%, four common CRP 
gene haplotypes are present in 23 unrelated individuals of European descent from the CEPH 
pedigrees (http://pga.gs.washington.edu/data/crp). These four haplotypes are identified by 
“haplotype tagging” SNPs. By genotyping three haplotype tagging SNPs we were able to 
infer all four haplotypes and consequently to describe the total common variation across the 
CRP gene. These three tagging SNPs were chosen partly based on their presence in existing 
literature and on their proximity to the CRP gene. Genotyping of the CRP 1184 C/T, 2042 C/T 
and 2911 C/G polymorphisms [also described in relation to the start of the coding sequence 
of exon 1 using the Human May 2004 (hg 17) assembly (http://genome.ucsc.edu), and also 
at http://www.ncbi.nlm.nih.gov/projects/SNP/ under identification numbers rs1130864 
(1184C/T), rs1205 (2042C/T) and rs3093068 (2911C/G)] was performed using samples stored 
earlier at -80 degrees centigrade. DNA was isolated using standard procedures. Genotypes 
were determined in 2-ng genomic DNA with the Taqman allelic discrimination assay (Applied 
Biosystems, Foster City, California). Primer and probe sequences were optimized by using the 
SNP assay-by-design service of Applied Biosystems (for details, see http://store.appliedbio-
systems.com). Reactions were performed with the Taqman Prism 7900HT 384 wells format in 
2 μl reaction volume. 
Haplotypes were estimated using PHASE software (http://archimedes.well.ox.ac.uk).20 
Haplotypes with a frequency of <0.001% were not used in the analyses. The remaining 4 
haplotypes were coded from 1 to 4 in decreasing order of their population frequency (coding 
from 1184C/T, 2042C/T and 2911C/G, haplotype 1=C-T-C, 2=T-C-C, 3=C-C-C and 4=C-C-G) 
(Figure 1).
Arterial Stiffness
In this study three measures of arterial stiffness were used: the carotid-femoral pulse wave 
velocity (PWV) as a measure of aortic stiffness and the distensibility coefficient (DC,) of the 
common carotid artery as a measure of common carotid arterial stiffness. In addition, pulse 
pressure (PP) was assessed as an indicator of arterial stiffness. All measures were obtained on 
the same day, during the same session, during the third follow-up examination. Details on all 
measures of stiffness have been described previously.6,7
Variation in the C-reactive Protein Gene and Arterial Stiff ness 69
Carotid-femoral PWV (m/s) was measured using an automatic device (Complior, Colson) 
and was calculated as the ratio between the distance traveled by the pulse wave and the 
foot-to-foot time delay.
Common carotid artery distensibility was assessed by measuring the vessel wall motion 
of the right common carotid artery using a duplex scanner (ATL Ultramark IV, operating 
frequency 7.5 MHz) connected to a vessel wall movement detector system.21,22 The cross-sec-
tional arterial wall DC (1/MPa) was calculated as a measure of arterial stiffness.23 A decreased 
DC implies increased carotid stiffness. 
PP (mmHg) was defined as the difference between systolic and diastolic blood pressure, 
using the mean systolic and diastolic blood pressure of two measurements obtained by 
measuring blood pressure on the right arm using a random-zero sphygmomanometer. 
Clinical Characteristics
Information on cardiovascular risk factors was collected during the third follow-up examina-
tion. Data on drug use and smoking habits were obtained during the home interview.
Smoking was classified as never, former or current smoking. At the research center, blood 
pressure was measured twice on the right arm using a random-zero sphygmomanometer. 
The average of the two blood pressure values was used in the analyses. Length and weight 
Figure 1. CRP Gene and Haplotypes
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were measured and body mass index (weight/height2) (BMI) was calculated. Serum total 
cholesterol and high-density lipoprotein (HDL) cholesterol values were determined by an 
automated enzymatic procedure (Boehringer Mannheim System). Diabetes mellitus (DM) 
was defined as use of anti-diabetic medication and/or a fasting serum glucose level of equal 
to or above 7.0 mmol/L.24 Evaluation of the atherosclerotic status of participants was accom-
plished using ultrasonography (carotid intima-media thickness [IMT]) and radiography (aorta 
calcification); these methods have been extensively described previously.25,26
Population for Analysis
The Rotterdam Study comprises 7893 subjects, of which 6007 subjects were successfully and 
completely genotyped for the CRP polymorphisms. A total of 4024 subjects underwent the 
physical examination of the third phase. PWV was measured in 3550 subjects; 69 subjects 
(1.9%) were excluded from the analyses because of poor quality of the PWV recordings, 
leaving 3481 subjects (3023 successfully genotyped for all polymorphisms). Common carotid 
distensibility was measured in 3098 subjects (2672 successfully genotyped for all polymor-
phisms). PP measurements could be determined for all subjects participating in the third 
phase (3601 successfully genotyped for all polymorphisms). For 2402 completely genotyped 
subjects, full data on both PWV, the distensibility coefficient and pulse pressure were avail-
able. For 3615 completely genotyped subjects data was available on one or more measures 
of arterial stiffness. CRP serum levels were successfully measured during the third phase in 
3824 subjects. Missing information on measures of arterial stiffness was almost entirely due 
to logistic reasons. 
Statistical Analyses
Chi-square tests were performed to test for deviations from Hardy-Weinberg equilibrium. 
Missing data on clinical characteristics were imputed using Expectation-Maximization al-
gorithms available in SPSS. For CRP measurements all values above mean plus three times 
the standard deviation were excluded, as correction for outliers. Natural-log transformed 
(ln-transformation) CRP serum levels were used to normalize the distribution of this variable. 
Haplotype analyses were allele-based: each haplotype-allele is considered individually in the 
analyses. The most common haplotype-allele is the reference (i.e., haplotype 1). Analyses on 
the associations of CRP levels and arterial stiffness were performed using linear regression. 
Analyses on genotypes and haplotypes in relation to CRP levels and arterial stiffness were 
performed using linear regression and analyses of variance. The analyses were adjusted for 
age and sex (and for PWV and DC also for mean arterial pressure (MAP) and heart rate), ad-
ditionally for systolic blood pressure (only when MAP was not in the model), BMI, HDL and 
total cholesterol levels, smoking, diabetes mellitus, and in the full model also for measures of 
atherosclerosis. A p-value of 0.05 and smaller was considered significant in all analyses. The 
statistical analyses were performed using SPSS version 11.0.1 for MS-Windows. 
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RESULTS
General characteristics of the subjects are described in Table 1. Genotype and allele propor-
tions were in Hardy Weinberg equilibrium. Haplotypes are described in Figure 1.
CRP Serum Level and Arterial Stiffness
The CRP serum level was positively associated with pulse wave velocity (p<0.001), also after 
full adjustment (Table 2). The CRP serum level was inversely associated with the distensibility 
coefficient (p<0.001), but only in the age and sex-adjusted analyses. The CRP serum level 
was positively associated with pulse pressure (p<0.001), which remained significant after 
additional adjustment for cardiovascular risk factors, but was borderline significant after 
additional adjustment for measures of atherosclerosis (p=0.06). 
Table 1. General Characteristics of the Study Population
Characteristic
Total number 3615
Age – yrs 72.4 ± 7.0
Male sex – % 43
Body mass index – kg/m2 27
Systolic blood pressure – mm Hg 144 ± 21
Diastolic blood pressure – mm Hg 75 ± 11
Mean Arterial Pressure – mm Hg 107 ± 13
Total cholesterol – mmol/l 5.8 ± 1.0
HDL-cholesterol – mmol/l 1.4 ± 0.4
Smoking – % Current
 Former
 Never
30
38
32
Diabetes – % 9
Pulse Wave Velocity* – m/s 13.6 ± 3.0
Distensibility Coefficient† – 1/MPa 10.4 ± 4.3
Pulse Pressure – mm Hg 68 ± 18
Intima Media Thickness – mm 0.77 ± 0.13
Aorta calcifications‡ – % 22
CRP§ – mg/L 2.4 (1.2-4.5)
Continuous values are depicted as mean ± SD
CRP = C-reactive protein
* Available for 3023 subjects
† Available for 2672 subjects
‡ Percentage of subjects with aorta calcification over a length of ≥ 2.5 cm
§ Median (interquartile range)
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CRP Serum Level by Genotype and Haplotype
CRP serum levels according to the genotype of the three CRP polymorphisms are shown in 
Figure 2. For all three polymorphisms we observed an allele dose effect (all p<0.001).
Differences in CRP serum level according to haplotypes are shown in Table 3. In comparison 
to the reference haplotype 1, the other haplotypes had a significantly higher serum level of 
Table 2. Relation between CRP Level and Arterial Stiffness
Pulse Wave Velocity 
(n=3252)
Distensibility Coefficient
(n=2876)
Pulse Pressure
(n=3721)
β-coefficient (SE) p β-coefficient (SE) p β-coefficient (SE) p
Model 1 0.206 (0.04) <0.001 –0.222 (0.063) <0.001 1.103 (0.279) <0.001
Model 2 0.168 (0.046) <0.001 –0.098 (0.067) 0.141 0.809 (0.289) 0.046
Model 3 0.143 (0.045) <0.001 –0.081 (0.066) 0.221 0.538 (0.283) 0.058
β-coefficient: regression coefficient based on ln-transformed CRP (C-reactive protein) levels
Model 1:  adjusted for age, sex (and for pulse wave velocity and the distensibility coefficient also for 
mean arterial pressure and heart rate) 
Model 2: model 1 + body mass index (BMI), total & HDL-cholesterol, smoking, diabetes mellitus
Model 3: model 2 + measures of atherosclerosis
Figure 2.  CRP level by CRP Genotype
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CRP (all p<0.001). Haplotype 2, 3 and 4 all contained one or more of the alleles associated 
with an increased CRP serum level in the genotype analyses.
CRP Gene and Pulse Wave Velocity
No significant associations between genotypes of the 1184 C/T or 2024 C/G polymorphisms 
and pulse wave velocity were found. Those with the 2911-GG genotype (n=18, mean 14.7 
m/s, CI 13.6-15.9) had a higher PWV compared with CG heterozygotes (n=336, mean 13.4 
m/s, CI 13.1-13.7) (p=0.03), but no significant trend was found, p=0.66. The haplotype-based 
analyses yielded no significant relations with arterial stiffness (Table 4).
Table 3. CRP levels by Haplotype of the CRP gene
Haplotype n CRP Level (mg/L) 95% CI
1* 1873 0.67 0.63 – 0.72
2 1809 0.87† 0.83 – 0.91
3 1716 0.79† 0.74 – 0.83
4 334 0.92† 0.81 – 1.02
Based on ln-transformed CRP (C-reactive protein) levels
Age and sex adjusted
*Haplotype 1 is reference
†Significant difference in comparison with reference haplotype 1, all p<0.001
Table 4. Measures of Arterial Stiffness by CRP Haplotype
Pulse Wave Velocity Distensibility Coefficient Pulse Pressure
Model Haplotype n m/s CI n 1/MPa CI n mmHg CI
1 1 1961 13.57 13.46 - 13.68 1732 10.38 10.22 - 10.54 2346 68.3 67.6 - 69.0
2 1903 13.67 13.56 - 13.78 1703 10.41 10.25 - 10.57 2285 68.5 67.8 - 69.2
3 1817 13.55 13.44 - 13.67 1597 10.42 10.26 - 10.58 2142 67.9 67.2 - 68.6
4 359 13.54 13.28 - 13.80 307 10.50 10.13 - 10.87 423 68.7 67.1 - 70.3
2 1 1961 13.57 13.46 - 13.68 1732 10.38 10.23 - 10.54 2346 68.3 67.6 - 68.9
2 1903 13.66 13.55 - 13.77 1703 10.41 10.26 - 10.57 2285 68.5 67.8 - 69.1
3 1817 13.56 13.45 - 13.67 1597 10.42 10.26 - 10.59 2142 67.9 67.2 - 68.6
4 359 13.53 13.27 - 13.78 307 10.45 10.08 - 10.81 423 68.7 67.1 - 70.3
3 1 1961 13.57 13.47 - 13.68 1732 10.39 10.23 - 10.54 2346 68.2 67.6 - 68.9
2 1903 13.67 13.56 - 13.78 1703 10.42 10.26 - 10.57 2285 68.5 67.8 - 69.2
3 1817 13.55 13.44 - 13.66 1597 10.41 10.25 - 10.57 2142 67.9 67.2 - 68.6
4 359 13.52 13.27 - 13.77 307 10.45 10.08 - 10.81 423 68.7 67.2 - 70.3
All differences in measures of stiffness between the genotypes were not significant
CRP = C-reactive protein
Model 1:  age, sex (and for pulse wave velocity and the distensibility coefficient also for mean arterial 
pressure and heart rate) 
Model 2: model 1 + body mass index, total + HDL-cholesterol, smoking, diabetes mellitus
Model 3: model 2 + measures of atherosclerosis
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CRP Gene and Distensibility Coefficient
Subjects with the 1184 TT genotype had a lower distensibility coefficient than heterozygotes 
(p = 0.04), also after adjustment for cardiovascular risk factors (Figure 4). The association, 
however, did not remain significant after additional adjustment for atherosclerosis. For 
polymorphisms 2042 C/G and 2911 C/T no significant differences in the distensibility coef-
ficient between the genotypes were found. In the haplotype-based analyses no significant 
differences were found (Table 4).
CRP Gene and Pulse Pressure
No significant associations were found of 1184 C/T (p=0.38), 2042 C/T (p=0.96) or 2911 C/G 
(p=0.49) with pulse pressure. The haplotype analyses also yielded no significant associations 
(Table 4).
Overall, analyses specified by gender yielded no essentially different results (data not 
shown).
DISCUSSION
We studied the association of the CRP polymorphisms 1184 C/T, 2042 C/T, 2911 C/G and 
haplotypes with arterial stiffness within the Rotterdam study. We found the CRP serum level 
to be positively associated with pulse wave velocity and with pulse pressure, independent of 
cardiovascular risk factors. The minor alleles of the 1184 C/T and 2911 C/G polymorphisms 
were positively associated with the CRP serum level, and the minor allele of the 2042 C/T 
polymorphism inversely. Overall, no consistent significant differences between the geno-
types and haplotypes of the CRP gene in pulse wave velocity, the distensibility coefficient or 
pulse pressure were found. 
The CRP 1184 C/T, 2042 C/T and 2911 C/G polymorphisms were chosen because together, 
they represent the total common genetic variation across the CRP gene. By genotyping these 
three haplotype tagging SNPs we were able to infer all four haplotypes, that describe the 
common variation across the CRP gene. Few studies have used this approach.27-29 Miller et al. 
and Carlson et al. used more tagging SNPs than in our study to describe common variation 
in the CRP gene.27,29 In these studies, however, ethnic diverse populations were used. For 
example, the population used in the study by Carlson et al. consisted of participants partly of 
European descent and partly of African descent. Therefore, more and other haplotypes were 
found and compared with the population of European descent used in our study. Both Miller 
et al. and Carlson et al. report associations between haplotypes and CRP levels that are in 
agreement with the associations between haplotypes and CRP levels in our study.28
While the studied genotypes and haplotypes were associated with CRP serum level, we 
found no consistent relation of the geno- and haplotypes of the CRP gene with arterial 
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stiffness. Only 2911-GG homozygotes had a higher pulse wave velocity in comparison to 
heterozygotes. Although this is in line with the association of the polymorphism with an 
increased CRP serum level, one has to take into account that the number of homozygous 
subjects was limited; this finding may therefore have been a chance finding. 
The absence of a relation between variation in the CRP gene with measures of arterial 
stiffness might suggest that the relation between the CRP serum level and arterial stiffness 
is not causal. The effect of variation in the CRP gene on CRP serum level, however, was only 
modest. Haplotype 2, 3 and 4 were associated with a higher CRP serum level compared with 
haplotype 1. The differences, however, varied only from 0.12-0.25 mg/L. In general, effects of 
genetic variation on a trait with a complex and multifactorial pathogenesis, such as arterial 
stiffness, are generally modest. Therefore, a small effect of genetic variation in CRP on arterial 
stiffness may have gone undetected and a judgment about causality cannot be given with 
certainty. 
The associations between the CRP polymorphisms/haplotypes and the level of CRP was 
described earlier in the Rotterdam Study.28 The same applies for the association between 
the CRP level (n=866) and pulse wave velocity.14 These studies, however, were based on CRP 
levels obtained at baseline. In the current study, we have used CRP levels obtained during the 
third examination phase of the Rotterdam Study. Our results are in concordance with these 
earlier results.
Although we found no clear association of genetic variation in the CRP gene and arterial 
stiffness, an association between the CRP level and arterial stiffness is nonetheless biologically 
plausible and may be explained in several ways.14 Increased CRP levels and impaired endo-
thelial dysfunction have found to be related before.30-34 Fichtlscherer et al. described CRP to 
be associated with decreased endothelial vasodilator function.34 CRP level is also described 
to be associated with various markers of endothelial dysfunction.32,33 Inflammatory processes 
inhibit endothelium-dependent vasodilatation.14,35 The endothelium itself produces vasoac-
tive substances, such as nitric oxide, which have been demonstrated to play a significant role 
in peripheral resistance, blood pressure and vascular reactivity.36,37 Furthermore, agonists that 
stimulate endothelial nitric oxide release, such as acetylcholine, reduce stiffness of muscular 
arteries in vivo.38,39 Basal nitric oxide production has been demonstrated to influence muscu-
lar arteries distensibility in vivo positively and the effect of acetylcholine on large arteries is 
also mainly nitric oxide-mediated.40 Increased CRP levels decrease nitric oxide production.31 
Therefore, as endothelium obviously plays an important role in the regulation of arterial 
stiffness, CRP-related impairment of endothelial function may very well lead to changes in 
arterial stiffness.14 
Our study is based on a large ongoing population-based study, in a relatively homogeneous 
population, as 98% of the participants in our study are Caucasian and are all living in the 
same area, a suburb of Rotterdam. We used both genotype and haplotype based analyses. 
We adjusted all analyses for established risk factors and measures of atherosclerosis. 
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To interpret the findings correctly, several methodological aspects of the measures of arte-
rial stiffness need to be discussed. First, pulse waves in the carotid artery and the femoral 
artery travel in opposite directions, while measurements of carotid-femoral pulse wave 
velocity is based on the assumption that the pulse wave travels from the carotid artery to 
the femoral artery. In this way, measuring the distance between the carotid and the femoral 
artery lead to an overestimation of the distance between the sites of the pulse waves result-
ing in overestimation of the velocity of the pulse waves. However, variations in anatomy are 
limited and this error may be considered similar for all subjects examined, therefore we do 
not think it has seriously biased our results. Second, the distance between the carotid and 
the femoral artery may be overestimated in (especially obese) subjects when this distance is 
measured by tape. To avoid this error we adjusted the analyses for body mass index. Third, in 
computing the carotid distensibility coefficient, we used the brachial pulse pressure rather 
than the carotid pulse pressure. Information on comparisons between the carotid and the 
brachial pulse pressure indicates that the carotid pulse pressure is lower than the brachial 
pulse pressure, but differences are relatively small.41
Data on measures of stiffness were not available for all subjects who visited the research 
center. Missing information was primarily due to logistic reasons, which is likely to be random 
and thus will not have biased our results. Furthermore, the advantage of the allele-based 
haplotype analysis is the increase in power in comparison with genotype-based analyses. 
However, the allele-based haplotype analyses offer no information on possible dominance 
or recessiveness. Finally, because our study was performed in a population of predominantly 
elderly Caucasian subjects, the generalizability of our findings to younger individuals or other 
ethnicities remains uncertain. 
In conclusion, genetic variation in the CRP gene, as expressed by polymorphisms 1184 
C/T, 2042 C/T and 2911 C/G and concurrent haplotypes, is not consistently and significantly 
associated with arterial stiffness. However, we cannot exclude a small effect, which was not 
detected in our study. Further and larger studies are needed for confirmation and to further 
elucidate the role of genetic variation in the CRP gene in arterial stiffness.
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Variation in the Transforming Growth Factor-β1 Gene 
and Arterial Stiffness
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Background and purpose - Arterial stiffness is a risk factor for cardiovascular disease. Trans-
forming growth factor β1 is a pleiotropic cytokine, with many functions, including influence 
on the vascular wall (e.g., on angiogenesis, endothelial cells and the extra-cellular matrix). 
We investigated five functional polymorphisms in the Transforming Growth Factor β1 gene 
(-800 G/A, -509 C/T, codon 10 Leu/Pro, codon 25 Arg/Pro and codon 263 Thr/Ile) in relation to 
arterial stiffness in a population-based study.
Methods - A total of 3863 participants of the Rotterdam Study, a prospective population-
based study, were included in the current study. The relations of the genotypes and haplo-
types with arterial stiffness (pulse wave velocity, distensibility coefficient and pulse pressure) 
were studied using analyses of variance and linear regression. The analyses were adjusted 
for age, sex, mean arterial pressure, heart rate, conventional cardiovascular risk factors and 
measures of atherosclerosis.
Results - There were no associations between pulse wave velocity and -800 G/A (p=0.56), 
-509 C/T (p=0.29), codon 10 (p=0.98), codon 25 (p=0.28). These polymorphisms were not 
associated with the distensibility coefficient or with pulse pressure. The haplotype based 
analyses yielded similar results.
Conclusions - The results of this study show that the TGF-β1 -800 G/A, -509 C/T, codon 10 
Leu/Pro and codon 25 Arg/Pro polymorphisms are not associated with arterial stiffness.
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INTRODUCTION
With increasing age, also arterial stiffness increases. Increased arterial stiffness is also associ-
ated with hypertension, diabetes mellitus (DM), end-stage renal disease and atherosclero-
sis.1-6 Recently, it has also been shown to be associated with increased risk of cardiovascular 
disease.7-9 The extent of the increase in stiffness may depend on various factors; it is likely 
that genetic variations play a role. Indeed, a recent study described heritability estimates of 
arterial stiffness (varying from 0.26 - 0.36).10
Transforming growth factor β (TGF-β) is a pleiotropic cytokine. In man, three isoforms (with 
largely similar functions) exist, of which TGF-β1 is the most common.11 Its effects include 
influence on T-cells, on the release of (other) cytokines and fibroblast growth factors, but it 
also exerts influence on the vascular wall, e.g. in angiogenesis, on endothelial cells and on 
modulation of the extra-cellular matrix.12-17 TGF-β also regulates (vascular) smooth muscle 
cell differentiation.18-21 Robertson et al. described that disruption of TGF-β signaling in mice 
led to decreased collagen in plaques. Others also found TGF-β to be associated with collagen 
upregulation in the vascular wall.13,15,18 Also Mallat et al. described TGF-β as a pro-fibrotic 
cytokine.14 Increased TGF-β has also been implicated in the fibrosclerotic process in varicose 
vessel walls.22 Variations in bioavailability of TGF-β levels may therefore influence arterial 
stiffness and the TGF-β gene is a candidate gene for further study of variation in arterial 
stiffness. 
The TGF-β1 gene (23.5 kb) is located on chromosome 19q13.2. There are several commonly 
known (potentially) functional polymorphisms in this gene. Cambien et al. described the 
-988 C/A, -800 G/A, -509 C/T polymorphisms (promoter region); a C-insertion at position 
+72 (non-translated region); and in addition codons 10 Leu/Pro (c10) and 25 Arg/Pro (c25) 
(signal peptide sequence) and 263 Thr/Ile (c263) (precursor part of the protein).23 Of these, 
+72 was in almost complete linkage disequilibrium with c25, while -988 C/A was extremely 
rare.23 Grainger et al. described the -509 C/T polymorphism to be associated with levels of 
TGF-β1.24
The TGF-β1 -800 G/A and -509 C/T polymorphisms are located in the promoter region; 
the full extent of their effect is still unknown, but due to their location, they are considered 
possible modulators of expression of the TGF-β gene and levels.23-25 The c10 and c25 polymor-
phisms are located in the signal peptide sequence, which is involved in export of synthesized 
proteins across membranes of the endoplasmatic reticulum, thereby possibly influencing 
TGF-β levels.23 The c10 and c25 polymorphisms are also located at potentially important 
positions that influence activation of the TGF-β protein.25 
To the best of our knowledge, these (potentially) functional polymorphisms have not been 
investigated in association with arterial stiffness before. We studied the association of the 
TGF-β1 -800 G/A, -509 C/T, c10, c25 and c263 polymorphisms and arterial stiffness in a large 
population-based study.
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METHODS
The Rotterdam Study is an ongoing prospective cohort study including 7983 participants 
of 55 years and older. Its general aims are to investigate determinants of chronic diseases.26 
During the first phase of this study (1990-1993), all inhabitants of a Rotterdam suburban area 
(Ommoord) aged 55 years and over were invited to participate in this study. The response rate 
was 78%. The third examination phase took place from 1997-1999, during which measures of 
arterial stiffness were performed. Approval of the Medical Ethics Committee of the Erasmus 
University Rotterdam was obtained for the Rotterdam Study. From all participants written 
informed consent was acquired. A more in depth description of the Rotterdam Study was 
published previously.26
Genotyping
Genomic DNA was extracted from samples of peripheral venous blood according to standard 
procedures. 1-2 ng genomic DNA was dispensed into 384-wells plates using a Caliper Sciclone 
ALH3000 pipetting robot (Caliper LS, Mountain View, CA, USA). Genotypes were determined 
using the Taqman allelic discrimination assay. The Assay-by-Design service (www.applied-
biosystems.com) was used to set up assays for the 800 G/A [rs1800468], -509 C/T [rs1800469], 
codon 10 Leu/Pro [T/C] [rs1982073]and codon 263 Thr/Ile [C/T] [rs1800472] polymorphisms. 
For codon 25 Arg/Pro [G/C] [rs1800471]an assay was set up using primer express 2.0 software 
(Applied Biosystems Inc., Foster City, CA, USA). The assays-by-design consisted of 5 ng of ge-
nomic DNA in a 2 ul volume and the following reagents: FAM and VIC probes (400 nM), prim-
ers (1,8 uM), 2x Taqman PCR master mix (ABgene). The assay for codon 25 consisted of 5 ng of 
genomic DNA in a 4 ul volume and the following reagents: FAM probes (250 nM), TET probe 
(500 nM), primers (300 nM), 2x Taqman PCR master mix (ABgene). Reagents were dispensed 
in a 384-well plate using the Deerac Equator NS808 (Deerac Fluidics, Dublin, Ireland). PCR 
cycling reaction were performed in 384 wells PCR plates in an ABI 9700 PCR system (Applied 
Biosystems Inc., Foster City, CA, USA) and consisted of initial denaturation for 15 minutes at 
95° C, and 40 cycles with denaturation of 15 seconds at 95° C and annealing and extension 
for 60 seconds at 60° C. Results were analysed by the ABI Taqman 7900HT using the sequence 
detection system 2.22 software (Applied Biosystems Inc., Foster City, CA, USA). To confirm the 
accuracy of genotyping results, 332 (5%) randomly selected samples were re-genotyped with 
the same method. All polymorphisms had an error rate lower than 1%. The polymorphisms 
were selected based on (potential) functionality (-800 G/A and -509 C/T located in promotor; 
codons 10, 25 and 263 resulting in an amino-acid change) and literature, describing previous 
research on these polymorphisms and cardiovascular disease.
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Haplotyping
Haplotypes were reconstructed using PHASE software (http://archimedes.well.ox.ac.uk). 
Genotype data of the four TGF-β1 polymorphisms in Hardy Weinberg equilibrium (-800 G/A, 
-509 C/T, codon 10 Leu/Pro and, codon 25 Arg/Pro) enabled us to distinguish the four most 
common haplotypes. They were coded as 1 to 4 in order of decreasing frequency in the popu-
lation (coding from -800 G/A, -509 C/T, c10 Leu/Pro, c25 Arg/Pro: haplotype 1 = G-C-Leu-Arg, 
haplotype 2 = G-T-Pro-Arg, haplotype 3 = A-C-Leu-Arg, haplotype 4 = G-C-Pro-Pro) (Figures 
1 & 2).
Figure 1. Linkage Disequilibrium between TGF-β1 Polymorphisms
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Figure 2. Overview of TGF-β1 Gene, Polymorphisms and Haplotypes
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Arterial Stiffness
In this study three measures of arterial stiffness were used: the carotid-femoral pulse wave 
velocity (PWV, or aortic stiffness) as a measure of aortic stiffness, the distensibility coefficient 
(DC, or carotid stiffness) of the common carotid artery as a measure of common carotid 
arterial stiffness and, in addition, pulse pressure (PP) was assessed as an indicator of arterial 
stiffness. All measures were obtained on the same day, during the same session, during the 
third follow-up examination. 
Carotid-femoral PWV (m/s) was measured using an automatic device (Complior, Colson) 
and was calculated as the ratio between the distance travelled by the pulse wave and the 
foot-to-foot time delay.
Common carotid artery distensibility was assessed by measuring the vessel wall motion 
of the right common carotid artery using a duplex scanner (ATL Ultramark IV, operating 
frequency 7.5 MHz) connected to a vessel wall movement detector system.27,28 The cross-
sectional arterial wall distensibility coefficient (DC) (1/MPa) was calculated as a measure of 
arterial stiffness.29 A decreased distensibility coefficient implies increased carotid stiffness. 
Pulse pressure (PP) (mmHg) was defined as the difference between systolic and diastolic 
blood pressure, using the mean systolic and diastolic blood pressure of two measurements 
obtained by measuring blood pressure on the right arm using a random-zero sphygmoma-
nometer. 
Details on all measures of stiffness, have been described previously.6,9
Clinical Characteristics
We collected information on cardiovascular risk factors during the third follow-up examina-
tion. During the home interview information was collected on medication use and smoking 
habits. Smoking was classified as never, former or current smoking. At the research centre, 
blood pressure was measured twice on the right arm using a random-zero sphygmomanom-
eter. The average of the two blood pressure values was used in the analyses. Hypertension 
was defined as having a systolic blood pressure of >= 160 mmHg and/or diastolic blood 
pressure of >= 100 mmHg and/or blood pressure lowering medication with an indication 
for hypertension. Height and weight were measured and body mass index (kg/m2) (BMI) was 
calculated. Serum total cholesterol and high-density lipoprotein (HDL) cholesterol values 
were determined by an automated enzymatic procedure (Boehringer Mannheim System). 
Diabetes mellitus (DM) was defined as use of anti-diabetic medication and/or a fasting serum 
glucose level of equal to or above 7.0 mmol/L.30 Evaluation of the atherosclerotic status of 
participants was accomplished using ultrasonography (carotid intima-media thickness [IMT]) 
and radiography (aorta calcification); these methods have been extensively described previ-
ously.31,32
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Population for Analysis
A total of 4024 subjects underwent the physical examination of the third phase and PWV was 
measured in 3550 subjects; 69 subjects (1.9%) were excluded from the analyses because of 
poor quality of the PWV recordings, leaving 3481 subjects, whereas common carotid disten-
sibility was measured in 3098 subjects. Information on the -800 G/A polymorphism and PWV 
measurements were available for 3221 subjects and on distensibility for 2845 subjects. For 
the -509 C/T polymorphism the corresponding numbers were 3174 and 2804 subjects. For 
codon 10, codon 25 and codon 263 corresponding numbers were 3113 and 2750 subjects. 
Data on pulse pressure was available for 3847 genotyped subjects. A total of 3863 subjects 
were successfully genotyped for at least one of the polymorphisms and information was 
available on either PWV, DC or PP. Of these, 3740 subjects were successfully haplotyped. Miss-
ing information on measures of arterial stiffness was almost entirely due to logistic reasons. 
Statistical Analyses
Chi-square tests were performed to test for deviations from Hardy-Weinberg equilibrium 
(HWE). Missing data in clinical characteristics were imputed using Expectation-Maximiza-
tion algorithms available in SPSS. The associations between the genotypes and haplotypes 
and arterial stiffness were investigated using analyses of variance and linear regression. The 
haplotype analyses were allele-based: each haplotype-allele (as opposed to a a haplotype-
allele pair) is considered and analyzed separately, using the outcomes and characteristics 
of the subject carrying that allele. The most common haplotype-allele is the reference (i.e., 
haplotype 1). All analyses were adjusted for age and sex, and (if applicable) additionally for 
mean arterial pressure (MAP), heart rate, body mass index, high-density lipoprotein (HDL) and 
total cholesterol levels, smoking, diabetes mellitus and measures of atherosclerosis (carotid 
IMT and aorta calcification). A p-value of 0.05 and smaller was considered significant in all 
analyses. The statistical analyses were performed using SPSS version 11.0.1 for MS-Windows. 
RESULTS
Genotype and allele proportions were in Hardy Weinberg Equilibrium, except for c263 (p = 
0.00078). Therefore, this polymorphism genotype was not included in the analyses. Haplo-
types are shown in Figures 1 & 2. General characteristics are described in Table 1.
No significant association was found between PWV and any of the polymorphisms, either 
in unadjusted analyses (model 1) or adjusted analyses (models 2 and 3) (Table 2). None of the 
tests for trend were significant (-800 G/A p = 0.559, -509 C/T p = 0.294, c10 p = 0.977 or c25 p = 
0.282). Full adjustment did not alter the findings. The haplotype-based analyses also showed 
no differences in PWV between the haplotypes (Table 3).
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The distensibility coefficient showed no association with any of the polymorphisms, except 
for a lower DC for subjects with the -509 TT in comparison to those with the CT-genotype 
(Table 2). No overall trends were shown for the -800 G/A polymorphism (p = 0.320), the -509 
C/T (p = 0.376), c10 (p = 0.215) or c25 (p = 0.866) in the unadjusted analyses. Further adjust-
ment did not alter these results. Also the haplotype-based analyses showed no differences in 
distensibility coefficient between any of the haplotypes (Table 3).
No association between pulse pressure and any of the genotypes was shown (Table 2). 
Also no trends were shown (-800 G/A p = 0.895; -509 C/T p = 0.549; c10 p = 0.824 and c25 p 
= 0.433). Further adjustment did not alter these results. Also the haplotype-based analyses 
showed no differences in pulse pressure between any of the haplotypes (Table 3).
The gender-stratified analyses showed no results essentially different from the overall 
analyses (data not shown). 
Table 1. General Characteristics
Characteristic
Total number 3863
Age – yrs 72.4 ± 7.0
Male sex – % 43
Body mass index – kg/m2 27 ± 7.0
Systolic blood pressure – mm Hg 143 ± 21
Diastolic blood pressure – mm Hg 75 ± 11
Mean Arterial Pressure – mm Hg 98 ± 13
Hypertension – % 33
Use of antihypertensives* – % 39
Total cholesterol – mmol/l 5.8 ± 1.0
HDL-cholesterol – mmol/l 1.4 ± 0.4
Smoking – % Current
 Former
 Never
30
38
32
Diabetes – % 9
Pulse Wave Velocity† – m/s 13.6 ± 3.0
Distensibility Coefficient‡ – 1/MPa 10.4 ± 4.3
Pulse Pressure – mm Hg 68.2 ± 17.5
Intima Media Thickness – mm 0.78 ± 0.13
Aorta calcifications§ – % 22
Continuous values are depicted as mean ± SD
*Based on any use of diuretics, β-blockers, Ca-antagonists, ACE-inhibitors and other antihypertensives
† Based on all participants with PWV information available (n = 3221)
‡ Based on all participants with DC information available (n = 2845)
§ Percentage of subjects with aorta calcification over a length of ≥ 2.5 cm
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Table 2. Measures of Arterial Stiffness by TGF-β Genotype 
n Pulse Wave 
Velocity (m/s)
p trend n Distensibility 
Coefficient 
(1/MPa)
p trend n Pulse 
Pressure  
(mm Hg)
p trend
–800 G/A GG 2669 13.58
(13.49-13.68)
0.559 2349 10.40
(10.27-10.54)
0.320 3203 68.20
(67.62-68.79)
0.895
GA 525 13.54
(13.33-13.76)
472 10.57
(10.27-10.87)
613 68.12
(66.78-69.46)
AA 27 13.24
(12.31-14.17)
24 10.56
(9.24-11.89)
31 67.94
(61.98-73.90)
–509 C/T CC 1576 13.56
(13.44-13.68)
0.294 1392 10.43
(10.26-10.60)
0.376 1887 68.37
(67.60-69.13)
0.549
CT 1279 13.59
(13.46-13.73)
1118 10.54
(10.34-10.73)
1526 68.07
(67.22-68.92)
TT 319 13.74
(13.47-14.01)
294 10.06
(9.68-10.44)
385 67.93
(66.24-69.62)
Codon 10 
Leu/Pro
Leu/
Leu
1231 13.63
(13.49-13.77)
0.977 1087 10.49
(10.29-10.69)
0.215 1482 68.14
(67.28-69.00)
0.824
Leu/
Pro
1413 13.53
(13.40-13.66)
1233 10.46
(10.27-1064)
1677 68.27
(67.46-69.08)
Pro/
Pro
469 13.69
(13.47-13.92)
430 10.22
(9.91-10.54)
565 68.30
(66.90-69.69)
Codon 25 
Arg/Pro
Arg/
Arg
2670 13.61
(13.52-13.71)
0.282 2353 10.43
(10.30-10.56)
0.866 3199 68.15
(67.56-68.73)
0.433
Arg/
Pro
432 13.46
(13.23-13.70)
381 10.51
(10.18-10.85)
507 68.55
(67.08-70.02)
Pro/
Pro
11 13.73
(12.27-15.19)
16 9.141
(7.52-10.77)
18 71.86
(64.06-79.66)
Measurements are depicted as: mean (95% confidence interval)
Adjusted for age and sex (and for pulse wave velocity and the distensibility coefficient also for mean 
arterial pressure and heart rate)
Table 3. Measures of Arterial Stiffness by TGF-β Haplotype
n Pulse Wave 
Velocity (m/s)
p trend n Distensibility 
Coefficient 
(1/MPa)
p trend n Pulse Pressure 
(mm Hg)
p trend
Haplotype 1 3294 13.60
(13.52-13.69)
0.239 2889 10.46
(13.34-13.58)
0.937 3961 68.23
(67.70-68.75)
0.813
2 1832 13.63
(13.51-13.74)
1630 10.35
(10.19-10.51)
2187 68.11
(67.40-68.81)
3 563 13.50
(13.30-13.71)
504 10.57
(10.28-10.862)
658 68.00
(66.72-69.29)
4 451 13.46
(13.23-13.68)
410 10.42
(10.10-10.74)
540 68.70
(67.28-70.12)
Measurements are depicted as: mean (95% confidence interval)
Adjusted for age and sex (and for pulse wave velocity and the distensibility coefficient also for mean 
arterial pressure and heart rate)
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DISCUSSION
We studied four well-known functional TGF-β1 polymorphisms (-800 G/A, -509 C/T, c10, c25) 
in relation to arterial stiffness. None of the polymorphisms were consistently and significantly 
associated with either pulse wave velocity, distensibility coefficient or pulse pressure in both 
genotype and haplotype-based analyses.
To the best of our knowledge, there are no previous studies on these polymorphisms and 
their association with arterial stiffness.
Although the TGF-β polymorphisms may influence expression or activity of TGF-β, and this, 
in turn, may influence arterial stiffness, we did not find these polymorphisms to be associated 
with arterial stiffness. We consider the finding of a significant difference in the distensibility 
coefficient between subjects with the -509 CT and TT genotype no valid evidence for an as-
sociation between the polymorphism and arterial stiffness, especially because this isolated 
finding was not supported by a corroborating trend or findings for PWV or PP. We hypothesize 
that any effects that these TGF-β polymorphisms might have on the vascular wall, do not lead 
to significant changes in arterial stiffness.
Our study is based on a large ongoing population-based study in a relatively homogeneous 
population, as 98% of the participants in our study are Caucasian and are all living in the 
same area, a suburb of Rotterdam. We used both genotype and haplotype based analyses. 
The distensibility coefficient has a strong correlation with mean arterial pressure. A high 
mean arterial pressure in the artery especially stretches the collagen fibers in the arterial wall, 
making the arteries less distensible. Consequently, the analyses were also adjusted for mean 
arterial pressure. We adjusted all analyses for established risk factors. As atherosclerosis and 
arterial stiffness are associated, we additionally adjusted for atherosclerosis.6
To interpret the findings correctly, several methodological aspects of the measures of arte-
rial stiffness need to be discussed. First, pulse waves in the carotid artery and the femoral ar-
tery travel in opposite directions, while measurements of carotid-femoral pulse wave velocity 
is based on the assumption that the pulse wave travels from the carotid artery to the femoral 
artery. In this way, measuring the distance between the carotid and the femoral artery lead 
to an overestimation of the distance between the sites of the pulse waves resulting in over-
estimation of the velocity of the pulse waves. However, variations in anatomy are limited and 
this error may be considered similar for all subjects and genotypes examined, therefore we 
do not think it has seriously biased our results. Second, the distance between the carotid and 
the femoral artery may be overestimated in (especially obese) subjects when this distance is 
measured by tape; to avoid this error we adjusted the analyses for body mass index.9 Third, 
in computing the carotid distensibility coefficient, we used the brachial pulse pressure rather 
than the carotid pulse pressure.9 Information on comparisons between the carotid and the 
brachial pulse pressure indicates that the carotid pulse pressure is lower than the brachial 
pulse pressure but differences are relatively small.33 Fourth, large topographic/anatomical 
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differences exist in the structure and function of the arterial system. As a consequence, 
arterial stiffness cannot be assessed by a single measurement at any random site within the 
arterial system. In the Rotterdam Study we use three diverse measures of arterial stiffness. We 
used pulse wave velocity, as this is the most generally accepted and robust measure of arte-
rial stiffness in general.34 Since the local measure of the carotid distensibility coefficient may 
also be of prognostic importance and offer additional information, we also used the carotid 
distensibility coefficient as a measure of stiffness.34 Additionally we used pulse pressure. This 
is not a direct measurement of stiffness, but it can be used as an additional non-invasive and 
readily obtainable indicator for arterial stiffness.  
Furthermore some general remarks need to be made. The effects of genetic variation on a 
trait with a complex and multifactorial pathogenesis, such as arterial stiffness, are generally 
modest. Power estimates for all analyses in this study were generally low (<80%). Our nega-
tive findings, therefore, do not exclude the possibility that small effects were not detected, 
however, it is unlikely that large effects were missed. Further, data on measures of stiffness 
were not available for all subjects. However, missing information was primarily due to logistic 
reasons, which is likely to be random and is unlikely to have introduced bias in our results. 
Furthermore, the cross-sectional design may limit the ability to infer a causal relationship 
between the TGF-β1 polymorphisms and arterial stiffness. Also, the generalizability of our 
findings to younger individuals or persons of other ethnicities remains uncertain, due to the 
fact that our population consisted of (mostly) elderly Caucasion subjects. Furthermore, the 
advantage of the allele-based haplotype analysis is the increase in power in comparison with 
genotype-based analyses. Also, the polymorphisms used in this study were selected based 
on potential functionality and literature. They were not selected as ‘tagging’ polymorphisms 
to cover all genetic variation in the TGF-β1 gene. Finally, the relation between the polymor-
phisms/haplotypes, arterial stiffness and plasma levels of TGF-β could not be investigated, 
because, unfortunately, no TGF-β levels were measured in the Rotterdam Study.
In conclusion: we found the TGF-β1 -800 G/A, -509 C/T, codon 10 Leu/Pro and codon 25 
Arg/Pro polymorphisms not to be associated with arterial stiffness, either in genotype or hap-
lotype-based analyses. However, we cannot exclude a small effect, which was not detected in 
our study. Additional studies are needed for confirmation and to further elucidate the effects 
of these potentially functional TGF-β1 polymorphisms on the vascular wall.
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Chapter 3.4
Variation in the Fibrinogen α and γ Genes and 
Arterial Stiffness
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Background and purpose - Arterial stiffness increases with age and has been found to pre-
dict cardiovascular disease. Fibrinogen is an acute phase protein and some studies showed 
an association with arterial stiffness. We studied genetic variation in the fibrinogen α (FGA) 
and γ (FGG) gene, by means of seven SNPs (FGA: -58 G/A, 1374 G/A, 1526 T/C and 312 Thr/Ala, 
and FGG: 4288 G/A, 6326 G/A and 7792 T/C) and the resultant haplotypes in relation to arte-
rial stiffness. 
Methods - This study (n=3891) was embedded in the Rotterdam Study, a prospective, popu-
lation-based study among subjects aged 55 years and older. Analyses on the associations 
of the fibrinogen plasma level, genotypes and haplotypes with aortic stiffness (pulse wave 
velocity), carotid stiffness (distensibility coefficient) and pulse pressure were performed us-
ing analyses of variance, linear regression and by using haplotypes analyses with haplotype 
1 as reference. The analyses were adjusted for age, sex, and, additionally, for mean arterial 
pressure, heart rate, known cardiovascular risk factors and measures of atherosclerosis. 
Results - Genotype analyses yielded significant associations of the FGA 1526 T/C (p=0.004), 
the FGA 312 Thr/Ala (p=0.008) and FGG 6326 G/A (p=0.024) polymorphisms with the fibrino-
gen plasma level. There were no consistent associations with measures of arterial stiffness at 
the genotype level. The fibrinogen plasma level was positively associated with aortic stiffness 
(p=0.015) and pulse pressure (p=0.049). Haplotype analyses showed FGA haplotype 4 to be 
associated with the fibrinogen plasma level (p=0.01) and pulse pressure (p<0.001). FGA 
haplotype 3 and FGG haplotype 4 were associated with aortic stiffness (p=0.03) and pulse 
pressure (p<0.001). No associations were found with carotid stiffness. 
Conclusions - These findings indicate that the fibrinogen plasma level and genetic variation 
in the fibrinogen α and γ gene may influence arterial stiffness. Further research is needed to 
confirm these findings and to elucidate the underlying mechanisms.
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INTRODUCTION
Normally, arterial stiffness increases with age and has been associated with hypertension, 
diabetes mellitus, end-stage renal disease and atherosclerosis.1-6 Arterial stiffness was found 
to predict cardiovascular events in various populations.7-10 
Acute-phase reactants and other inflammatory markers were found to be associated with 
arterial stiffness.11-17 Fibrinogen is a well-known coagulation factor, but in addition, it is an 
important acute-phase protein and it influences several processes, such as inflammation, 
angiogenesis and matrix interactions.18,19 Fibrinogen levels were previously associated with 
cardiovascular disease, which was recently reaffirmed in a large meta-analysis.20 Fibrinogen 
levels were also been observed to be associated with arterial stiffness. Among 114 Japanese 
diabetics, fibrinogen levels were higher among those with a high cardio-ankle vascular 
index, a measure of arterial stiffness.15 This was also shown in 2709 participants of the Strong 
Heart Study, where stiffness, assessed by pulse pressure/stroke index, was higher in those 
with elevated fibrinogen levels.16 In 2262 healthy Swedish men from the Malmö Diet and 
Cancer Study, elevated levels of fibrinogen and other inflammation-sensitive proteins were 
associated with increased pulse pressure.17 Overall, the heritability of the fibrinogen level 
was estimated at 45%, which suggests that genetic variation influences the bioavailability of 
fibrinogen.21 Therefore, fibrinogen genes are candidate genes for further study of determi-
nants of arterial stiffness.
Fibrinogen consists of two sets of three peptide chains (Aα, Bβ and γ) and is encoded 
by three genes (fibrinogen α [FGA], fibrinogen β [FGB] and fibrinogen γ [FGG]) located on 
chromosome 4q28 in a region of approximately 50 kb. The FGA and FGG genes are in close 
physical proximity and show a high degree of linkage disequilibrium (D’ ≥ 0.94) between 
them. Various polymorphisms were identified in the FGA and FGG genes. Common (hap-
lotype-tagging) polymorphisms in the FGA gene are -58 G/A, 1374 G/A, 1526 T/C and 312 
Thr/Ala and in the FGG gene 4288 G/A, 6326 G/A and 7792 T/C. Several of these were found 
to influence blood clot structure, clinical outcomes (such as embolisms, deep venous throm-
bosis and myocardial infarction) and fibrinogen levels.22-28 To our knowledge, however, these 
fibrinogen polymorphisms were not previously studied in relation to arterial stiffness. 
We studied genetic variation in the closely related FGA and FGG genes, using seven poly-
morphisms (FGA: -58 G/A, 1374 G/A, 1526 T/C and 312 Thr/Ala, and FGG: 4288 G/A, 6326 G/A 
and 7792 T/C) and the haplotypes they form, in relation to the fibrinogen plasma level and 
arterial stiffness in a large population-based study.
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METHODS
The Rotterdam Study is an ongoing prospective cohort study including 7983 participants 
aged 55 years and older. Its general aims are to investigate determinants of chronic diseases, 
including cardiovascular disease, dementia and osteoporosis.29 During the first phase of this 
study (1990-1993), all inhabitants of a Rotterdam suburb (Ommoord) aged 55 years and over 
were invited to participate in this study. The response rate was 78%. The third examination 
phase took place from 1997-1999, during which measurements of arterial stiffness were 
performed. Approval of the Medical Ethics Committee of the Erasmus University Rotterdam 
was obtained for the Rotterdam Study. All participants provided written informed consent. A 
more in depth description of the design of the Rotterdam Study was published previously.29
Fibrinogen Plasma Level
Platelet poor plasma was frozen in liquid nitrogen and stored at -80°C until analysis. Fibrino-
gen measurements were done in a random baseline sample (n=2968). The fibrinogen plasma 
level was derived from the clotting curve of the prothrombin time assay using Thromborel 
S as a reagent on an automated coagulation laboratory (ACL 300, Instrumentation Labora-
tory).
Genotyping 
Genomic DNA was isolated from peripheral venous blood, previously obtained at baseline 
during the first examination session, according to standard protocols. The Seattle SNPs 
Program for Genomic Applications identified common SNPs in the fibrinogen genes based 
on 23 unrelated individuals of European descent from the CEPH pedigrees and constructed 
haplotypes based on this dataset.30 Tagging SNPs were selected, based on this database. All 
participants were genotyped for seven tagging SNPs. In this study, these SNPs have been 
coded according to the HUGO (Human Genome Organisation) guidelines: FGA: -58 G/A, 1374 
G/A, 1526 T/C, 4253 A/G (more commonly known as: 312 Thr/Ala) and FGG: 4288 G/A, 6326 
G/A and 7792 T/C (these correspond with Seattle SNP codes FGA: 2224 G/A, 3655 G/A, 3807 T/
C and 312 Thr/Ala, and FGG: 5836 G/A, 7874 G/A and 9340 T/C). Genotypes were determined 
using 2-ng genomic DNA with Taqman allelic discrimination assay (Applied Biosystems, 
Foster City, California). Primer and probe sequences were optimized using the SNP assay-by-
design service of Applied Biosystems (http://store.appliedbiosystems.com). Reactions were 
performed with the Taqman Prism 7900HT in 384-wells format. Details on genotyping were 
described previously.31
Haplotyping
Haplotypes were inferred by means of the haplo.em function of the Haplo Stats package 
(http://cran.r-project.org/src/contrib/Descriptions/haplo.stats.html) that functions as a 
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component of the statistical program R (http://www.r-project.org/).32,33 Coding from FGA: 
-58 G/A, 1374 G/A, 1526 T/C and 312 Thr/Ala, and FGG: 4288 G/A, 6326 G/A and 7792 T/C, 
we denoted five FGA haplotypes (coded as haplotype 1 through 5 in order of decreasing 
frequency) and four FGG haplotypes (coded as 1 through 4 in order of decreasing frequency) 
(Table 1). The other haplotypes had a frequency of < 1% and were not considered in the 
analyses.
Arterial Stiffness
In this study, three measures of arterial stiffness were used: the carotid-femoral pulse wave 
velocity (PWV) as a measure of aortic stiffness and the distensibility coefficient (DC) of the 
common carotid artery as a measure of common carotid arterial stiffness. In addition, pulse 
pressure (PP) was assessed as an indicator of arterial stiffness. All measures were obtained 
during the same session, during the third follow-up examination. Details on all measures of 
stiffness were described previously.6,7
Carotid-femoral PWV (m/s) was measured using an automatic device (Complior, Colson) 
and was calculated as the ratio between the distance traveled by the pulse wave and the 
foot-to-foot time delay.
Common carotid artery distensibility was assessed by measuring the vessel wall motion 
of the right common carotid artery using a duplex scanner (ATL Ultramark IV, operating 
frequency 7.5 MHz) connected to a vessel wall movement detector system.34,35 The cross-
sectional arterial wall distensibility coefficient (1/MPa) was calculated as a measure of arterial 
stiffness.36 A decreased distensibility coefficient implies increased carotid stiffness. 
Pulse pressure (mmHg) was defined as the difference between systolic and diastolic blood 
pressure, using the mean systolic and diastolic blood pressure of two measurements obtained 
by measuring blood pressure on the right arm using a random-zero sphygmomanometer. 
Table 1. Fibrinogen α and γ Haplotypes
Fibrinogen α Fibrinogen γ
Haplotype –58 G/A
rs2070011
1374 G/A
rs2070014
1526 T/C
rs2070016
312 Thr/Ala
rs5060 
n (%) 4288 G/A
rs2066860
6326 G/A
rs2066861
7792 T/C
rs1049636
n (%)
1 G G T Thr 1993 (30.6) G G T 2677 (41.1)
2 A G T Ala 1772 (27.2) G G C 1896 (29.1)
3 G A T Thr 1120 (17.2) G A T 1687 (25.9)
4 G G C Thr 827 (12.7) A G T 241 (3.7)
5 A G T Thr 775 (11.9)
Other 27 (< 1) 13 (< 1)
The structure of each haplotype is depicted here, by way of displaying the alleles of each polymorphism, 
that are included in the haplotype (e.g. haplotype 1 consists of the alleles: –58-G, 1374-G, 1526-T and 
312-Thr)
Minor alleles within the haplotypes are marked in bold
Based on n=6514 (total of successfully genotyped participants of the Rotterdam Study)
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Clinical Characteristics
Information on cardiovascular risk factors was collected during all examination phases, includ-
ing the third phase. Data on medication and smoking habits were obtained during a home 
interview. At the research center, blood pressure was measured twice on the right arm using 
a random-zero sphygmomanometer. The average of the two blood pressure values was used 
in the analyses. Length and weight were measured and body mass index (weight/height2) 
(BMI) was calculated. Serum total cholesterol and high-density lipoprotein (HDL) cholesterol 
values were determined by an automated enzymatic procedure (Boehringer Mannheim Sys-
tem). Diabetes mellitus (DM) was defined as use of anti-diabetic medication and/or a fasting 
serum glucose level equal to or above 7.0 mmol/L.37 Evaluation of the atherosclerotic status 
of participants was accomplished using ultrasonography (carotid intima-media thickness 
[IMT]) and radiography (aortic calcification); these methods were described previously.38,39
Population for Analysis
The Rotterdam Study comprises 7983 subjects. Of these, 6514 were (successfully) genotyped. 
A total of 4797 subjects participated in the third phase of the Rotterdam Study. Of these, 4024 
subjects underwent the full physical examination in the third phase. PWV was measured in 
3550 subjects; 69 subjects (1.9%) were excluded from the analyses because of poor quality 
of the PWV recordings, leaving 3481 subjects. Common carotid distensibility was measured 
in 3098 subjects. Data on successful genotyping of at least one polymorphism and on at 
least one measure of arterial stiffness were available for 3891 participants. Genotyping data 
on all polymorphisms and at least one measure of arterial stiffness were available for 3474 
subjects. Missing information on measures of arterial stiffness was almost entirely due to 
logistic reasons. Fibrinogen plasma levels were available for 2968 participants, comprising a 
random sample from the baseline examination.
Statistical Analyses
Chi-square tests were performed to test for deviations from Hardy-Weinberg equilibrium. Miss-
ing data on clinical characteristics were imputed using Expectation-Maximization algorithms 
available in SPSS. Natural-log transformed (ln-transformation) values of the fibrinogen level 
were used to normalize the distribution. The associations of genotypes with the fibrinogen 
level and arterial stiffness were investigated using analyses of variance (using SPSS version 
11.0.1 for MS-Windows). The associations of haplotypes with the fibrinogen plasma level and 
measures of arterial stiffness were analyzed using the programme Haplo.Stats, that functions 
as a component part of the statistical program R (http://www.r-project.org).32,33,40 The haplo.
glm analysis is based on a generalized linear model and computes the regression of a trait 
on haplotypes and other covariates. Analyses were adjusted for age and sex and, when ap-
plicable, additionally for mean arterial pressure (MAP) and heart rate, and furthermore for 
systolic and diastolic blood pressure, body mass index (BMI), high-density lipoprotein (HDL) 
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and total cholesterol levels, smoking, diabetes mellitus and measures of atherosclerosis. A 
p-value of 0.05 and smaller was considered significant in all analyses.
RESULTS
Genotype and allele frequencies were in Hardy Weinberg equilibrium. Haplotype reconstruc-
tion resulted in five FGA haplotypes with frequencies of >1% and four FGG haplotypes with 
frequencies of >1%. The structure of the haplotypes is described in Table 1. General charac-
teristics of the population are described in Table 2.
Fibrinogen Plasma Level and Arterial Stiffness
The fibrinogen plasma level was positively associated with aortic stiffness (β 0.87, p=0.015, 
n=1169); this association remained after adjusting for traditional cardiovascular risk factors 
(Table 3). Only after additional adjustment for measures of atherosclerosis estimates were 
attenuated, but remained near significant (β 0.65, p=0.06). No association of the fibrinogen 
plasma level with carotid stiffness was found, but the fibrinogen plasma level was positively 
associated with pulse pressure (β 3.79, p=0.049, n=1641) and remained so after additional 
adjustments.
Table 2. General Characteristics of the Study Population
Characteristic
Total number 3891
Age – yrs 72.4 ± 7.1
Male sex – % 42.5
Body mass index – kg/m2 27 ± 7
Systolic blood pressure – mm Hg 143 ± 21
Diastolic blood pressure – mm Hg 75 ± 11
Mean Arterial Pressure – mm Hg 98 ± 13
Total cholesterol – mmol/l 5.8 ± 1.0
HDL-cholesterol – mmol/l 1.4 ± 0.4
Smoking  Current – %
 Former – %
 Never – %
30
38
32
Diabetes – % 9
Pulse Wave Velocity – m/s 13.6 ± 3.0
Distensibility Coefficient – 1/MPa 10.4 ± 4.3
Pulse Pressure – mm Hg 68 ± 17
Intima Media Thickness – mm 0.78 ± 0.13
Aortic calcifications* – % 22
Values depicted as mean ± SD
* % Aortic calcifications of ≥ 2.5 cm length
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 Table 3. Fibrinogen Level and Arterial Stiffness
Pulse Wave Velocity
(n=1169)
Distensibility Coefficient 
(n=1157)
Pulse Pressure
(n=1641)
β-coefficient (SE) p β-coefficient (SE) p β-coefficient (SE) p
Model 1 0.865 (0.354) 0.015 – 0.714 (0.431) 0.098 3.793 (1.921) 0.049
Model 2 0.808 (0.353) 0.022 – 0.517 (0.433) 0.233 2.393 (1.038) 0.021
Model 3 0.654 (0.349) 0.061 – 0.510 (0.429) 0.235 2.209 (1.032) 0.032
β-coefficient: based on ln-transformed fibrinogen levels
Model 1:  adjusted for age, sex (and for pulse wave velocity and distensibility coefficient also mean 
arterial pressure and heart rate) 
Model 2: model 1 + body mass index, total and HDL-cholesterol, smoking, diabetes mellitus
Model 3: model 2 + measures of atherosclerosis
Table 4. Fibrinogen Levels by Genotype
Polymorphism Genotype N Level (g/L) p* p for trend
FGA –58 G/A GG 972 2.82 ns ns
GA 1247 2.82 ns
AA 390 2.78 ns
FGA 1374 G/A GG 1772 2.81 ns ns
GA 731 2.80 ns
AA 86 2.91 ns
FGA 1526 T/C TT 1970 2.79
p=0.004
p=0.004
TC 582 2.87
CC 36 2.87 ns
FGA 312 Thr/Ala Thr/Thr 1340 2.82 p=0.008† ns
Thr/Ala 1031 2.82
p=0.010
Ala/Ala 198 2.69
FGG 4288 G/A GG 2402 2.81 ns ns
GA 197 2.82 ns
AA 1 3.77 ns
FGG 6326 G/A GG 1404 2.82 p=0.001‡ p=0.024
GA 998 2.82
p=0.002
AA 185 2.67
FGG 7792 T/C TT 1299 2.79 ns ns
TC 1104 2.83 ns
CC 205 2.80 ns
Age and sex adjusted
*for differences in fibrinogen level between genotypes
ns = not significant
†compared with Ala/Ala
‡compared with AA
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Fibrinogen Plasma Level and Genotype/Haplotype
Fibrinogen plasma levels were increased for those carrying the FGA 1526 C-allele (p for trend 
= 0.004) and decreased for those carrying the FGA 312 Ala variant (Ala-Ala homozygotes 
lower level than Thr-Thr homozygotes, p=0.008) and the FGG 6326 A-allele (p for trend = 
0.024) (Table 4). 
The regression analyses showed that the fibrinogen plasma level was associated with FGA 
haplotype 4 (containing the 1526 C-allele, which was associated with higher levels) (p=0.01) 
(Table 5). The fibrinogen plasma level was not associated with the other haplotypes.
Genotypes and Haplotypes and Arterial Stiffness
Genotype analyses showed no significant associations of the SNPs with any measure of arte-
rial stiffness, except for FGA 312 Thr/Ala (Thr-Thr homozygotes had a higher carotid stiffness 
than heterozygotes, p=0.03), FGG 6326 G/A (GG homozygotes had a higher carotid stiffness 
than heterozygotes, in the fully adjusted model, p=0.05), and FGG 4288 G/A (GG-homozy-
gotes had a lower pulse pressure than AA-homozygotes, p=0.03). This association, however, 
was based on only 3 subjects. No significant trends were observed.
In the haplotype regression analyses using haplotype 1 as reference, FGA haplotype 3 was 
associated with a lower aortic stiffness (PWV) (β coefficient of -0.20, p=0.03) and, concor-
dantly, with a lower pulse pressure (β coefficient of -0.56, p<0.01) (Table 6). Significance was 
preserved after full adjustment. FGA haplotype 4, containing the 1526-C allele which was 
associated with a higher fibrinogen level, was associated with an increased pulse pressure 
(β coefficient of 0.43, p<0.01). FGG haplotype 4 was associated with a lower pulse pressure 
(β coefficient -1.71, p<0.01). Significance of these findings was retained after full adjustment 
(data not shown). The remaining haplotypes were not associated with arterial stiffness. 
Table 5. FGA and FGG Haplotypes in Relation to the Fibrinogen Level
Haplotype n β-coefficient (SE) p-value
Fibrinogen α gene
1 (reference) 907
2 816 -0.01 (0.01) 0.56
3 519 0.00 (0.01) 0.70
4 376 0.03 (0.01) 0.01
5 340 0.01 (0.01) 0.44
Fibrinogen γ gene
1 (reference) 1208
2 862 -0.00 (0.01) 0.86
3 784 -0.02 (0.01) 0.07
4 114 0.00 (0.02) 0.83
β-coefficient: based on ln-transformed fibrinogen levels
Based on total population with data on geno/haplotyping and fibrinogen levels (n=2968)
Analyses, using the Haplo.Stats haplo.glm function, are age and sex adjusted
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Gender-stratified analyses on the association between genotypes and haplotypes with 
arterial stiffness yielded no findings essentially different from the overall analyses (data not 
shown).
DISCUSSION
In this population-based study, we found that the fibrinogen plasma level was associated 
with aortic stiffness and pulse pressure, independent of cardiovascular risk factors and ath-
erosclerosis. Genotype analyses yielded significant associations of the FGA 1526 T/C, the FGA 
312 Thr/Ala and FGG 6326 G/A polymorphisms with the fibrinogen plasma level, but revealed 
no overall and consistent associations with measures of arterial stiffness. Haplotype analyses 
showed FGA haplotype 4 to be associated with a higher fibrinogen plasma level and a higher 
pulse pressure. FGA haplotype 3 and FGG haplotype 4 were associated with a lower aortic 
stiffness and lower pulse pressure. 
Several studies have demonstrated the association between the fibrinogen level and 
arterial stiffness.15-17 Our findings of a significant association of the fibrinogen plasma level 
with aortic stiffness and pulse pressure are in concordance with these earlier findings. After 
adjustment for atherosclerosis, the observed association between the fibrinogen plasma 
level and arterial stiffness was borderline significant. Further research is needed to clarify 
Table 6. FGA and FGG Haplotypes in Relation to Arterial Stiffness 
Pulse wave velocity 
(n=2886)
Distensibility coefficient 
(n=2550)
Pulse pressure  (n=3459)
Haplotype β-coefficient (SE) p β-coefficient (SE) p β-coefficient (SE) p
FGA
1 (reference)
2 -0.06 (0.08) 0.44 0.14 (0.11) 0.22 -0.20 (0.37) 0.58
3 -0.20 (0.09) 0.03* -0.06 (0.13) 0.66 -0.56 (0.15) <0.001*
4 -0.14 (0.10) 0.17 0.15 (0.15) 0.33 0.43 (0.07) <0.001*
5 -0.10 (0.11) 0.35 0.05 (0.16) 0.73 0.01 (0.05) 0.87
FGG
1 (reference)
2 -0.11 (0.07) 0.14 -0.06 (0.11) 0.55 -0.04 (0.45) 0.93
3 0.02 (0.08) 0.77 0.05 (0.11) 0.63 -0.30 (0.47) 0.52
4 0.18 (0.18) 0.30 -0.17 (0.26) 0.51 -1.71 (0.07) <0.001*
Analyses, using Haplo.Stats haplo.glm function, were adjusted for age and sex, and for pulse wave velocity 
and the distensibility coefficient additionally for heart rate and mean arterial pressure
FGA = fibrinogen α 
FGG = fibrinogen γ
* Significant also after adjusting for systolic and diastolic blood pressure, body mass index, total and HDL-
cholesterol levels, smoking, diabetes mellitus and measures of atherosclerosis
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whether the relationship between the fibrinogen plasma level and pulse wave velocity is 
independent of atherosclerosis. The fibrinogen measurements were performed at baseline, 
while arterial stiffness was measured during the third examination phase. It is possible that 
the levels changed during the period between the first and third examination phase, which 
may have underestimated our estimates. 
Strong heritability estimates for the fibrinogen level were previously found (0.20-0.50).21 
However, to date few studies have investigated the association between genetic variation 
in the FGA and FGG genes with respect to level of fibrinogen. In a recent study in nearly 
4000 American subjects, several polymorphisms were associated with the fibrinogen level; 
the FGA 1526 C-allele was associated with higher levels, the 312-Ala-allele was associated 
with lower levels, as was the FGA -58 A-allele, which appears to be functional in vitro.27,28 Our 
findings on the FGA 1526 C-allele and 312 Ala-allele are in concordance with these results. No 
association of the FGG 4288 G/A polymorphism and the fibrinogen plasma level was found 
in our study, but the 7792 C-allele was associated with higher levels.27 In addition, we found 
that the risk allele of the FGG 6326 G/A polymorphism was associated with a lower fibrinogen 
plasma level. Overall, our findings on genotypes and the fibrinogen plasma level are in line 
with the literature.
We found no consistent trends for genotypes and measures of arterial stiffness, but the geno-
typic differences in stiffness that were statistically significant are in line with our findings on the 
fibrinogen plasma level. FGA haplotype 4 was associated with increased pulse pressure, which 
is in agreement with the fact that this haplotype contains the 1526 C-allele, which by itself was 
associated with a higher fibrinogen level. FGA haplotype 3 was associated with a lower aortic 
stiffness and lower pulse pressure and FGG haplotype 4 with a lower pulse pressure. The risk 
alleles in these haplotypes (FGA 1374-A and FGG 4288-A, respectively) were, by themselves, not 
associated with the fibrinogen level. The association between haplotypes and arterial stiffness 
may very well be due to an effect of other polymorphisms in these haplotypes. Generally, the 
precise functional effects of fibrinogen haplotypes and polymorphisms are largely unknown, 
certainly with respect to the mechanisms that underlie arterial stiffness.
Fibrinogen is probably best known as a coagulation factor. In addition, it is also an acute-
phase protein and is associated with inflammation, angiogenesis and matrix interactions.18,19 
Through these processes fibrinogen may be associated with arterial stiffness. Indeed, the 
fibrinogen level was observed to be associated with arterial stiffness in some studies.15-17 
However, the precise mechanisms remain to be discovered. It is unclear whether the asso-
ciation between the fibrinogen level and arterial stiffness, is a causal association. From our 
findings on the influence of genetic variation in FGA and FGG on arterial stiffness we cannot 
conclude a causal relation between fibrinogen level and stiffness because genetic variation 
in these genes may also affect structure and thereby function of fibrinogen. Therefore, the ef-
fect on stiffness may also be through an effect on function of fibrinogen rather than through 
an effect on level of fibrinogen. 
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Our study is based on a large ongoing population-based study in a relatively homogeneous 
population, as 98% of the participants in our study are Caucasian and are all living in the 
same area, a suburb of Rotterdam. To interpret the findings correctly, several methodological 
issues should be considered. First, pulse waves in the carotid artery and the femoral artery 
travel in opposite directions, while measurements of carotid-femoral pulse wave velocity are 
based on the assumption that the pulse wave travels from the carotid artery to the femoral 
artery. In this way, measuring the distance between the carotid and the femoral artery lead 
to an overestimation of the distance between the sites of the pulse waves resulting in over-
estimation of the velocity of the pulse waves. However, variations in anatomy are limited and 
this error may be considered similar for all subjects examined, therefore we do not think it 
has seriously biased our results. Second, the distance between the carotid and the femoral 
artery may be overestimated in (especially adipose) subjects when this distance is measured 
by tape. To avoid this error we adjusted the analyses for body mass index. Third, in computing 
the carotid distensibility coefficient, we used the brachial pulse pressure rather than the ca-
rotid pulse pressure. Information on comparisons between the carotid and the brachial pulse 
pressure indicates that the carotid pulse pressure is lower than the brachial pulse pressure, 
but differences are relatively small.41 Furthermore, some data on measures of stiffness were 
not available for all subjects who visited the research center. Missing information was primar-
ily due to logistic reasons, which is likely to be random and thus will not have biased our 
results. Additionally, although this study included nearly 4000 subjects, the possibility cannot 
be excluded that a potential association remained undetected, especially as the effects of 
genetic variation on a trait with a complex and multifactorial pathogenesis, such as arterial 
stiffness, are generally modest. Finally, because our study was performed in a population 
of predominantly elderly Caucasian subjects, the generalizability of our findings to younger 
individuals or other ethnicities remains uncertain. 
In conclusion, our findings indicate that fibrinogen plasma level and genetic variation in 
the fibrinogen α and γ gene are associated with arterial stiffness. Further studies are needed 
to confirm these findings and to elucidate the underlying pathogenetic mechanisms.
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Background and purpose - Arterial stiffness has been found to predict the risk of cardiovas-
cular disease and it generally increases with age. The renin-angiotensin system influences 
not only the circulating volume and blood pressure, but also arterial stiffness. We studied the 
associations of three renin-angiotensin system polymorphisms, ACE I/D, angiotensinogen 
235 M/T and angiotensin II receptor type I 573 C/T, with arterial stiffness.
Methods - The study was embedded in the Rotterdam Study, a prospective, population-
based study among subjects aged 55 years and older. Arterial stiffness was measured during 
the third phase of the Rotterdam Study (1997-1999). The association of the polymorphisms 
with pulse wave velocity, the carotid distensibility coefficient and pulse pressure was investi-
gated in 3706 subjects using analyses of variance. All analyses were stratified by gender and 
adjusted for age, mean arterial pressure, heart rate, known cardiovascular risk factors and 
measures of atherosclerosis. 
Results - We found no association of the ACE I/D polymorphism with pulse wave velocity, 
but the D-allele was associated with a lower distensibility coefficient (p=0.05) and higher 
pulse pressure (p=0.01). For the angiotensinogen 235 M/T polymorphism no significant as-
sociations with either pulse wave velocity (p=0.71), the distensibility coefficient (p=0.16) or 
pulse pressure (p=0.34) were found. Also, we found no significant associations of pulse wave 
velocity (p=0.32), the distensibility coefficient (p=0.08) and pulse pressure (p=0.09) with the 
angiotensin II receptor type 1 573C/T polymorphism. 
Conclusions – Of the genetic variations in the renin-angiotensin system, that we studied, we 
only found the ACE I/D polymorphism, to be associated with reduced carotid distensibility 
and increased pulse pressure.
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INTRODUCTION
Although arterial stiffness generally increases with age, vessel wall stiffness leads to an in-
creased blood and pulse pressure and has been found to be independently associated with 
an increased risk of cardiovascular disease.1-8 
The renin-angiotensin system (RAS) influences the vascular system in many ways. Renin 
converts angiotensinogen (AGT) into the inactive angiotensin I (AT-I); angiotensin-convert-
ing enzyme (ACE) converts the AT-I into the active angiotensin II (AT-II), which is the main 
product of the RAS.9 This system is involved in regulation of blood pressure and circulating 
volume. AT-II is a potent vasoconstrictor and stimulates the release of aldosteron; this results 
in an increase in blood pressure. In addition, the RAS plays an important role in vascular 
regulation and atherogenesis, it influences cell growth and proliferation and endothelial 
dysfunction.10-12 
Genetic variation in components of this system may affect the vascular wall and arterial 
stiffness. The most studied polymorphism in the RAS system is the ACE I/D polymorphism. 
This polymorphism concerns the insertion (or deletion) of a 287 bp sequence of DNA in 
the ACE gene and was described by Rigat et al.13 Although it is located in an intron, the 
D-variant of this polymorphism is associated with increased ACE-levels, suggesting a tight 
link with other functional, but so far unknown, polymorphisms, and is commonly used as 
marker for increased ACE levels.12-15 Indeed, the intron 16 ACE Insertion/Deletion (ACE I/D) 
polymorphism has been associated with carotid intima-media thickness and arterial stiffness 
in several studies.16-21 
In our population we found the ACE I/D polymorphism to be associated with carotid stiff-
ness (the distensibility coefficient) in an earlier study.21 This prompted us to study genetic 
variation in the renin-angiotensin system in more detail, including the ACE I/D polymorphism 
and additional polymorphisms angiotensinogen (AGT) 235 M/T and angiotensin II receptor 
type I (AT1R) 573 C/T, in relation to pulse wave velocity, the distensibility coefficient, and 
additionally pulse pressure, in a large population-based study.
METHODS
The Rotterdam Study is an ongoing prospective cohort study including 7983 participants of 
55 years and older.22 During the first phase of this study (1990-1993), all inhabitants of a Rot-
terdam suburban area (Ommoord) aged 55 years and over were invited to participate in this 
study. The response rate was 78%. The third examination phase took place from 1997-1999, 
during which measurements of arterial stiffness were performed. Approval of the Medical 
Ethics Committee of the Erasmus University Rotterdam was obtained and written informed 
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consent was acquired. A more in depth description of the design of the Rotterdam Study has 
been published previously.22
Genotyping
Genomic DNA was isolated from blood samples using standard methods.23 Methods of geno-
typing for the ACE I/D, angiotensinogen 235 M/T and angiotensin II receptor type I 573 C/T 
polymorphisms were described in detail previously.21,24
Arterial Stiffness
Arterial stiffness was measured by two methods, i.e. the carotid-femoral pulse wave velocity 
(PWV) as a measure of aortic stiffness and the distensibility coefficient (DC) of the common 
carotid artery as a measure of common carotid arterial stiffness. In addition, pulse pressure 
(PP) was assessed as an indicator of arterial stiffness. All measures were obtained during the 
same session during the third examination phase. Details on all measures of stiffness have 
been described previously.5,8
Carotid-femoral PWV (m/s) was measured using an automatic device (Complior, Colson) 
and was calculated as the ratio between the distance travelled by the pulse wave and the 
foot-to-foot time delay.
Common carotid artery distensibility was assessed by measuring the vessel wall motion 
of the right common carotid artery using a duplex scanner (ATL Ultramark IV, operating 
frequency 7.5 MHz) connected to a vessel wall movement detector system.25,26 The cross-
sectional arterial wall distensibility coefficient (DC) (1/MPa) was calculated as a measure of 
arterial stiffness.27 A decreased distensibility coefficient implies increased carotid stiffness. 
Pulse pressure (PP) (mmHg) was defined as the difference between systolic and diastolic 
blood pressure, using the mean systolic and diastolic blood pressure of two measurements 
obtained by measuring blood pressure on the right arm using a random-zero sphygmoma-
nometer. 
Clinical Characteristics
Information on cardiovascular risk factors was collected during the third follow-up examina-
tion. These data include information on drug use, smoking habits, blood pressure, height, 
weight, body mass index (weight/height2) (BMI), serum total cholesterol and high-density 
lipoprotein (HDL) cholesterol, diabetes mellitus (DM) and on the atherosclerotic status of 
participants (carotid intima-media thickness [IMT]) and radiography (aorta calcification). All 
methods have been extensively described previously.8,28-30
Population for Analysis
The Rotterdam Study comprises 7983 subjects. A total of 4797 subjects participated in the 
third phase of the Rotterdam Study. Of these, 4024 subjects underwent a physical examina-
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tion of the third phase. PWV was measured in 3550 subjects; 69 subjects (1.9%) were excluded 
from the analyses because of poor quality of the PWV recordings, leaving 3481 subjects. Com-
mon carotid distensibility was measured in 3098 subjects. Missing information on measures 
of arterial stiffness was almost entirely due to logistic reasons. Complete genotyping data 
on all polymorphisms and at least one measure of arterial stiffness was available for 3706 
participants. 
Statistical Analyses
Chi-square tests were performed to test for deviations from Hardy-Weinberg equilibrium. 
Missing data on clinical characteristics were imputed using Expectation-Maximization al-
gorithms available in SPSS. The associations between genotypes and arterial stiffness were 
investigated using analyses of variance and linear regression. All analyses were adjusted 
for age, sex and (for PWV and DC) also for mean arterial pressure (MAP) and heart rate. Ad-
ditionally, the analyses were adjusted for body mass index, high-density lipoprotein (HDL) 
and total cholesterol levels, smoking, diabetes mellitus and measures of atherosclerosis. A 
p-value of 0.05 or smaller was considered significant in all analyses. The statistical analyses 
were performed using SPSS version 11.0.1 for MS-Windows. 
RESULTS
General characteristics have been described in Table 1. Genotype and allele proportions were 
in Hardy Weinberg equilibrium.
As reported earlier, the ACE D-allele was significantly associated with a decreased distensibil-
ity coefficient (i.e., increased carotid stiffness), p for trend = 0.05, also after full adjustment, 
p=0.03 (Table 2).21 In the current study the D-allele was also associated with a significantly 
increased pulse pressure, p for trend = 0.01 (Table 2). 
Analyses did not show evidence for an association of the AGT M/T polymorphism and pulse 
wave velocity, the distensibility coefficient or pulse pressure (Table 2).
For the AT1R 573 C/T polymorphism the analyses, although not significant, suggested a 
trend of an increased distensibility coefficient (i.e., a lower carotid stiffness) (p=0.08) and con-
cordantly lower pulse pressure (p=0.09) for T-carriers (Table 2). However, differences between 
the genotypes were not significant. No associations with pulse wave velocity were found. Full 
adjustment did not alter these results.
All gender-stratified analyses yielded findings essentially similar to the overall analyses 
(data not shown).
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Table 1. General Characteristics
Characteristic
Total number 3706
Age – yrs 72.4 ± 7.1
Male sex – % 42
Body mass index – kg/m2 27 ± 4
Systolic blood pressure – mm Hg 143 ± 21
Diastolic blood pressure – mm Hg 75 ± 11
Mean Arterial Pressure – mm Hg 98 ± 13
Pulse Pressure – mm Hg 68 ± 17
Total cholesterol – mmol/l 5.8 ± 1.0
HDL-cholesterol – mmol/l 1.4 ± 0.4
Smoking  Current – %
  Former – %
  Never – %
27
38
35
Diabetes – % 9
Pulse Wave Velocity – m/s 13.6 ± 3.0
Distensibility Coefficient – 1/MPa 10.4 ± 4.4
Intima Media Thickness – mm 0.76 ± 0.13
Aortic calcifications* – % 22
* % Aortic calcifications of ≥ 2.5 cm length
Continuous values are depicted as mean ± SD
Table 2. Arterial Stiffness by Genotype
ACE I/D n II n ID n DD Trend
Pulse Wave Velocity (m/s) 777 13.45 (13.26-13.65) 1704 13.53 (13.40-13.66) 925 13.57 (13.39-13.74) p = 0.73*
Distensibility Coefficient 
(1/MPa)
675 10.65 (10.37-10.93) 1508 10.24 (10.06-10.43) 818 10.27 (10.02-10.52) p = 0.05*
Pulse Pressure (mmHg) 828 66.6 (65.4-67.7) 1876 68.5 (67.8-69.3) 986 68.6 (67.6-69.7) p = 0.01
AGT 235 M/T MM MT TT
Pulse Wave Velocity (m/s) 1158 13.98 (13.74-14.22) 1447 14.00 (13.79-14.20) 494 14.20 (13.83-14.57) p = 0.71
Distensibility Coefficient 
(1/MPa)
1022 11.25 (10.91-11.58) 1273 11.22 (10.93-11.51) 543 10.84 (10.35-11.33) p = 0.16
Pulse Pressure (mmHg) 1352 67.1 (65.7-68.5) 1742 67.7 (66.5-68.9) 596 67.8 (65.7-69.9) p = 0.34
AT1R C/T CC CT TT
Pulse Wave Velocity (m/s) 867 14.20 (13.92-14.47) 1501 13.97 (13.77-14.17) 731 13.93 (13.62-14.24) p = 0.32
Distensibility Coefficient 
(1/MPa)
752 10.89 (10.51-11.27) 1332 11.30 (11.01-11.58) 664 11.23 (10.81-11.64) p = 0.08
Pulse Pressure (mmHg) 1014 68.2 (66.6-69.7) 1799 67.2 (66.0-68.4) 877 67.3 (65.5-69.0) p = 0.09
Presented values: mean (95% confidence interval)
Age and sex adjusted, and for pulse wave velocity and the distensibility coefficient also for heart rate and 
mean arterial pressure 
*Results from Mattace-Raso et al. Atherosclerosis, 200421
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DISCUSSION
We studied the ACE I/D, the angiotensinogen 235 M/T and angiotensin II receptor type 1 
573 C/T polymorphisms in relation to arterial stiffness in a large population-based study. 
We found no evidence for an association with pulse wave velocity for any of the studied 
polymorphisms. The ACE D-allele was significantly associated with a higher carotid stiffness 
(i.e., a decreased distensibility coefficient) and an increased pulse pressure. The AGT 235 M/T 
and AT1R 573 C/T polymorphisms were not significantly associated with carotid stiffness or 
pulse pressure, although our results suggested a (non-significant) trend for an association of 
the AT1R 573 C/T polymorphism with carotid stiffness and pulse pressure.
The renin-angiotensin system influences not only blood pressure and vascular tonus, 
but also arterial stiffness. The effects of the RAS appears not to be limited to the actions of 
angiotensin II; multiple other parts of the system, such as aldosteron and renin, may influence 
stiffness.31 The potential effect on arterial stiffness is further supported by findings that medi-
cation acting on the RAS, such as ACE inhibitors and AT-II receptor blockers, reduce arterial 
stiffness.31-33
We found the D-allele of the ACE I/D polymorphism to be associated with a higher carotid 
stiffness (i.e., a lower distensibility coefficient) and a higher pulse pressure. The former as-
sociation was already shown in the Rotterdam Study in a previous study.21 Two other studies 
also evaluated this polymorphism in relation to arterial stiffness. In a relatively small French 
study no important influence of the I/D polymorphism on pulse wave velocity was found 
among 128 normotensives, while among 311 hypertensives a slightly higher PWV was pres-
ent for those with the II-genotype.20 Another study also found a higher PWV for those with the 
II-genotype, however, the association was only present among 137 type 2 diabetics and not 
among 260 non-diabetic controls.19 Our study is much larger and is performed in a general 
population setting. In another, also more general, population-based study among 756 Flem-
ish subjects decreased compliance (i.e., increased stiffness) was found to be associated with 
the D-allele.18 It has been generally established that the D-allele is associated with increased 
ACE levels, which, in turn, may influence arterial stiffness.12-15,21 Increased ACE levels, in turn, 
may influence arterial stiffness. Our findings are in line herewith.
We found no significant associations between the angiotensin 235 M/T polymorphism 
and arterial stiffness. The angiotensinogen polymorphism 235 M/T was first described by 
Jeunemaitre et al., and the T-variant has been associated with increased levels of angio-
tensinogen.34,35 Previous studies on the AGT 235 M/T polymorphism and arterial stiffness 
were small and results were not consistent.36,37 The T-allele was found to be associated with 
increased arterial stiffness in a relatively small study of 98 hypertensives.36 Another study, 
however, among 441 European hypertensives failed to show an association between the 235 
M/T polymorphism and pulse wave velocity.37 
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Variation in the angiotensin II type 1 receptor (AT1R) gene was found to be associated with 
pulse wave velocity.37,38 Few studies have investigated the AT1R 573 C/T polymorphism, first 
described by Bonnardeaux et al., and it has also, to our knowledge, not been studied earlier 
in relation to arterial stiffness.39,40 The 573 C/T polymorphism is in linkage disequilibrium (LD) 
with the AT1R 1166 A/C polymorphism, whereby the 573 T-allele is found to be linked with 
the 1166 A-allele.41 Other studies have described a lower pulse wave velocity in association 
with the 1166 A-allele.37,38 Our findings were not significant, but showed a tendency for the 
T-allele to be related to a lower arterial stiffness, especially in our analyses of carotid stiffness 
(the distensibility coefficient) and pulse pressure. Given the LD between the 573 C/T and 
1166 A/C polymorphisms, our results appear in line with these earlier findings and support 
the need for further research, preferably with characterization of more markers in the AT1R 
gene. 
To interpret the findings correctly, several methodological aspects of the measures of arte-
rial stiffness need to be discussed. First, pulse waves in the carotid artery and the femoral 
artery travel in opposite directions, while measurements of carotid-femoral pulse wave 
velocity is based on the assumption that the pulse wave travels from the carotid artery to 
the femoral artery. In this way, measuring the distance between the carotid and the femoral 
artery lead to an overestimation of the velocity of the pulse waves. However, variations in 
anatomy are limited and this error may be considered similar for all subjects examined. 
Second, the distance between the carotid and the femoral artery may be overestimated in 
subjects with a large abdomen when measured by tape. To avoid this error we adjusted the 
analyses for body mass index. Third, in computing the carotid distensibility coefficient, we 
used the brachial pulse pressure rather than the carotid pulse pressure. Information indicates 
that the carotid pulse pressure is lower than the brachial pulse pressure, but differences are 
relatively small.42
Our study is based on a large ongoing cohort study. We adjusted for established risk factors 
and measures of atherosclerosis. Missing information on arterial stiffness was primarily due 
to logistic reasons, which is likely to be random. Also, in a large pathway such as RAS the 
effect of a single gene is often very small. Therefore, it is possible that small effects were not 
observed.
In conclusion, our findings suggest that of the genetic variations in the renin-angiotensin 
system, that we studied, only the ACE I/D polymorphism, is associated with carotid distensi-
bility and pulse pressure. At this point, however, we do not exclude the possibility, that other 
polymorphism in the RAS system are involved in arterial stiffness. The findings support the 
need for further research on genetic variation in components of the RAS system and stiffness 
of the vascular wall.
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Insertion/Deletion Gene Polymorphism of the Angiotensin 
Converting Enzyme and Blood Pressure Changes in Older 
Adults
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Background and purpose - The insertion/ deletion (I/D) polymorphism of the ACE gene may 
be involved in determining blood pressure changes. Aim of the present study was to assess 
the relationship between the ACE I/D gene and the change of blood pressure levels during 
follow up. We calculated the difference between mean levels of SBP, DBP and PP obtained 
during the two observations as follows: BP mean levels obtained at third phase- BP mean 
levels at baseline, and subsequently we investigated the association of the ACE I/D polymor-
phism and the mean changes of SBP, DBP and PP levels.
Methods - The study was conducted within the Rotterdam Study, a population-based cohort 
study including subjects aged 55 years and older. Information on the II, ID and DD genotypes 
of the ACE gene and mean change of blood pressure levels were available in 3966 subjects. 
Results - In adjusted models, subjects with the D allele had higher mean changes of systolic 
and pulse pressure than subjects with the I allele. The mean changes of systolic blood pres-
sure were 6.1 (4.7-7.5), 8.2 (7.5-9.3) and 7.4 (5.9-8.5) mmHg in subjects with the II, ID and 
DD genotype, respectively. Corresponding mean changes of PP through genotypes were 4.3 
(3.3-5.4), 6.0 (5.3-6.7) and 5.9 (4.9-6.9) mmHg, respectively. No difference was found for mean 
change of diastolic blood pressure among genotypes.
Conclusions - The results of this population-based study show that the ACE ID/DD genotypes 
are associated with increased mean changes of systolic and pulse pressure.
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INTRODUCTION 
There is increasing evidence that pulse pressure in older age is an independent predictor of 
risk of cardiovascular disease in the general population.1-3 Findings from the Framingham 
Heart Study showed that with increasing age, there was a gradual shift in predictive value 
from diastolic blood pressure to systolic blood pressure and then to pulse pressure.4 From 
60 years and older pulse pressure became superior to systolic blood pressure and diastolic 
blood pressure in predicting coronary heart disease. 
Genetic factors might influence blood pressure levels and several studies have inves-
tigated the possible relation between the angiotensin converting enzyme (ACE) I/D gene 
polymorphism and blood pressure levels; however, results have been controversial. Large 
population-based studies have shown the effect of the ACE I/D polymorphism on blood 
pressure levels in men and a higher prevalence of hypertension has been found in smokers 
with the D allele. 5,6,7,8 Recent studies suggested that the ACE I/D gene polymorphism might 
modulate independently age- related increases of pulse pressure; however considering the 
cross-sectional nature of the investigation these results require to be confirmed by longitu-
dinal studies.9,10 The aim of the present study was to investigate whether the ACE gene I/D 
polymorphism could modulate blood pressure changes in a large population-based study of 
older adults.
METHODS
This study was conducted within the framework of the Rotterdam Study, an ongoing pro-
spective population-based cohort study among subjects aged 55 years or over, living in Om-
moord, a suburb of Rotterdam, The Netherlands. The rationale and design of the Rotterdam 
Study have been described elsewhere.11 The Medical Ethics Committee of Erasmus Medical 
Center approved the study and written consent was obtained from all participants. Baseline 
data were collected from 1990 to 1993 and the third examination phase took place from 
1997 to 1999. In total, 7983 (response rate 78%) subjects agreed to participate and were 
interviewed at home.
Blood Pressure Measurements and Cardiovascular Risk Factors
Information on cardiovascular risk factors was collected during the baseline and the follow 
up examination. Data on use of blood pressure-lowering medication and smoking habits 
were obtained during the home interview. Blood pressure was measured twice, at the right 
upper arm using a random zero sphygmomanometer, with the individual in the sitting posi-
tion after a minimum of 5-minutes rest. Participants were asked to abstain from smoking and 
drinking alcoholic or caffeine-containing beverages at least 2 hours before blood pressure 
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measurements were taken. The average of two measurements, obtained at a single visit, 
was used for analysis. Systolic (SBP), first Korotkoff phase and diastolic (DBP), fifth Korotkoff 
phase, blood pressure were measured. Pulse pressure (PP) was calculated (SBP-DBP). Body 
mass index [weight /height2] was calculated. Serum total cholesterol and high-density lipo-
protein (HDL) cholesterol values were determined by an automated enzymatic procedure 
(Boehringer Mannheim System). Diabetes mellitus was defined as the use of blood glucose 
lowering medication and/or a fasting serum glucose level equal to or greater than 7.0 mmol/
l.12 Hypertension was defined as a blood pressure level ≥160/90 mmHg and/or the use of 
antihypertensive medication.
Genotyping
The II, ID and DD genotypes were determined at baseline, in blood samples obtained at 
baseline, using the polymerase chain reaction technique (PCR) using a PE9600 PCR machine 
according to the method of Lindpaintner et al. with some modifications.13 The results of 
amplification were 319-bp and 597-bp amplicons for the D and I alleles respectively. Because 
the D allele in heterozygous samples is preferentially amplified, there is a tendency of mis-
classification for about 4 to 5 percent of ID genotypes to DD. In order to avoid this misclas-
sification, a second independent PCR has been performed with a primer pair that recognizes 
an insertion specific sequence. The reaction yielded a 335-bp amplicon only if the I allele was 
present. In the post PCR analyses, 10 µl of PCR product was loaded on 3% Agarose gel. Two 
independent investigators have read pictures from each gel and all ambiguous samples were 
analysed a second time.
Population for Analysis
Blood pressure measurements were available in 7009 subjects participating at baseline 
examination and in 4170 subjects who participated the third examination phase. In total, 
blood pressure measurements and information on the ACE genotype were available in 3966 
subjects. Missing information on measures of blood pressures or ACE genotype was almost 
entirely due to logistic reasons.
Statistical Analyses
The ACE genotype was tested as three class variables (presence of 0, 1, or 2 D alleles). The 
Hardy-Weinberg equilibrium was tested by a Chi-square test. The association of the ACE 
genotype with changes of blood pressure levels was investigated by analysis of variance after 
adjustment for age, gender, body mass index, diabetes mellitus, smoking, total cholesterol, 
high- density lipoprotein cholesterol and use of antihypertensive medication. We calculatd 
the difference between mean levels of SBP, DBP and PP obtained during the two observa-
tions as follows: BP mean levels obtained at third phase- BP mean levels at baseline, and 
subsequently we investigated the association of the ACE I/D polymorphism and the mean 
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changes of SBP, DBP and PP levels. Next, the association between blood pressure changes 
and the ACE genotype was investigated in categories of gender, age (subjects younger and 
older than 70 years) and hypertension.
RESULTS
Characteristics of the study subjects are presented in Table 1. ACE genotype and allele pro-
portion were in Hardy-Weinberg equilibrium. At baseline, no difference was seen between 
mean levels of pulse pressure or the prevalence of hypertension and the I/D polymorphism 
of the ACE gene. Subjects with the ID and DD genotype had a statistically significantly higher 
increase of mean levels of SBP and PP when compared with subjects with the II genotype. 
(Table 2). In analyses adjusted for potential confounders, mean changes and corresponding 
Table 1. Characteristics of the Population at Baseline (n= 3966)
II (878) ID (2018) DD (1070)
Age (years) 65.2 66.2 66.1 
Men (%) 42.7 42.2 40.7
Body mass index (kg/m2) 26.3 26.2 26.3
Smokers (%) 22.9 22.2 18.3 
Diabetes mellitus (%) 5.7 8.8 5.2
Total cholesterol (mmol/l) 6.6 6.6 6.6
HDL-Cholesterol (mmol/l) 1.3 1.3 1.3
Use of antihypertensive drugs (%) 23.9 27.8 26.3
Hypertension (%) 36.1 40.1 36.6
Systolic blood pressure (mmHg) 141.1 144.1 143.9
Diastolic blood pressure (mmHg) 74.9 75.4 75.1
Pulse pressure (mmHg) 61.6 62.7 62.9
HDL- cholesterol: high- density lipoprotein cholesterol
Table 2. Mean Change of Systolic, Diastolic and Pulse Pressure Levels According to the ACE Gene I/D 
Genotype
II (878) ID (2018) DD (1070)
Mean change of SBP (mmHg) 6.1 (4.7-7.5) 8.2 (7.5-9.3)* 7.4 (5.9-8.5)
Mean change of DBP (mmHg) 1.5 (0.6-2.1) 2.0 (1.6-2.5) 1.2 (0.5-1.9)
Mean change of PP (mmHg) 4.3 (3.3-5.4) 6.0 (5.3-6.7) † 5.9 (4.9-6.9) ‡
Models adjusted for age, gender, use of antihypertensive medications, body mass index, diabetes 
mellitus, smoking, total cholesterol, high- density lipoprotein cholesterol
SBP: systolic blood pressure. DBP: diastolic blood pressure. PP: pulse pressure.
* Statistically significantly different from II genotype (p = 0.005)
† Statistically significantly different from II genotype (p = 0.01)
‡ Statistically significantly different from II genotype (p = 0.03)
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95% confidence intervals (CI) of SBP were 6.1 (4.7-7.5), 8.2 (7.5-9.3) and 7.4 (5.9-8.5) mmHg 
in subjects with the II, ID and DD genotype, respectively. Corresponding changes of DBP 
levels were 1.5 (0.6-2.1), 2.0 (1.6-2.5) and 1.2 (0.5-1.9) mmHg. Finally, corresponding mean 
changes of PP through genotypes were 4.3 (3.3-5.4), 6.0 (5.3-6.7) and 5.9 (4.9-6.9) mmHg, 
respectively. Results of analyses performed in strata of age are presented in Table 3. Overall 
in men we observed the most pronounced differences in blood pressure, the change in SBP 
in heterozygotes almost being doubled compared to I-allele homozygotes. These heterozy-
gotes also had a high DBP and PP. In women we generally observed the same trend, although 
not significant. When comparing those under and over 70 years of age, the effects on SBP 
and PP were only observed in the latter group. SBP was increased for D-allele carriers in those 
with and without hypertension, whereas a significant association with PP was only observed 
in hypertensives.
Table 3. Mean Change of Systolic, Diastolic and Pulse Pressure Levels According to the ACE Gene I/D 
Genotype in Categories of Gender, Age and Hypertension
Men Women
II (375) ID (852) DD (436) II (509) ID (1166) DD (634)
Mean change of SBP 
(mmHg)
4.7 (2.6-6.8) 8.4 (7.0-9.8)* 6.9 (4.9-8.8) 6.7 (4.9-8.5) 7.9 (6.7-9.1) 7.3 (5.6-8.9)
Mean change of DBP 
(mmHg)
0.6 (-0.5-1.8) 2.2 (1.4-3.0)* 1.4 (0.3-2.5) 2.1 (1.1-3.1) 1.9 (1.2-2.6) 1.1(0.2-1.9)
Mean change of PP 
(mmHg)
4.1 (2.5-5.7) 6.1 (5.1-7.2)* 5.4 (3.9-6.9) 4.6 (3.1-6.0) 5.9 (4.9-6.9) 6.2 (4.9-7.5)
<70 years ≥70 years
II (663) ID (1437) DD (758) II (215) ID (580) DD (313)
Mean change of SBP 
(mmHg)
7.4 (5.8-8.9) 9.1 (8.1-10.2) 7.4 (6.0-8.8) 1.4 (-1.6-4.4) 5.4 (3.5-7.2)* 6.3 (3.8-8.8)*
Mean change of DBP 
(mmHg)
1.8 (0.9-2.6) 2.1 (1.5-2.7) 1.4 (0.6-2.2) 0.6 (-0.9-2.3) 1.9 (0.9-2.9) 0.6 (-0.7-2.0)
Mean change of PP 
(mmHg)
5.6 (4.5-6.8) 7.0 (6.2-7.8) 5.9 (4.8-7.0) 0.8 (-1.6-3.3) 3.4 (1.9-4.9) 5.7(3.7-7.8) *
No Hypertension Hypertension
II (531) ID (1208) DD (678) II (317) ID (810) DD (392)
Mean change of SBP 
(mmHg)
8.9 (7.4-10.5) 11.3 (10.2-12.3)* 8.6 (7.2-10) 0.4 (-2 3.1) 3.4 (1.8-5.1)* 4.5 (2.2-6.7)*
Mean change of DBP 
(mmHg)
3.2 (2.3-4.1) 3.9 (3.3-4.5) 2.5 (1.4-3.1) -1.4 (-2.7-0.02) -0.6 (-1.5-0.1) -0.6 (-1.8-0.6)
Mean change of PP 
(mmHg)
5.8 (4.5-7.1) 7.3 (6.5-8.2) 6.3 (5.2-7.5) 1.9 (0.3-3.9) 4.0 (2.8-5.2) 5.1 (3.3-6.8)*
Models adjusted for age, gender, use of antihypertensive medications, body mass index, diabetes 
mellitus, smoking, total cholesterol, high- density lipoprotein cholesterol.
SBP: systolic blood pressure. DBP: diastolic blood pressure. PP: pulse pressure.
*Statistically significantly different from II genotype (p < 0.05)
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DISCUSSION
In this large population-based study we have found that subjects with the ID and DD geno-
type of the ACE I/D gene polymorphism had a higher increase of both pulse and systolic blood 
pressure during follow-up when compared with subjects with the II genotype. We found no 
difference of diastolic blood pressure changes among genotypes.
Blood pressure levels changes with age and it has been shown that pulse pressure, which 
is a consequence of large artery stiffness, increases linearly with age and is the dominant 
hemodynamic factor in older adults.14 Long-term follow-up studies in large populations have 
emphasized that the levels of pulse and systolic blood pressure, in addition to their rates of 
change with age, contribute substantially to cardiovascular risk, therefore it is interesting to 
know which variables can influence the development of wide pulse pressure.3,4,15 Previous 
studies studies found the D allele of the ACE gene to be associated with mean increases of 
pulse pressure in subjects with hypertension.9,10 However, these studies were cross-sectional 
and included relatively small number of participants. To the best of our knowledge no large 
population-based ongoing study has investigated the association of the ACE I/D gene poly-
morphism and pulse pressure changes over time. In a previous study, we found that the D 
allele of the ACE gene was associated with increased arterial stiffness, which is responsible for 
wide pulse pressure.16 This is the first large prospective population-based study investigating 
whether the ACE I/D gene polymorphism is associated with changes of the pulse pressure 
during follow-up; in this study we found that subjects with the D allele of the ACE gene poly-
morphism present a higher increase of pulse and systolic blood pressure when compared 
with subjects with the I allele over time. The mean increase of the systolic and pulse blood 
pressure levels is higher in older subjects.
The mechanisms that may modulate the relation between ACE gene and wide pulse 
pressure levels are not completely clear. Higher circulating levels and tissue ACE activity are 
present in subjects with the D compared to the I allele.17-19 ACE catalyzes the conversion of an-
giotensin I to angiotensin II and the breakdown of bradykinin to kinin degradation products. 
Both angiotensin II and bradykinin are potent peptide hormones that play a role in vascular 
wall homeostasis reducing vascular tone, vascular smooth muscle cell growth and produc-
tion of extracellular matrix.20-23 These processes may then lead to progressive degeneration 
of arterial media with fractures and fragmentation of elastic lamellae, increased collagen and 
calcium content and dilation and hypertrophy of the large arteries with subsequent increased 
arterial stiffness. Hence, chronic exposure to high levels of circulating and tissue ACE may 
predispose to increased arterial stiffness and eventually to higher pulse pressure. 
We found the highest mean increases of the systolic and pulse blood pressure in subjects 
with the ID polymorphism, the differences in systolic and pulse blood pressure between 
subjects with the ID and the DD polymorphism were minimal and were not statistically sig-
nificant. One possible explanation for these results could be a higher morbidity and mortality 
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rate in subjects with the DD polymorphism and stiff arteries; in this case, these subjects were 
not able to be included in the study. Conversely, in stratified analyses, we found that older 
subjects (>70 years) and hypertensive subjects with the DD polymorphism had the highest 
mean increase of the pulse pressure.
Some aspects of this study need to be discussed. Information on blood pressure levels was 
not available for all participants which was primarily due to logistic reasons, therefore, we be-
lieve that this will not have biased the results. Secondly, information on blood pressure levels 
were obtained on a single occasion and the use of multiple blood pressure measurements 
or the use of ambulatory monitoring would improve accuracy and precision. Thirdly, we did 
not exclude subjects who used anti-hypertensive medication and this could bias our results. 
However, we performed multivariate analyses adjusted also for the use of antihypertensive 
medication we think that in this way we could avoid bias. Finally, since the population of 
the Rotterdam study consisted mostly of Caucasians, results may not apply to other ethnic 
groups.
In conclusion, in a large population-based study we found that subjects with the ID and 
DD genotype of the ACE I/D gene polymorphism had a higher increase of both pulse and 
systolic blood pressure during follow-up when compared with subjects with the II genotype. 
However, determining the relative contribution of genetic and environmental factors in the 
development of complex diseases is difficult. As regulation of blood pressure levels most 
probably results from a complex of interactions between gene–gene and gene–environment 
factors, the findings of the present study on candidate genes for blood pressure levels should 
be carefully interpreted.
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Chapter 4.3
Variation in the Matrix Metalloproteinase 3 Gene and 
Arterial Stiffness
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Background and purpose - Arterial stiffness increases with age and has been found to 
predict cardiovascular disease. Matrix metalloproteinase (MMP)-3 is a member of a group 
of endopeptidases and plays an important role in the turnover of the extra-cellular matrix 
and composition of the vascular wall. We studied the total common genetic variation in the 
MMP-3 gene by means of three polymorphisms, MMP-3 1187 5A/6A, 2092 A/G and 9775 T/A 
and resultant haplotypes in relation to arterial stiffness.
Methods - This study (n=3892) was embedded in the Rotterdam Study, a prospective, popu-
lation-based study among subjects aged 55 years and older. The associations of genotypes 
with pulse wave velocity, the carotid distensibility coefficient and pulse pressure were ex-
amined using analyses of variance. The associations between haplotypes and measures of 
arterial stiffness were assessed using the Haplo.Stats programme. All analyses were adjusted 
for age, sex, known cardiovascular risk factors and measures of atherosclerosis, and where 
appropriate also for mean arterial pressure and heart rate. 
Results - A lower pulse wave velocity was found for those homozygous for the 6A-allele in 
comparison to 5A/6A heterozygotes (p=0.02), and also for 2092-G homozygotes in com-
parison with wildtype 2092 AA homozygotes (p=0.04). No associations were found between 
genetic variation in MMP-3 genes and the other measures of arterial stiffness. The haplotype-
analyses yielded no relations with measures of stiffness.
Conclusions - The 6A6A genotype of the MMP-3 5A/6A and the GG genotype of the 2092 
A/G polymorphisms were associated with a lower pulse wave velocity. No associations were 
observed of genetic variation in MMP-3 with carotid distensibility and pulse pressure. Further 
studies are needed to elucidate the influence of genetic variation in the MMP-3 gene on 
arterial stiffness.
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INTRODUCTION
Generally, arterial stiffness increases with age and has been associated with hypertension, 
diabetes mellitus (DM), end-stage renal disease and atherosclerosis.1-6 Arterial stiffness has 
been found to predict cardiovascular events in various populations.7-10 
Matrix metalloproteinase-3 (MMP-3), or stromelysin-1, was first described by Chin et al.. It is 
an important member of a family of endopeptidases involved in the turnover of extracellular 
matrix in a variety of tissues and is also involved in the remodeling of the vascular wall.11-13 
MMP-3 affects several substrates, such as elastin, laminin and several collagens, and it is also 
involved in the activation of other MMP’s (e.g. MMP-8, -9 and -13).12,14 Variations in bioavail-
ability of MMP-3 may influence arterial stiffness and the MMP-3 gene is a candidate gene for 
further study of determinants of arterial stiffness. 
The MMP-3 gene is located on chromosome 11 in regions 11q22.2-22.3. The functional 
5A/6A promoter polymorphism was first identified by Ye et al. and has been described to 
influence MMP-3 levels, blood pressure, carotid artery stenosis and arterial stiffness.13,15-17 
However, results so far have been ambiguous, as both alleles have been associated with 
adverse outcomes and increased expression of MMP-3.12,14 The 5A-allele has been associated 
with myocardial infarction, aneurysms and arterial stiffness.15,18-20 On the other hand, the 6A-
allele has been found to be associated with increased carotid intima-media thickness (IMT), 
vascular restenosis and also with arterial stiffness.15,21-24
We studied genetic variation in the MMP-3 gene in relation to arterial stiffness within a 
population-based cohort study.
METHODS
The Rotterdam Study is an ongoing prospective cohort study including 7983 participants 
of 55 years and older. Its general aims are to investigate determinants of chronic diseases, 
including cardiovascular disease, dementia and osteoporosis.25 During the first phase of 
this study (1990-1993), all inhabitants of a Rotterdam suburban area (Ommoord) aged 55 
years and over were invited to participate in this study. The response rate was 78%. The third 
examination phase took place from 1997-1999, during which measurements of arterial stiff-
ness were performed. Approval of the Medical Ethics Committee of the Erasmus University 
Rotterdam was obtained for the Rotterdam Study. From all participants written informed 
consent was acquired. A more in depth description of the design of the Rotterdam Study has 
been published previously.25
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Genotyping 
Genomic DNA was isolated from peripheral venous blood, previously obtained at baseline 
during the first examination session, according to standard protocols. We used the TaqmanTM 
assay from Applied Biosystems Inc. (ABI) for genotyping of the polymorphisms. The poly-
morphisms have been described at http://www.ncbi.nlm.nih.gov/SNP under identification 
numbers rs3025058 (1187 5A/6A), rs522616 (2092 A/G), and rs563096 (9775 T/A). Details on 
these methods have been described previously.26
Haplotyping
The Seattle SNPs Program for Genomic Applications (http://pga.gs.washington.edu) has, 
based on 23 unrelated individuals of European descent from the CEPH pedigrees, identified 
41 SNPs in the gene encoding MMP-3. By genotyping three tagging SNPs with overall fre-
quencies above 4%, we inferred four haplotypes representing the complete genetic variation 
in the MMP-3 gene in populations of European descent. Haplotype alleles were inferred by 
means of the haplo.em function of the program Haplo.stats package (http://cran.r-project.
org/src/contrib/ Descriptions/haplo.stats.html) that functions as a component of the sta-
tistical program R (http://www.r-project.org/). Haplotype alleles were coded as haplotype 
numbers 1 through 4 in order of decreasing frequency in the population. Coding from 1187 
5A/6A, 2092 A/G to 9775 T/A, we denoted the four most frequent haplotypes: haplotype 1 
as 5A-A-T, haplotype 2 as 6A-G-T, haplotype 3 as 6A-A-T, and haplotype 4 as 6A-A-A (Table 1). 
The other haplotypes had a frequency of < 1% and were not considered in the analyses.
Table 1. Haplotypes based on MMP-3
5A/6A 2092 A/G 9775 T/A
Haplotype rs3025058 rs522616 rs563096 n Frequency
1 5A A T 3069 51.1%
2 6A G T 1207 20.1%
3 6A A T 919 15.3%
4 6A A A 811 13.5%
other 1 < 1%
The structure of each haplotype is depicted here, by way of displaying the alleles of each polymorphism, 
that are included in the haplotype
Based on n=6007 (number of participants successfully genotyped and haplotyped in total Rotterdam 
Study population)
Arterial Stiffness
Arterial stiffness was measured by two methods, i.e. the carotid-femoral pulse wave velocity 
(PWV) as a measure of aortic stiffness and the distensibility coefficient (DC) of the common 
carotid artery as a measure of common carotid arterial stiffness. In addition, pulse pressure 
(PP) was assessed as an indicator of arterial stiffness. All measures were obtained on the same 
day, during the same session during the third examination phase. 
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Carotid-femoral PWV (m/s) was measured using an automatic device (Complior, Colson) 
and was calculated as the ratio between the distance travelled by the pulse wave and the 
foot-to-foot time delay.
Common carotid artery distensibility was assessed by measuring the vessel wall motion 
of the right common carotid artery using a duplex scanner (ATL Ultramark IV, operating 
frequency 7.5 MHz) connected to a vessel wall movement detector system.27,28 The cross-
sectional arterial wall distensibility coefficient (DC) (1/MPa) was calculated as a measure of 
arterial stiffness.29 A decreased distensibility coefficient implies increased carotid stiffness. 
Pulse pressure (PP) (mmHg) was defined as the difference between systolic and diastolic 
blood pressure, using the mean systolic and diastolic blood pressure of two measurements 
obtained by measuring blood pressure on the right arm using a random-zero sphygmoma-
nometer. 
Details on all measures of stiffness, have been extensively described previously.6,9
Clinical Characteristics
Information on cardiovascular risk factors was collected during the third follow-up examina-
tion. Data on drug use and smoking habits were obtained during the home interview.
At the research center, blood pressure was measured twice on the right arm using a 
random-zero sphygmomanometer. The average of the two blood pressure values was used 
in the analyses. Length and weight were measured and body mass index (weight/height2) 
(BMI) was calculated. Serum total cholesterol and high-density lipoprotein (HDL) cholesterol 
values were determined by an automated enzymatic procedure (Boehringer Mannheim 
System). Diabetes mellitus (DM) was defined as use of anti-diabetic medication and/or a 
fasting serum glucose level of equal to or above 7.0 mmol/L.30 Evaluation of the atheroscle-
rotic status of participants was accomplished using ultrasonography (carotid intima-media 
thickness [IMT]) and radiography (aorta calcification); these methods have been extensively 
described previously.31,32
Population for Analysis
The Rotterdam Study comprises 7983 subjects. Of these, 6007 were successfully and com-
pletely genotyped. A total of 4797 subjects participated in the third phase of the Rotterdam 
Study. Of these, 4024 subjects underwent the full physical examination of the third phase. PWV 
was measured in 3550 subjects; 69 subjects (1.9%) were excluded from the analyses because 
of poor quality of the PWV recordings, leaving 3481 subjects. Common carotid distensibility 
was measured in 3098 subjects. Data on successful genotyping of at least one polymorphism 
and on at least one measure of arterial stiffness was available for 3892 participants. Missing 
information on measures of arterial stiffness was almost entirely due to logistic reasons. 
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Statistical Analyses
Chi-square tests were performed to test for deviations from Hardy-Weinberg equilibrium. 
Missing data on clinical characteristics were imputed using Expectation-Maximization al-
gorithms available in SPSS. The associations between genotypes and arterial stiffness were 
investigated using analyses of variance (SPSS). The associations between haplotypes and 
arterial stiffness were analyzed using the function haplo.glm available in the program Haplo 
Stats.33-35 The haplo.glm analysis is based on a generalized linear model and computes the 
regression of a trait on haplotypes and other covariates. All analyses were adjusted for age 
and sex and, when analyzing PWV and DC, also for mean arterial pressure (MAP) and heart 
rate. Additionally, the analyses were adjusted for body mass index, HDL and total cholesterol 
levels, smoking and diabetes mellitus, and in the full model also for measures of atheroscle-
rosis. A p-value of 0.05 and smaller was considered significant in all analyses. The statistical 
analyses were performed using SPSS version 11.0.1 for MS-Windows. 
RESULTS
General characteristics of the study population are described in Table 2. All genotype and 
allele proportions were in Hardy Weinberg equilibrium. 
Table 2. General Characteristics of Study Population
Characteristic
Total number 3892
Age – yrs 72.4 ± 7.1
Male sex – % 43
Body mass index – kg/m2 27 ± 7
Systolic blood pressure – mm Hg 143 ± 21
Diastolic blood pressure – mm Hg 75 ± 11
Mean Arterial Pressure – mm Hg 98 ± 13
Total cholesterol – mmol/l 5.8 ± 1.0
HDL-cholesterol – mmol/l 1.4 ± 0.4
Smoking  Current – %
  Former – %
  Never – %
30
38
32
Diabetes – % 9
Pulse Wave Velocity – m/s 13.6 ± 3.0
Distensibility Coefficient – 1/MPa 10.5 ± 4.3
Pulse Pressure – mm Hg 68 ± 18
Intima Media Thickness – mm 0.78 ± 0.13
Aortic calcifications* – % 22
Values depicted as mean ± SD
* % Aortic calcifications of ≥ 2.5 cm length
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5A/6A polymorphism
Pulse wave velocity was 0.3 m/s lower for 6A-homozygotes in comparison with heterozygotes 
(5A/6A) (p=0.02), also after full adjustment (Table 3). However, no significant trend was found 
across genotypes. No differences in the distensibility coefficient or pulse pressure were found 
between the genotypes (Table 3). 
2092 A/G polymorphism
GG homozygotes had a significantly lower pulse wave velocity (0.5 m/s) than wildtype ho-
mozygotes (AA) (p=0.04) (Table 3). The difference remained significant after full adjustment. 
After adjustment for traditional cardiovascular risk factors and, additionally, for measures 
of atherosclerosis, GG-homozygotes also had a significantly lower pulse wave velocity in 
comparison with AG-heterozygotes (p=0.04), but no significant trend was found. For the 
distensibility coefficient and for pulse pressure no significant differences between genotypes 
were observed (Table 3). 
9775 T/A polymorphism
Analyses showed no significant differences in pulse wave velocity, the distensibility coef-
ficient and pulse pressure between genotypes (Table 3). 
MMP-3 haploptypes
Haplotype reconstruction resulted in six haplotypes. Four of these haplotypes had frequen-
cies of >1%: haplotype 1 (5A-A-T, 51%), haplotype 2 (6A-G-T, 20%), haplotype 3 (6A-A-T, 15%), 
Table 3. Arterial Stiffness by MMP-3 Genotype
MMP-3 5A/6A n Pulse Wave Velocity 
(m/s)
n Distensibility 
Coefficient (1/MPa)
n Pulse Pressure 
(mmHg)
5A/5A 851 13.5 (13.4-13.7) 752 10.4 (10.2-10.7) 996 67.9 (66.9-69.0)
5A/6A 1515 13.7 (13.5-13.8) 1356 10.5 (10.3-10.7) 1833 68.2 (67.4-68.9)
6A/6A 757 13.4 (13.2-13.6)* 663 10.4 (10.2-10.7) 912 68.4 (67.3-69.5)
MMP-3 2092 A/G
AA 2041 13.6 (13.5-13.7) 1799 10.5 (10.3-10.6) 2420 68.3 (67.7-69.0)
AG 987 13.6 (13.4-13.7) 876 10.4 (10.2-10.6) 1193 67.8 (66.8-68.7)
GG 136 13.1 (12.7-13.6)** 124 10.1 (9.5-10.7) 170 69.3 (66.8-71.9)
MMP-3 9775 T/A
TT 2354 13.6 (13.5-13.7) 2086 10.4 (10.3-10.6) 2812 68.1 (67.4-68.7)
AT 746 13.6 (13.4-13.8) 659 10.4 (10.1-10.6) 894 68.6 (67.5-69.7)
AA 50 14.0 (13.3-14.6) 40 11.2 (10.1-12.2) 58 70.0 (65.7-74.4)
Results show mean (95% confidence interval)
Analyses were adjusted for age and sex, and for pulse wave velocity and the distensibility coefficient also 
for mean arterial pressure and heart rate
*6A/6A < 5A/6A p=0.02
**GG < AA p=0.04
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and haplotype 4 (6A-A-A, 14%) (Table 1). Analyses yielded no evidence for any other associa-
tions of the haplotypes with either pulse wave velocity, the distensibility coefficient or pulse 
pressure (Table 4). Additional adjustment did not alter these findings.
Gender-stratified analyses yielded no results essentially different from the sex-combined 
analyses.
DISCUSSION
We studied genetic variation in the MMP-3 gene, using three polymorphisms 5A/6A, 2092 
A/G and 9775 T/A and resultant haplotypes in relation to arterial stiffness. Subjects homo-
zygous for the 6A-allele had a lower pulse wave velocity than heterozygotes. Furthermore, 
subjects homozygous for the 2092-G allele had a lower pulse wave velocity than wildtype 
homozygotes. No significant associations of haplotypes with either pulse wave velocity, the 
distensibility coefficient or pulse pressure were found.
The 5A/6A polymorphism is located in the promoter of the MMP-3 gene and may influ-
ence transcription. The 5A-allele is generally associated with increased expression of the 
gene.14,15,36 Consequently, one may expect increased matrix and elastin degradation associ-
ated with the 5A-allele and decreased degradation with the 6A-allele. Indeed, the 5A-allele 
has been associated with pathology related to increased matrix degradation, e.g. with 
coronary and aortic aneurysms and plaque rupture-induced myocardial infarction.20,37,38 In 
turn, the 6A-allele has been associated with pathology associated with matrix accumulation 
and decreased degradation, such as carotid stenosis and increased IMT.21,22,24 Literature on 
this polymorphism and its relation with arterial stiffness is very limited. Medley et al. found a 
higher stiffness in both the 5A and 6A homozygotes in 77 elderly Australians.15 In 213 healthy 
Australians the 5A-allele was associated with increased large artery stiffness. Also, 5A-ho-
mozygotes had a higher systolic blood pressure than 6A-allele carriers in 1111 Australians.17 
Table 4. Measures of Arterial Stiffness by MMP-3 Haplotypes 
Pulse Wave Velocity (m/s)
(n=2969)
Distensibility coefficient 
(1/MPa) 
(n=2635)
Pulse pressure (mmHg)
(n=3561)
Haplotype β-coefficient (SE) P-value β-coefficient (SE) P-value β-coefficient (SE) P-value
1 (5A-A-T)*
2 (6A-G-T) -0.11 (0.08) 0.16 -0.09 (0.11) 0.41 -1.03 (0.55) 0.06
3 (6A-A-T) -0.07 (0.09) 0.44 0.08 (0.13) 0.53 0.16 (0.64) 0.80
4 (6A-A-A) 0.04 (0.10) 0.64 0.06 (0.14) 0.68 -0.10 (0.66) 0.88
Analyses adjusted for age and sex, and, for pulse wave velocity and the distensibility coefficient, also for 
mean arterial pressure and heart rate
Results are based on the haplo.glm analysis; the β-coefficient reflects the regression coefficient
* Haplotype 1 is used as the reference
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We found 6A-homozygotes to have a lower pulse wave velocity than 5A/6A heterozygotes. 
This may be explained by the fact that elastic properties are mostly mediated by the matrix, 
therefore, decreased degradation of elastic components may result in decreased stiffening of 
the vascular wall.15 This finding, however, was not supported by findings for the distensibility 
coefficient and pulse pressure. 
Both MMP-3 2092 A/G and 9775 T/A have not, to our knowledge, been studied before in 
relation to arterial stiffness or described in relation to other conditions in other studies. We 
found the 2092 G-allele to be associated with decreased pulse wave velocity. However, the 
effects of 2092 A/G and 9775 T/A polymorphisms on gene expression and matrix degradation 
are unknown and remain to be elucidated in further studies. This finding was also not sup-
ported by concordant findings for the distensibility coefficient and pulse pressure.
We found no significant association of the haplotypes with any of the measures of arterial 
stiffness. However, in the genotype analyses there is evidence for a recessive effect. We did 
not specifically test for a recessive model in the haplotype analyses. This does not exclude the 
possibility that individual polymorphisms affect arterial stiffness. The number of haplotype 
groups was larger than the number of genotypes. Any effects of an individual polymorphism, 
such as the functional 5A/6A polymorphism, may therefore have gone undetected in the 
haplotype analyses due to the decrease in power.
To interpret the findings correctly, several methodological aspects of the measures of arte-
rial stiffness need to be discussed. First, pulse waves in the carotid artery and the femoral 
artery travel in opposite directions, while measurements of carotid-femoral pulse wave 
velocity are based on the assumption that the pulse wave travels from the carotid artery to 
the femoral artery. In this way, measuring the distance between the carotid and the femoral 
artery lead to an overestimation of the distance between the sites of the pulse waves result-
ing in overestimation of the velocity of the pulse waves. However, variations in anatomy are 
limited and this error may be considered similar for all subjects examined, therefore we do 
not think it has seriously biased our results. Second, the distance between the carotid and 
the femoral artery may be overestimated in (especially obese) subjects when this distance is 
measured by tape. To avoid this error we adjusted the analyses for body mass index. Third, in 
computing the carotid distensibility coefficient, we used the brachial pulse pressure rather 
than the carotid pulse pressure. Information on comparisons between the carotid and the 
brachial pulse pressure indicates that the carotid pulse pressure is lower than the brachial 
pulse pressure but differences are relatively small.39
Finally, some other methodological issues need to be discussed. Our study is based on a 
large ongoing population-based study. We adjusted for established risk factors and athero-
sclerosis. Data on measures of stiffness were not available for all subjects who visited the 
research center. Missing information was primarily due to logistic reasons, which is likely to 
be random and thus will not have biased our results. Furthermore, one has to appreciate that 
any effects of genetic variation on a trait with a complex and multifactorial pathogenesis, 
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such as arterial stiffness, are generally modest. Finally, because our study was performed in a 
population of predominantly elderly Caucasian subjects, the generalizability of our findings 
to younger individuals or other ethnicities remains uncertain. 
In summary, we studied genetic variation in the MMP-3 gene by means of three polymor-
phisms (5A/6A, 2092 A/G and 9775 T/A) in relation to arterial stiffness. We found that the 
6A allele of the MMP-3 5A/6A and the G-allele 2092 A/G polymorphisms have a moderate 
inverse effect on pulse wave velocity. No associations were found between genetic variation 
in MMP-3 and other measures of arterial stiffness. Additional and larger studies are needed to 
confirm our findings and to further elucidate the influence of genetic variation in the MMP-3 
gene on arterial stiffness.
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The aim of the studies described in this thesis was to study the influence of genetic variation 
in genes that may affect arterial stiffness and cardiovascular events. Of each study the merits 
and limitations have been described in detail in the previous chapters. The current chapter 
will provide a more general discussion and includes the background of this thesis, the main 
findings and suggestions for future research.
BACKGROUND
Arterial Stiffness
An important function of the arterial system, is that the (elastic) arteries store volume energy 
in order to limit the rise in the systolic blood pressure. Generally in the arterial system the 
pulsatility of the blood flow, generated by the heart, is decreased, which eventually results in 
a continuous flow at the level of the capillaries. The function of the arterial system is mainly 
achieved by the structure of the wall of the blood vessels, especially that of the arterial wall. 
The stiffness of a blood vessel is dependent on several structural components of the arte-
rial wall, such as collagen and elastin. At low pressures, especially the elastin fibers which 
are very stretchable but less rigid, determine stiffness.1 In high pressure situations, collagen 
plays a larger part in determining stiffness, as this can withstand greater stress, but is not 
as stretchable as elastin fibers.2,3 The combination of these structural elements allow for a 
cushioning effect, the so-called “Windkessel effect”: normally, during systole about 40% of 
the cardiac stroke volume is forwarded to the peripheral arteries. The remainder is stored in 
the capacitive arteries (large arteries), whereby the arterial wall is distended. During diastole, 
the arteries recoil and thus propel the blood into the peripheral circulation. Changes in arte-
rial stiffness will therefore have haemodynamic consequences. With increasing age, arterial 
stiffness increases due to changes in the structure of the arterial wall: elastin will thin and 
fracture, and in addition, collagen deposition will increase.4-6 This increased arterial stiffness 
is the dominant haemodynamic factor, responsible for the increase in systolic blood pressure, 
decrease in diastolic blood pressure and increase in pulse pressure later in life.7
The Rotterdam Study
The studies presented in this thesis are based on the Rotterdam Study (ERGO Onderzoek, 
an ongoing prospective population-based cohort study, which started in 1990. The original 
cohort consists of 7983 subjects, aged 55 years and over, who live in Ommoord, a suburb of 
Rotterdam. Recently, also subjects aged 45 years and over, became eligible for inclusion in 
this study. Its overall aim is to investigate determinants of chronic disabling diseases, such as 
cardiovascular disease, dementia and osteoporosis.8 Baseline data were obtained during the 
first phase of this study (1990-1993). This phase included a home interview and two visits to 
the research center. Extensive information was obtained, including information on cardio-
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vascular risk factors, measurements of atherosclerosis and blood samples. These procedures 
were repeated at consecutive phases of the study. 
Measures of arterial stiffness were obtained during the third examination phase (1997-
1999). These measurements included aortic pulse wave velocity (PWV), the carotid distensi-
bility coefficient and pulse pressure. A total of 4797 subjects participated in the third phase 
of the Rotterdam Study. Of these, 4024 subjects underwent the full physical examination of 
the third phase. PWV was measured in 3550 subjects; 69 subjects (1.9%) were excluded from 
the analyses because of poor quality of the PWV recordings, leaving 3481 subjects. Com-
mon carotid distensibility was measured in 3098 subjects. Pulse pressure was available for all 
subjects participating in the third phase.
General practitioners (GPs) in the research district, with whom 85% of the participants of the 
Rotterdam Study were enlisted, reported fatal and non-fatal cardiovascular events. Research 
assistants verified all information by checking medical records at the GPs’ offices. All medical 
records of the participants under the care of general practitioners outside the study area were 
checked annually for possible events. Letters and, in case of hospitalization, discharge reports 
from medical specialists were obtained. With respect to the vital status of participants, infor-
mation was also obtained regularly from the municipal health authorities in Rotterdam. After 
notification, the cause and circumstances of death were established by a questionnaire from 
the GPs. Two research physicians independently coded all reported events according to the 
International Classification of Diseases, 10th edition (ICD-10).9 Codes on which the research 
physicians disagreed were discussed in order to reach consensus. Finally, a medical expert in 
cardiovascular disease, whose judgement was considered final, reviewed all events. CHD was 
defined (based upon ICD-10) as the occurrence of an MI (I21), revascularization procedure 
(percutaneous transluminal coronary angioplasty or coronary artery bypass graft) (Z95.5 & 
Z95.1), ischaemic heart disease (I20, I22-25), sudden cardiac death (I46), ventricular fibrillation 
or tachycardia (I49), congestive heart failure (I50) or sudden death undefined (R96) during fol-
low-up. Sudden death was defined as death occurring instantaneously or within 1 hour after 
onset of symptoms. Incident MI was defined as the occurrence of a fatal or non-fatal MI after the 
baseline examination. Information on all potential strokes and transient ischaemic attacks were 
reviewed by both a research physician and an experienced stroke neurologist (P.J.K.) to verify all 
diagnoses. Subarachnoid hemorrhages and retinal strokes were excluded. Stroke was subclas-
sified as ischaemic when a CT or MRI scan, made within 4 weeks after the stroke occurred, ruled 
out other diagnoses, or when indirect evidence (deficit limited to 1 limb or completely resolved 
within 72 hours, atrial fibrillation in absence of anticoagulants) pointed at an ischaemic nature 
of the stroke. A stroke was subclassified as hemorrhagic when a relevant hemorrhage was 
shown on CT or MRI scan, or when the subject lost consciousness permanently or died within 
hours after onset of focal signs. If a stroke could not be subclassified, it was called unspecified.
Genotyping was performed on blood samples obtained at baseline and stored at -80 
degrees Centigrade.
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MAIN FINDINGS
Interleukin 6 -174 G/C Promoter Polymorphism and Risk of Myocardial Infarction and Coronary Heart Disease
Inflammatory processes play a pivotal role in the pathogenesis of atherosclerosis.10-13 C-reac-
tive protein (CRP) and IL-6 levels have been found to be associated with risk of cardiovascular 
disease.14-23 The IL-6 -174 G/C polymorphism is a functional polymorphism. However, findings 
of previous studies on the relation between this polymorphism and risk of cardiovascular 
diseases are inconsistent. We found this polymorphism not to be associated with coronary 
heart disease, both in the Rotterdam Study, as well as in a meta-analysis of nearly 20,000 
subjects. We did find, however, the C-allele to be associated with increased plasma levels of 
CRP. No significant association with IL-6 plasma levels was found. These levels, however, were 
only determined in a small subgroup. 
Transforming Growth Factor β1 and Risk of Myocardial Infarction and Stroke
Transforming growth factor β1 (TGF-β1) is a pleiotropic cytokine with a central role in in-
flammation. However, TGF-β has many different functions, both pro- and anti-atherogenic. 
Some consider the overall effect of TGF-β to be protective, reducing the risk of cardio- and 
cerebrovascular disease.24-30 Others describe TGF-β as inducing or facilitating cardio- and 
cerebrovascular pathology such as vascular stenosis and thrombogenesis.31-36 Little is known 
about the relation of variations within the gene and risk of cardio- and cerebrovascular 
disease. We investigated five polymorphisms in the TGF-β1 gene (-800 G/A, -509 C/T, codon 
10 Leu/Pro, codon 25 Arg/Pro and codon 263 Thr/Ile) in relation to risk of myocardial infarc-
tion and stroke. No association with risk of myocardial infarction was found. A significantly 
increased risk of stroke, both overall and ischaemic, was found, associated with the risk alleles 
of the -509 C/T polymorphism (relative risk of 1.24) and the codon 10 polymorphism (relative 
risk of 1.26). Both the -509 C/T and codon 10 polymorphism are potentially functional and 
the associations between the polymorphisms and (ischaemic) stroke may very well be due 
to changes in expression or activity of TGF-β. It remains unclear why similar effects on risk of 
myocardial infarction were not observed.
Interleukin 6 -174 G/C Promoter Polymorphisms and Arterial Stiffness
Interleukin 6 (IL-6) is a pleiotropic cytokine with many different functions. It plays an impor-
tant role in the acute-phase response and inflammatory cascade, such as up-regulation of 
acute-phase proteins as CRP.37-40 An association between IL-6 levels and increased arterial 
stiffness has been described.41-43 Also elevated CRP levels have been shown to be associated 
with increasing pulse pressure and increased arterial stiffness.43-46 Fishman et al. described 
the functional -174 G/C promoter polymorphism in the IL-6 gene.47 This polymorphism ap-
pears to influence the IL-6 gene transcription and is associated with elevated CRP levels.47-51 
We studied the association of the -174 G/C polymorphism, arterial stiffness and plasma levels 
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of interleukin 6 and C-reactive protein within the Rotterdam study. We found the C-allele of 
the -174 G/C polymorphism to be associated with increased pulse wave velocity. Although 
not significant, results on pulse pressure suggested a similar pattern. Concordantly, CRP 
plasma levels were associated with increased arterial stiffness. IL-6 plasma levels were not 
significantly associated with arterial stiffness.
Variation in the CRP Gene and Arterial Stiffness
CRP is an inflammatory marker and was found to be associated with arterial stiffness. Genetic 
factors account for part of the variance in CRP levels. We studied the association of the CRP 
polymorphisms 1184 C/T, 2042 C/T, 2911 C/G and haplotypes with arterial stiffness within the 
Rotterdam study. CRP serum levels were significantly associated with pulse wave velocity and 
pulse pressure. Also, CRP serum levels were associated with the individual polymorphisms: 
1184 C/T (positively), 2042 C/T (inversely) and 2911 C/G (positively). Genotype and haplotype 
analyses showed no consistent significant associations between pulse wave velocity, the 
distensibility coefficient or pulse pressure. These findings might suggest that CRP itself is 
not causally related to arterial stiffness. However, genetic variation in the CRP gene has only 
a small effect on CRP level. Therefore, a small effect of genetic variation in CRP on arterial 
stiffness may have gone undetected and a judgment about causality cannot be given with 
certainty.
Variation in the TGF-β1 Gene and Arterial Stiffness
Transforming growth factor β1 (TGF-β1) is a pleiotropic cytokine. Its many effects include 
influence on T-cells, on the release of (other) cytokines and fibroblast growth factor, but it 
also exerts influence on the vascular wall, e.g. on angiogenesis, on endothelial cells and on 
modulation of the extra-cellular matrix.14,24,28,52-55 We investigated five potentially functional 
polymorphisms in the TGF-β1 gene (-800 G/A, -509 C/T, codon 10 Leu/Pro, codon 25 Arg/Pro 
and codon 263 Thr/Ile) in relation to arterial stiffness, both as separate genotypes, as well as 
in haplotypes.56-58 No associations with pulse wave velocity, distensibility coefficient or pulse 
pressure were found. We hypothesize that any effects that these TGF-β polymorphisms might 
have on the vascular wall, do not lead to significant changes in arterial stiffness.
Variation in the Fibrinogen α and γ Genes and Arterial Stiffness
Fibrinogen is an acute phase protein and has been associated with arterial stiffness. We 
studied genetic variation in the fibrinogen α (FGA) and γ gene (FGG), by means of seven SNPs 
(FGA: -58 G/A, 1374 G/A, 1526 T/C and 312 Thr/Ala, and FGG: 4288 G/A, 6326 G/A and 7792 
T/C) and concordant haplotypes in relation to arterial stiffness and pulse pressure. Fibrinogen 
plasma levels were positively associated with aortic stiffness (pulse wave velocity) and pulse 
pressure. Analyses showed fibrinogen plasma levels to be positively associated with the FGA 
1526 T/C SNP, and haplotype 4 (containing the 1526 C-allele), and inversely with the FGA 312 
General Discussion 155
Thr/Ala SNP and FGG 6326 G/A SNP. Aortic stiffness was inversely associated with fibrinogen 
α haplotype 3. Pulse pressure was positively associated with fibrinogen α haplotype 4, and 
inversely with haplotype 3 and fibrinogen γ haplotype 4. These findings indicate that fibrino-
gen levels and genetic variation in the fibrinogen α and γ gene are associated with arterial 
stiffness. However, we cannot conclude a causal relation between fibrinogen plasma level 
and stiffness with certainty, because genetic variation in these genes may (also) also affect 
structure and thereby function of fibrinogen.
Variation in Renin Angiotensin System Genes and Arterial Stiffness
The renin-angiotensin system (RAS) influences the vascular system in many ways. Renin 
converts angiotensinogen (AGT) into the inactive angiotensin I (AT-I); angiotensin-convert-
ing enzyme (ACE) converts the AT-I into the active angiotensin II (AT-II), which is the main 
product of the RAS.59 This system is involved in regulation of blood pressure and circulating 
volume. In addition the RAS plays an important role in vascular regulation and atherogenesis, 
it influences cell growth and proliferation and endothelial dysfunction.60-62 Genetic variation 
in components of this system influences the vascular wall and arterial stiffness.63 We studied 
polymorphisms of angiotensin II (ACE I/D), angiotensinogen (AGT 235 M/T) and the angioten-
sin II receptor type I (AT1R 573 C/T) in relation to arterial stiffness. The ACE I/D polymorphism 
was not associated with pulse wave velocity, but the D-allele was shown to be associated with 
decreased distensibility coefficient (in a previous study) and with increased pulse pressure 
(current study).64 For the angiotensinogen 235 M/T polymorphism no significant associations 
with either pulse wave velocity, the distensibility coefficient or pulse pressure were found. 
Also, no associations with the angiotensin II receptor type 1 573C/T polymorphism were 
observed. Our findings suggest genetic variation in genes of the renin-angiotensin system, 
especially ACE I/D, to be moderately associated with carotid stiffness and pulse pressure.
Insertion/Deletion Gene Polymorphism of the ACE and Blood Pressure Changes
The insertion/deletion (I/D) polymorphism of the ACE gene may also be involved in blood 
pressure changes. Aim of the present study was to assess the relationship between the ACE 
I/D gene and the change of blood pressure levels during follow up. The association of the ACE 
I/D polymorphism and mean changes in SBP, DBP and pulse pressure levels between the first 
and third examination phase of the Rotterdam Study was studied. In adjusted models, sub-
jects with the D allele had higher mean changes of systolic and pulse pressure than subjects 
with the I allele. No difference was found for mean change of diastolic blood pressure among 
genotypes. These results suggest the ACE ID/DD genotypes to be associated with increased 
mean changes of systolic and pulse pressure.
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Variation in the Matrix Metalloproteinase 3 Gene and Arterial Stiffness
Matrix metalloproteinase (MMP)-3 is a member of a group of endopeptidases and plays an 
important role in the turnover of the extra-cellular matrix and composition of the vascular 
wall. We studied genetic variation in the MMP-3 gene by means of three polymorphisms, 
MMP-3 5A/6A, 2092 A/G and 9775 T/A and concordant haplotypes, in relation to arterial 
stiffness. We found a lower pulse wave velocity for those homozygous for the 6A-allele in 
comparison to 5A6A heterozygotes, and also for 2092-G homozygotes in comparison with 
2092 A/G heterozygotes and wildtype 2092 AA homozygotes. No associations were found for 
the 9775 T/A polymorphism and for the other measures of arterial stiffness. The haplotype-
analyses yielded no significant findings. Our findings suggest the risk alleles of the MMP-3 
5A/6A and 2092 A/G polymorphisms to have an inverse effect on pulse wave velocity. The 
findings were not supported by the results on other measures of stiffness. Haplotype analyses 
showed no associations with arterial stiffness. 
METHODOLOGICAL ASPECTS
Study Design
In this thesis several study designs were used: the studies on arterial stiffness were generally 
cross-sectional in design. The two studies on coronary heart disease and stroke were cohort 
studies. 
When studying determinants of a certain outcome in a longitudinal design, these are 
generally obtained or measured before the outcome occurs. This is feasible in case the end-
points are well-described in time, such as myocardial infarction or stroke. With respect to 
genetic variation as a determinant, time of “measurement” is generally less relevant, because 
this variation is constant throughout life and does not change. However, also for genetic 
determinants there may be ‘selective survival’. Risk allele carriers may have died before onset 
of the study due to other diseases, also associated with the genetic variation. 
Also for non-genetic determinants (e.g. fibrinogen levels) timing of measurements is 
sometimes difficult. Often one is interested in lifelong exposure. However, it is not always 
clear which measurements best reflect this lifelong exposure. In the Rotterdam Study, for 
example, measurements may have been performed at baseline (e.g. fibrinogen levels), but 
sometimes also at later moments during the study (e.g. CRP). When studying an outcome as 
arterial stiffness, which lacks a clear onset, it may be even more difficult to assess which of the 
measurements of the determinant is the best measure of exposure. 
Measures of Stiffness
Large topographic/anatomical differences in structure and function of the arterial system 
exist. As a consequence, arterial stiffness cannot be measured at any random site within 
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the arterial system. To present a representative assessment of arterial stiffness, we used 
three diverse measures of arterial stiffness in the Rotterdam Study: pulse wave velocity as 
a measure of aortic stiffness (a more general measure of arterial stiffness), the distensibility 
coefficient as a measure of carotid stiffness (a local measure) and additionally pulse pressure, 
as an indicator of stiffness.
Pulse wave velocity is generally considered and accepted as the most robust and non-
invasive method to assess arterial stiffness in general.65 It is easy to perform and is reproduc-
ible. It is a direct measurement and is has been shown to be an independent predictor of 
cardiovascular disease.65-67 Carotid-femoral PWV is a measure for aortic stiffness. It primarily 
involves the aorta, of which the supradiaphragmatic part plays a major role in the buffering 
function of the arterial system (together with the carotid arteries). In addition, “local” PWV (i.e. 
non-aortic PWV), such as brachial PWV was shown to have no predictive value.68 Recording 
of the pressure waveforms can be done with various devices and techniques, but generally 
all methods using mechanotransducers (such as the Complior, Colson, that was used in the 
Rotterdam Study) or applanation tonometers are well accepted for PWV measurements.
In addition to the regional measurement PWV, we also used a local measure of stiffness 
(the distensibility coefficient). Local measurements of stiffness (i.e. measured at a single 
site, which does not reflect a larger area, such as the carotid-femoral PWV) may also be of 
prognostic importance, depending on the site of measurement. Carotid stiffness is one of 
the most important of the local measurements, since the carotid arteries are a frequent 
site of atherosclerosis and atheroma formation. Local measurements are mostly obtained 
using ultrasound systems, as was also the case in the Rotterdam Study. Ultrasounds are also, 
at the moment, the only means to determine arterial distensibility non-invasively. Several 
methods are used, such as the distensibility coefficient, the compliance coefficient, and the 
stroke change in diameter and lumen. There appears to be no preference for a specific index, 
however, the distensibility coefficient is among the indices recommended as part of the sug-
gested standard in a recent consensus paper on measurement of arterial stiffness.65 Generally, 
all superficial arteries can be used, i.e., those arteries accessible for ultrasonographic evalu-
ation. Although both PWV and the distensibility coefficient offer information on stiffness, in 
hypertensives/diabetics aortic stiffness increases more with age and other cardiovascular risk 
factors than carotid stiffness.69 Therefore, the addition of the distensibility coefficient is both 
useful and important, especially in patients with increased cardiovascular risk.
Systemic arterial stiffness can also be assessed non-invasively by using methods based on 
analogies with electrical models (using capacitance and resistance in series).65 But to date, 
measuring systemic arterial stiffness using these methods has not found to be of indepen-
dent predictive value for cardiovascular disease.65
Central pulse-wave analyses (central pulse pressure, central systolic pressure and the 
Augmentation Index AIx) are indirect measures of stiffness. PWV and DC are, by contrast, 
direct measurements. Central pulse pressure and AIx also have several disadvantages (e.g. 
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they do not represent intrinsically arterial stiffness, they are more sensitive to influence of 
medication and heart rate). Age, however, is of greater influence on PWV, than on AIx, which 
is an advantage of the latter method because other determinants can be better studied 
when age plays a lesser role. Despite the limitations, central pulse wave analyses provide 
useful information on arterial stiffness. Central pulse pressure, mentioned above, however, 
is not as easily obtainable as peripheral pulse pressure. Peripheral pulse pressure is also no 
direct measurement of arterial stiffness, but can be used as an indicator of arterial stiffness. 
Peripheral pulse pressure is an easily obtainable measurement. However, peripheral pulse 
pressure is higher than pulse pressure in central arteries and such peripheral measurements 
(e.g. brachial pulse pressure) overestimate central SBP and pulse pressure, especially in 
younger subjects (with less stiff arteries), and can therefore not be used as a proxy for central 
pulse pressure. We use the peripheral pulse pressure as an easy and readily available, but 
additional, indicator of arterial stiffness.
Although many methods of assessing arterial stiffness are related or based on similar prin-
ciples, the diversity may limit possibilities to compare and evaluate studies. The diversity may 
complicate the choice for a “gold standard” measure of arterial stiffness. This “gold standard” 
does not have to be limited to a single index of arterial stiffness, but may be comprised of 
standards for regional and local measurements. Recently, an overview was published by the 
European Network for Non-invasive Investigation of Large Arteries, in which several indices 
were suggested as the “gold standard”.65 It is a positive development, that the need for 
standardization is being recognized and these processes will hopefully lead to a choice and 
general acceptance of a global “gold standard”.70
Methodology of Measuring Arterial Stiffness
To interpret the findings on arterial stiffness correctly, several methodological aspects of the 
measures of arterial stiffness that we used in this thesis need to be discussed. First, pulse waves 
in the carotid artery and the femoral artery travel in opposite directions, while measurements 
of carotid-femoral pulse wave velocity is based on the assumption that the pulse wave travels 
from the carotid artery to the femoral artery. In this way, measuring the distance between the 
carotid and the femoral artery lead to an overestimation of the distance between the sites 
of the pulse waves resulting in overestimation of the velocity of the pulse waves. However, 
variations in anatomy are limited and this error may be considered similar for all subjects 
examined, therefore we do not think it has seriously biased our results. Second, the distance 
between the carotid and the femoral artery may be overestimated in, especially obese, 
subjects when this distance is measured by tape. To avoid this error we adjusted the analyses 
for body mass index. Third, in computing the carotid distensibility coefficient, we used the 
brachial pulse pressure rather than the carotid pulse pressure. Information on comparisons 
between the carotid and the brachial pulse pressure indicates that the carotid pulse pressure 
is lower than the brachial pulse pressure, but differences are relatively small.71 Finally, brachial 
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pulse pressure can be used as an easy and readily available indicator of arterial stiffness, but 
is not a direct measurement of stiffness.
Genetic Research
The process of findings genes of complex diseases, and thereby potential targets and subjects 
for treatment, can involve several strategies. 
The classical approach is linkage analysis, i.e., to analyse the co-segregation of two of more 
loci in a family. The aim is to determine whether the two chromosomes demarked by differing 
alleles at those loci, segregate independently according to the Laws of Mendel, or tend to 
be inherited together more often than not (in violation of the Laws of Mendel).72 This is a 
powerful approach for studying disorders in which a single or limited number of genes are 
involved. However, for complex diseases or conditions such as arterial stiffness and other 
cardiovascular pathology, in which a large number of genetic and environmental factors are 
involved, it may not be the most appropriate approach.
A single genetic variation in a gene, usually a polymorphism, may only render a moderate 
effect on the risk of a disease. It may, however, contribute to the discovery or exploration of 
(molecular) pathways, underlying the disease of interest.73 A disadvantage is that a significant 
association implies a correlation between (certain variation in) a gene and an outcome; this 
does not necessarily imply a causal relation.74 However, an association of a gene/genetic 
variation with an outcome is unlikely to be confounded by other factors. Therefore, an as-
sociation between a gene and outcome may provide more information on potential causality 
than associations of environmental factors with disease.
A considerable amount of research into the genetic background and basis of complex 
diseases has been performed using candidate gene association studies. This type of study 
offers an advantage in the ability to detect genes with small effects, assuming the study 
population size is large. This may play an important role in the genetics of complex diseases 
or conditions, such as arterial stiffness.75,76
Although studying a single polymorphism may sometimes yield highly significant results, 
many studies of this type have resulted in marginal effects. Confirmation studies often yielded 
conflicting results. Recently, large SNP databases have become available, containing data on 
polymorphisms across the entire human genome, which enable us to also study multiple 
genetic variations to cover genetic variation over larger areas with a relatively small number 
of polymorphisms, which are tagging a stretch of DNA (haplotype), thereby improving the 
power and reducing the problem of multiple testing when testing all SNPs in the gene. 
However, finding an association with a haplotype, does not pinpoint the specific (functional) 
polymorphism(s) in the haplotype associated with the disease. 
The studies, described in this thesis, are based on the Rotterdam Study cohort. As a large 
population-based cohort, it is a suitable population for both traditional candidate gene 
association studies, as well as gene-finding genome-screen studies (i.e., testing a trait for 
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linkage to polymorphic markers spread regularly throughout the genome; linkage may mark 
genes that are associated with the trait). Although the Rotterdam Study is a large-sized study, 
it remains possible that true associations have remained uncovered, especially when the 
studied effects are small and the polymorphisms are rare. Although the overall effect may be 
small, possibly due to gene-gene interactions, findings may be relevant in subgroups and the 
genes involved may still be clinically relevant. On the other hand, using a large dataset may 
also yield associations that are false positive findings. 
Therefore, replication of results in other studies is necessary for confirmation of the find-
ings. 
Power issues are not limited to studies using a small number of polymorphisms, such as 
in genotype or haplotype analyses. Especially studies in which large numbers of polymor-
phisms are genotyped (such as a genome screen) are affected, because in these studies, the 
possibility of spurious results is relatively high due to the vast number of statistical tests.77 
Correction for “multiple testing” requires large samples to reach adequate power and replica-
tion studies.
Causal Associations
The studies described in this thesis, aimed to investigate genes that may affect inflammation 
and the vascular wall in relation to arterial stiffness. Whenever available, also associations 
with levels of proteins were included.
A significant association implies only a correlation between variation in a gene and an out-
come; it does not enable us to draw conclusions on potential causal relations.76 However, if 
genetic variation in a gene specifically affects levels, then differences in levels have effectively 
been allocated at random at the moment of conception, i.e. “Mendelian randomization”.78 
An association between genetic variation and an outcome would then provide convincing 
evidence for a causal relation between a risk factor and the outcome. However, this is only 
valid when the genetic variation only affects levels, and not the function of the factor, and 
when the differences in levels are not a mere reflection of confounding by other factors.78
To assess the relation between inflammation and arterial stiffness, variation in two inflam-
matory genes (IL-6, CRP) was investigated. Genetic variation in the IL-6 gene was associated 
with measures of arterial stiffness. Also levels of CRP were associated with arterial stiffness. 
On the other hand, variation in the CRP gene was not associated with arterial stiffness. It 
should be mentioned, however, that the genetic variation in the CRP gene only has a small ef-
fect on the CRP level. Therefore, a small effect of variation in the CRP gene on arterial stiffness 
may have gone undetected. Therefore, although our findings do suggest the possibility of 
causality with respect to the relation between inflammation and arterial stiffness, our results 
cannot support a final conclusion on causality. Further research to this end is needed.
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In general, we studied several genes, all coding for proteins with multiple and different 
functions. In addition, we studied a trait that can be considered complex and multifactorial 
by means of three different measures, which cover various anatomical regions. This taken 
together may explain some variability in our findings
FUTURE RESEARCH 
In addition to the genes that are described in this thesis, other genes may also affect arterial 
stiffness. These other genes are therefore potential candidates for further study of arterial 
stiffness.
As one of the important components of the vascular wall, collagen is an obvious candidate 
for further studies into arterial stiffness. There are several types of collagen, but in the hu-
man vascular wall the major types of collagen are type I and type III, and to a lesser extent 
also type IV, V, VI and VIII.79 To our knowledge, the role of collagen and genetic variation in 
collagen genes in arterial stiffness, has not been extensively studied, yet, there is evidence 
for collagen to influence arterial stiffness.80,81 Although current knowledge on genetic varia-
tion in collagen genes is still limited, they are certainly likely candidate genes for study into 
arterial stiffness.
The other major component of the vascular wall is elastin, and again, this is an obvious 
candidate for further study. Arterial stiffness is dependent on the elastin component.82 In-
deed, an association of an elastin polymorphism (422 Ser/Gly) with the distensibility of elastic 
arteries was found.83 Although research on this topic so far has been limited, elastin and the 
elastin gene may provide another worthwhile goal in the study of arterial stiffness.
In addition to structural components of the vascular wall, such as collagen, elastin and 
other components, also the process of the turnover of the vascular wall may provide interest-
ing subjects for studying arterial stiffness. In this thesis, we investigated genetic variation 
in the MMP-3 gene. However, not only MMP-3, but also the other MMPs, e.g. MMP-1 and 
9, may influence degradation of vascular wall components and may thus influence arterial 
stiffness.80,84
Another interesting area is the vascular endothelium and its influence on arterial stiffness. 
The endothelium itself produces vasoactive substances, such as nitric oxide, which have 
been demonstrated to play a significant role in peripheral resistance, blood pressure and 
vascular reactivity.85,86 Also agonists that stimulate endothelial nitric oxide release, such as 
acetylcholine, reduce stiffness of muscular arteries in vivo.87,88 Basal nitric oxide production 
has been demonstrated to influence muscular arteries distensibility in vivo positively and 
the effect of acetylcholine on large arteries is also mainly nitric oxide-mediated.89 Therefore, 
genetic variation in endothelial (dys)function is an interesting candidate for studying arte-
rial stiffness. Recently, a correlation between endothelial function and arterial stiffness was 
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found in a small study.90 Furthermore, as inflammatory processes also inhibit endothelium-
dependent vasodilatation, the inflammatory pathway may offer further opportunities to 
study stiffness, such as cytokines and inflammatory markers, other than the ones described 
in this thesis.44,91 
The suggestions here for further research are certainly not complete and only offer a limited 
number of options. The increasing amount of information from studies on the pathophysiol-
ogy and determinants of arterial stiffness, both genetic and otherwise, indicates that arterial 
stiffness is by no means a simple unifactorial condition, but a multifactorial complex trait. 
Therefore, increasing knowledge will offer additional insight and more potential candidates 
for further study, both on associations with arterial stiffness, but also to elucidate and explore 
more in depth the underlying biological mechanisms by which determinants affect arterial 
stiffness. 
As for methodology, future studies should not be limited to candidate gene studies. 
Genome wide association studies will be used more often, especially as ongoing technical 
developments allow for easy and relatively low-cost genotyping of increasing, cq. vast, 
numbers of markers (e.g. on so-called ‘arrays’). Using a whole genome screen subjects are 
genotyped for polymorphisms placed across the entire genome at regular distances from 
each other. This enables us to localize markers highly associated with the outcome and to 
thus identify genes, which may play a role in the disease of interest, but were not known 
to be related to the disease before. Such an approach may also yield new topics and new 
insights for the study of arterial stiffness. The Rotterdam Study based genome screen, which 
is currently being performed, will provide a rich source of data to detect common variants 
with small effects. 
An alternative for using population-based methods, is the use of a (genetically) isolated 
population in the search of susceptibility genes for complex diseases. Generally, one assumes 
affected subjects in these populations, to have a tendency to share ancestral haplotypes and 
thus common disease mutations.92 The ERF (Erasmus Rucphen Family Study, a family-based 
study in a genetic isolate) population offers great potential to study arterial stiffness in such 
a setting, enabling us to search for a disease locus and potentially “new” genes involved in 
stiffness. Data from the ERF Study, including a genome screen in this population (to detect 
rare variants with large effects), will hopefully yield many interesting findings, but will also 
offer challenges on genetic-statistical level, as this is novel and largely uncharted terrain. The 
future availability of the Rotterdam Study genome screen will provide a rich source of data 
and many new options to study various topics in its own right. It will, however, also form a 
convenient and usable dataset to replicate findings from the ERF Study, in order to confirm 
findings. On the other hand, findings from the Rotterdam Study may be confirmed in the ERF 
study. However, one must bear in mind that differences may exist between the populations, 
as one is population-based and the other is based on a genetically isolated population.
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We feel that it is important, that the number of possible arterial stiffness measures will be 
decreased and that the scientific community will reach global consensus on a “gold standard” 
for arterial stiffness. This does not necessarily imply that the standard should only consist of 
one measurement. Given the anatomical differences, the standard may also consist of several 
measures, covering both regional and local arterial stiffness.
Arterial stiffness has only recently been established as a risk factor for cardiovascular 
disease. Further research is needed to explore the possibilities for use of measuring stiffness 
in general medical practice. Previous, current and future research and increasing knowledge 
on the pathophysiology and underlying mechanisms of arterial stiffness will offer many 
possibilities for (pharmaceutical) research, which may hopefully result in development of 
therapeutic options. In case research results show increased levels of certain proteins to influ-
ence the structure of the vascular wall, then medication that affect these levels or sensitivity 
of receptors for those proteins, may offer possibilities to slow down an increase in stiffness, 
or even reduce stiffness.
OVERALL CONCLUSION
Arterial stiffness is, at least in part, heritable, but the genes that form the basis of the regula-
tion and pathogenesis of arterial stiffness are still largely unknown. In this thesis we aimed to 
investigate variation in several genes that may influence arterial stiffness. We found variations 
in certain genes, such as the IL-6 and fibrinogen gene, to be associated with increased arterial 
stiffness, and also an association of CRP and fibrinogen levels with stiffness. Variations in the 
MMP-3 gene and the ACE gene were also associated with stiffness, whereas variations in the 
CRP and TGF-β gene were not clearly associated with arterial stiffness.
The pathogenetic background of increased arterial stiffness is still largely uncovered. Our 
results suggest that inflammation is associated with arterial stiffness, but we cannot conclude 
a causal role for inflammatory mediators. Our results further implicate that not a single, but 
multiple systems influence arterial stiffness. This multifactoriality emphasizes the importance 
of further study into (other) genes that may be involved in regulation of arterial stiffness 
and to further elucidate the underlying mechanisms. When it becomes clearer which systems 
are involved and when a “gold standard” for measuring arterial stiffness has been globally 
accepted, one may begin speculating on possibilities of practical risk profiling and possible 
(aims for) interventions. Although in this thesis only genetic variation in a few genes was 
described, our results demonstrate the complex nature of arterial stiffness and substantiate 
the need for further research in this field.
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SUMMARY
Arterial stiffness increases with age. It is also associated with various diseases, such as diabetes 
mellitus and hypertension. Recently, arterial stiffness has also been found to independently 
predict cardiovascular disease. The pathogenesis of arterial stiffness, however, has not been 
fully explored. The aim of the studies described in this thesis was to study the influence of 
variation in genes that may affect arterial stiffness and cardiovascular events. All studies were 
based on the Rotterdam Study, a population-based cohort study, originally including 7983 
participants of 55 years and older.
Chapter 1 offers a general introduction to the studies and topics that are described in this 
thesis. 
The first studies in this thesis focused on variation in inflammatory genes in relation to 
cardiovascular events such as myocardial infarction and stroke. 
Chapter 2.1 describes the association between the well-known inflammatory interleukin 6 
(IL-6) -174 G/C promoter polymorphism and risk of coronary heart disease. Inflammatory 
processes play an important role in the pathogenesis of coronary heart disease. However, 
no evidence was found for an association between the IL-6 -174 G/C polymorphism and 
coronary heart disease in the Rotterdam Study, nor in a meta-analysis on this topic. The risk 
allele of the IL-6 -174 G/C polymorphism was, however, associated with increased levels of 
C-reactive protein (CRP). 
In chapter 2.2 several polymorphisms in the transforming growth factor β1 (TGF-β1) gene, 
which influences inflammatory processes, were studied in relation to risk of myocardial 
infarction and stroke. We found the risk alleles of the -509 C/T and codon 10 Leu/Pro poly-
morphisms, both functional, to be associated with an increased risk of ischaemic stroke. This 
supports an atherogenic role for TGF-β in the pathogenesis of stroke.
The remaining studies focused on inflammatory genes and genes that affect the structure 
of the vascular wall in relation to arterial stiffness (pulse wave velocity, the carotid distensibil-
ity coefficient and pulse pressure). Inflammatory processes may influence arterial stiffness, 
therefore we examined several genes related to inflammation. 
Chapter 3.1 described the association of the IL-6 -174 G/C polymorphism, CRP and arterial 
stiffness. Both the risk allele of this polymorphism as well as the CRP-level were associated 
with increased pulse wave velocity, supporting a causal role of inflammatory processes in 
arterial stiffness. 
In chapter 3.2, variation in the CRP gene was studied in relation to arterial stiffness. CRP is an 
inflammatory protein and CRP level has been associated with arterial stiffness. Genetic varia-
tion in the CRP gene was associated with CRP level. Geno- and haplotype analyses, however, 
yielded no evidence for an association between genetic variation in the CRP gene and arterial 
stiffness. This finding might suggest that CRP itself is not causally related to arterial stiffness. 
However, genetic variation in the CRP gene has only a small effect on CRP level. Therefore, a 
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small effect of genetic variation in CRP on arterial stiffness may have gone undetected and a 
judgment about causality cannot be given with certainty.
Chapter 3.3 focused on polymorphisms in the TGF-β1 gene in relation to arterial stiffness. 
We found none of the studied polymorphisms, or resultant haplotypes, to be associated with 
arterial stiffness. Although a possible small effect may have gone undetected, these polymor-
phisms appear to have no large effects on stiffness, despite their functionality. 
Chapter 3.4 described the association between variation in the fibrinogen α and γ genes 
and arterial stiffness. Fibrinogen is an acute phase protein and may also influence the vas-
cular wall. We found genetic variation in the fibrinogen α and γ genes to be associated with 
the level of fibrinogen and with pulse wave velocity and pulse pressure. However, we cannot 
conclude a causal relation between fibrinogen level and stiffness, because genetic variation 
in these genes may also affect structure and thereby function of fibrinogen. Therefore, the 
effect on stiffness may be through an effect on function of fibrinogen rather than through 
an effect on level of fibrinogen. Although fibrinogen is thought to be associated with inflam-
mation and matrix interactions, the precise mechanisms by which fibrinogen might affect 
arterial stiffness remains to be elucidated. 
Arterial stiffness may also be influenced by genes that structurally affect the vascular wall 
or the composition of the vascular wall. 
Genes of the renin-angiotensin (RAS) system are an important example. In chapter 4.1, 
variation in the angiotensin-II, angiotensinogen and angiotensin-II receptor type I genes in 
relation to arterial stiffness is described. The D-allele of the angiotensin converting enzyme 
(ACE) I/D polymorphism was associated with carotid distensibility. We found the D-allele also 
to be associated with pulse pressure. The variations in the other genes of the RAS system 
were not associated with arterial stiffness.
Chapter 4.2 focused on the ACE I/D polymorphism in relation to changes in blood and 
pulse pressure during follow up. The findings suggest the D-allele to be associated with 
larger changes in systolic and pulse pressure over time.
Finally, chapter 4.3 described the association between variation in the matrix-metallopro-
teinase-3 (MMP-3) gene and arterial stiffness. MMP-3 influences the extra-cellular matrix and 
composition of the vascular wall. Indeed, the risk alleles of the 5A/6A and 2092 A/G polymor-
phisms appeared inversely associated with pulse wave velocity, although haplotype analyses 
yielded no significant relation between MMP-3 haplotypes and measures of arterial stiffness. 
Our findings on the relation of the functional 5A/6A polymorphism with arterial stiffness sug-
gest MMP-3 to affect arterial stiffness, possibly due to its effects on matrix degradation. 
In the general discussion, chapter 5, the main findings of this thesis are discussed. The 
results indicate that variations in some genes that affect inflammatory processes and the 
structure of the vascular wall, are associated with arterial stiffness. However, due to generally 
modest effects of genetic variation on complex traits, in addition to limited knowledge on 
the pathogenetic mechanisms by which arterial stiffness is influenced, additional research is 
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needed before one can draw more definite conclusions on questions of causality. Our find-
ings support, nevertheless, the view that arterial stiffness can be considered a multifactorial 
and complex trait. For clinical and practical applications of arterial stiffness, we emphasize 
the need for standardization in measurement techniques.
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SAMENVATTING
Arteriële vaatstijfheid neemt toe met de leeftijd. Het is ook geassocieerd met verscheidene 
ziektes, zoals diabetes mellitus en hypertensie. Recentelijk is ook ontdekt dat arteriële vaat-
stijfheid van onafhankelijke voorspellende waarde is bij cardiovasculaire ziekte. De pathoge-
nese van arteriële vaatstijfheid is echter nog grotendeels onbekend. Het doel van de studies, 
die beschreven zijn in dit proefschrift, was dan ook de invloed te onderzoeken van variaties in 
genen die mogelijk van invloed zijn op arteriële vaatstijfheid en cardiovasculaire events. Alle 
studies zijn gebaseerd op de ERGO Studie (Rotterdam Study), een zgn. “population-based” 
cohort studie, die van origine 7983 deelnemers van 55 jaar en ouder omvat.
Hoofdstuk 1 biedt een algemene inleiding op de studies en onderwerpen die in dit proef-
schrift worden beschreven.
De eerste studies richten zich op variaties in ontstekingsgenen en hun relatie met cardio-
vasculaire events. 
Hoofdstuk 2.1 beschrijft de associatie tussen het bekende inflammatoire interleukine 
6 (IL-6) -174 G/C promotor polymorphisme en het risico op coronaire hartziekte. Ontste-
kingsprocessen spelen een belangrijke rol in de pathogenese van coronaire hartziekte. Wij 
vonden echter in de ERGO Studie geen bewijs voor een associatie tussen het IL-6 -174 G/C 
polymorphisme en coronaire hartziekte, noch in een meta-analyse over dit onderwerp. Het 
risico-allel van het IL-6 -174 G/C polymorphisme was echter wel geassocieerd met hogere 
C-reactive protein (CRP) waardes.
In hoofdstuk 2.2 worden verscheidene polymorphismen bestudeerd in het transforming 
growth factor β1 (TGF-β1) gen, dat ontstekingsprocessen beïnvloedt, in relatie tot het risico 
op een myocardinfarct en beroerte (CVA). Wij vonden de risico allelen van de -509 C/T en co-
don 10 Leu/Pro polymorphismen, beide functioneel, geassocieerd met een verhoogd risico 
op een ischaemisch CVA. Deze bevindingen ondersteunen een atherogene rol van TGF-β in 
de pathogenese van een CVA.
De resterende studies richten zich op genen, die ontsteking en de bouw van de vaatwand 
kunnen beïnvloeden, en hun relatie met arteriële vaatstijfheid (als maten hiervoor zijn ge-
bruikt de zgn. polsgolfsnelheid [pulse wave velocity], de distensibiliteitscoëfficiënt van de 
carotiden [carotid distensibility coefficient] en de polsdruk [pulse pressure]). Ontstekingspro-
cessen kunnen mogelijk invloed uitoefenen op arteriële vaatstijfheid. Om die reden hebben 
wij verscheidene genen bestudeerd die gerelateerd zijn aan ontstekingsprocessen.
Hoofdstuk 3.1 beschrijft de associatie tussen het IL-6 -174 G/C polymorphisme, het CRP 
niveau en arteriële vaatstijfheid. Zowel het risico allel als het CRP niveau waren geassocieerd 
met een hogere “pulse wave velocity”, hetgeen een causale rol van ontstekingsprocessen bij 
arteriële vaatstijfheid ondersteunt.
In hoofdstuk 3.2 is variatie in het CRP gen bestudeerd in relatie tot arteriële stijfheid. Vari-
atie in het CRP gen bleek geassocieerd met het CRP niveau. Geno- en haplotype analyses 
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leverden echter geen bewijs voor een associatie tussen variatie in het CRP gen en arteriële 
vaatstijfheid. Deze bevinding zou kunnen suggereren dat variatie in het CRP gen geen cau-
sale relatie heeft met arteriële vaatstijfheid. Echter, genetische variatie in het CRP gen heeft 
echter maar een klein effect op het CRP niveau. Om die reden kan een klein effect van deze 
genetische variatie op arteriële vaatstijfheid onopgemerkt gebleven zijn en kan een definitief 
oordeel over causaliteit niet gegeven worden.
Hoofdstuk 3.4 beschrijft de associatie tussen variatie in de fibrinogeen α en γ genen en ar-
teriële vaatstijfheid. Fibrinogeen is een acute fase eiwit en beïnvloedt mogelijk de vaatwand. 
Wij vonden dat variatie in de fibrinogeen α en γ genen geassocieerd is met het fibrinogeen 
niveau, met “pulse wave velocity” en “pulse pressure”. Echter, wij kunnen niet met zekerheid 
een concluderen dat er een causale relatie bestaat tussen het fibrinogeen niveau en vaatstijf-
heid, omdat variatie in deze genen ook de structuur en daarmee de functie van fibrinogeen 
zou kunnen beïnvloeden. Derhalve zou het effect op vaatstijfheid mogelijk ook gemedieerd 
kunnen zijn door het effect op de functie van fibrinogeen, meer dan door het effect op het 
niveau. Hoewel fibrinogeen beschouwd wordt ontstekingsprocessen en matrix interactie te 
beïnvloeden, moeten de mechanismen hoe fibrinogeen vaatstijfheid zou kunnen beïnvloe-
den nog nader onderzocht worden.
Arteriële vaatstijfheid zou ook beïnvloed kunnen worden door genen die een effect zouden 
kunnen hebben op de structuur en samenstelling van de vaatwand. 
Genen van het renine-angiotensine (RAS) systeem zijn hiervan een belangrijk voorbeeld. 
In hoofdstuk 4.1 wordt ingegaan op de relatie tussen variatie in de angiotensine-II, angio-
tensinogeen en angiotensine-II receptor type I genen en arteriële vaatstijfheid. Het D-allel 
van het “angiotensin converting enzyme” (ACE) I/D polymorphisme was geassocieerd met de 
distensibiliteit van de carotiden en met “pulse pressure”. De variaties in de andere RAS genen 
bleken niet geassocieerd met arteriële vaatstijfheid.
Hoofdstuk 4.2 beschrijft de relatie tussen het ACE I/D polymorphisme en veranderingen 
in bloeddruk en “pulse pressure” in een vervolgonderzoek. De bevindingen suggereren dat 
het D-allel door de tijd heen geassocieerd is met toegenomen veranderingen in systolische 
bloeddruk en polsdruk.
Tot slot wordt in hoofdstuk 4.3 de associatie beschreven tussen variatie in het matrix 
metalloproteinase 3 (MMP-3) gen en arteriële vaatstijfheid. MMP-3 beïnvloedt de extracel-
lulaire matrix en de samenstelling van de vaatwand. De risico-allelen van de 5A/6A en 2092 
A/G polymorphismen waren (negatief ) geassocieerd met “pulse wave velocity”. Haplotype 
analyses leverden echter geen bewijs voor een associatie tussen variatie in het MMP-3 gen 
en arteriële vaatstijfheid. Desalniettemin suggereren onze bevindingen over het functionele 
5A/6A polymorphisme en arteriële vaatstijfheid, dat MMP-3 vaatstijfheid zou kunnen beïn-
vloeden, mogelijk door de effecten op matrix degradatie.
In de algemene bespreking, hoofdstuk 5, worden de voornaamste bevindingen van dit 
proefschrift besproken. De resultaten suggereren dat variaties in een aantal genen, die 
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invloed hebben op ontstekingsprocessen en de structuur van de vaatwand, geassocieerd 
zijn met arteriële vaatstijfheid. Daar genetische variatie in het algemeen echter meestal 
slechts beperkte invloed heeft op complexe processen en de kennis over de pathogenese 
van arteriële vaatstijfheid beperkt is, is verder onderzoek nodig voor definitievere conclusies 
getrokken kunnen worden over causaliteitsvraagstukken. Onze bevindingen ondersteunen 
desalniettemin het inzicht dat arteriële vaatstijfheid als een complex en multifactorieel 
proces beschouwd kan worden. Voor klinische en practische toepassingen van vaatstijfheid, 
benadrukken wij het belang van standaardisatie in meettechnieken.
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